"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CA,A,CA 1232083 A,181-984-346-720-354,1988-01-26,1988,CA 471318 A,1985-01-02,US 56782984 A,1984-01-03,MICROWAVE TRANSISTOR PACKAGE,"A microwave transistor package is provided having a thermal and electrical conductive refractory type substrate. A ground plane plate is provided, such plate having an openended compartment therein, the open end of such compartment being disposed adjacent an upper surface portion of the ground plane plate. A bottom surface of such plate is disposed on an upper, inner surface region of the substrate. The thermal coefficient of expansion of the ground plane plate is substantially greater than the thermal coefficient of expansion of the substrate. An electrical insulator is disposed within the compartment, such insulator having a relatively high thermal transfer characteristic and having upper and lower conductive layers with side wall portions disposed adjacent side wall portions of the compartment. A first apertured ceramic insulating layer having conductive metallization regions disposed on the upper surface of the ceramic insulator extending from the apertured edge of the ceramic insulator to the outer edge of the ceramic insulator is provided. The lower surface of the ceramic insulator is disposed over the substrate and about peripheral portions of the inner surface region of the substrate. A second apertured ceramic insulating layer is disposed over and aligned with the first apertured ceramic insulating layer, the upper surface of the second ceramic insulating layer being metallized and bondable to a cover for such package. The package is fabricated by brazing together, in a single step, the pair of ceramic insulating layers, the electrical insulator and the substrate.",RAYTHEON CO,BORKOWSKI MICHAEL T;;LAIGHTON DAVID G;;ALTSCHUL BARRY,,https://lens.org/181-984-346-720-354,Granted Patent,no,0,0,2,2,0,H01L23/66;;H01L24/49;;H01L2223/6644;;H01L2224/48091;;H01L2224/49175;;H01L2924/01005;;H01L2924/01006;;H01L2924/01029;;H01L2924/01042;;H01L2924/01047;;H01L2924/0105;;H01L2924/01074;;H01L2924/01079;;H01L2924/01083;;H01L2924/01322;;H01L2924/15153;;H01L2924/1517;;H01L2924/16195;;H01L2924/19041;;H01L2924/3011;;H01L24/48;;H01L2924/014;;H01L2924/30111;;H01L2924/00014;;H01L2924/12033;;H01L23/66;;H01L2924/01006;;H01L2924/01029;;H01L2924/01025;;H01L2924/01079;;H01L2924/0105;;H01L2224/48091;;H01L2224/49175;;H01L2924/3011;;H01L2223/6644;;H01L2924/01322;;H01L2924/01042;;H01L2924/01083;;H01L24/49;;H01L2924/01074;;H01L2924/15153;;H01L2924/1517;;H01L2924/16195;;H01L2924/01047;;H01L2924/01005;;H01L2924/19041;;H01L24/48;;H01L2924/014;;H01L2924/30111;;H01L2924/00014;;H01L2924/12033,H01L23/66,356-109,0,0,,,,EXPIRED
2,US,A,US 4649416 A,164-036-030-070-205,1987-03-10,1987,US 56782984 A,1984-01-03,US 56782984 A,1984-01-03,Microwave transistor package,"A microwave transistor package is provided having a thermal and electrical conductive refractory type substrate. A ground plane plate is provided, such plate having an open-ended compartment therein, the open end of such compartment being disposed adjacent an upper surface portion of the ground plane plate. A bottom surface of such plate is disposed on an upper, inner surface region of the substrate. The thermal coefficient of expansion of the ground plane plate is substantially greater than the thermal coefficient of expansion of the substrate. An electrical insulator is disposed within the compartment, such insulator having a relatively high thermal transfer characteristic and having upper and lower conductive layers with side wall portions disposed adjacent side wall portions of the compartment. A first apertured ceramic insulating layer having conductive metallization regions disposed on the upper surface of the ceramic insulator extending from the apertured edge of the ceramic insulator to the outer edge of the ceramic insulator is provided. The lower surface of the ceramic insulator is disposed over the substrate and about peripheral portions of the inner surface region of the substrate. A second apertured ceramic insulating layer is disposed over and aligned with the first apertured ceramic insulating layer, the upper surface of the second ceramic insulating layer being metallized and bondable to a cover for such package. The package is fabricated by brazing together, in a single step, the pair of ceramic insulating layers, the electrical insulator and the substrate.",RAYTHEON CO,BORKOWSKI MICHAEL T;;LAIGHTON DAVID G;;ALTSCHUL BARRY,RAYTHEON COMPANY (1983-12-30),https://lens.org/164-036-030-070-205,Granted Patent,yes,12,44,2,2,0,H01L23/66;;H01L24/49;;H01L2223/6644;;H01L2224/48091;;H01L2224/49175;;H01L2924/01005;;H01L2924/01006;;H01L2924/01029;;H01L2924/01042;;H01L2924/01047;;H01L2924/0105;;H01L2924/01074;;H01L2924/01079;;H01L2924/01083;;H01L2924/01322;;H01L2924/15153;;H01L2924/1517;;H01L2924/16195;;H01L2924/19041;;H01L2924/3011;;H01L24/48;;H01L2924/014;;H01L2924/30111;;H01L2924/00014;;H01L2924/12033;;H01L23/66;;H01L2924/01006;;H01L2924/01029;;H01L2924/01025;;H01L2924/01079;;H01L2924/0105;;H01L2224/48091;;H01L2224/49175;;H01L2924/3011;;H01L2223/6644;;H01L2924/01322;;H01L2924/01042;;H01L2924/01083;;H01L24/49;;H01L2924/01074;;H01L2924/15153;;H01L2924/1517;;H01L2924/16195;;H01L2924/01047;;H01L2924/01005;;H01L2924/19041;;H01L24/48;;H01L2924/014;;H01L2924/30111;;H01L2924/00014;;H01L2924/12033,H01L23/66,H1K KRC           RC,0,0,,,,EXPIRED
3,EP,A1,EP 2712317 A1,016-041-334-903-616,2014-04-02,2014,EP 12762996 A,2012-03-28,US 201161516227 P;;US 2012/0030832 W,2011-03-31,PREVENTION OF INFECTION,,POP TEST CORTISOL LLC;;BRIEN REBECCA O,O'BRIEN REBECCA;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON,POP TEST ONCOLOGY LLC (2018-06-06),https://lens.org/016-041-334-903-616,Patent Application,yes,0,0,7,7,0,A61K31/56;;A61K31/56;;A61K31/573;;A61P31/00;;A61P37/04,A61K31/56;;A61K31/00;;A61K31/04;;A61K31/57;;A61K31/573;;A61K31/58;;A61P37/04,,0,0,,,,ACTIVE
4,US,A1,US 2015/0105360 A1,159-184-961-789-22X,2015-04-16,2015,US 201414570338 A,2014-12-15,US 201414570338 A;;US 201313837408 A;;US 201261741925 P,2012-07-30,Therapeutic Compositions and Method,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/159-184-961-789-22X,Patent Application,yes,3,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K35/28;;A61K31/58;;A61K35/545,514/174,5,4,095-830-115-447-769;;008-950-294-575-168;;150-470-522-691-124;;041-967-023-131-706,7985091;;16019588;;10.1080/10253890400019672;;20553093;;10.1517/13543776.2010.493876;;10.1016/j.clindermatol.2006.04.012;;16828407,"MedlinePlus Medical Encyclopedia. Cushing syndrome. Datasheet [online]. NIH/NLM. [retrieved on 2016-03-21]. Page last updated 02 March 2016. Retrieved from the Internet: <URL: http://www.nlm.nih.gov/medlineplus/ency/article/000410.htm> pp. 1-5. specif. pg. 2;;Gordon, C.B. et al. 1994. Impaired wound healing in Cushing's syndrome: the role of heat shock proteins. Surgery 116(6): 1082-1087. specif. pg. 1082;;Peeters, B.W.M.M. et al. 2004. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress 7(4): 233-241. specif. pp. 233, 236;;Berlin, M. 2010. Recent advances in the development of novel glucocorticoid receptor modulators. Expert Opinion on Therapeutic Patents 20(7): 855-873. specif. pp. 855, 857, 863;;Shibli-Rahhal, A. et al. 2006. Cushing's syndrome. Clinics in Dermatology 24: 260-265. specif. pp. 260, 261",DISCONTINUED
5,EP,A1,EP 3455627 A1,061-913-635-450-478,2019-03-20,2019,EP 16898797 A,2016-04-12,US 2016/0027108 W,2016-04-12,"DEVICES AND FORMULATIONS FOR DETECTING, SCREENING AND MONITORING LEVELS OF CERTAIN CONSTITUENTS IN BODILY FLUIDS AND METHOD",,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/061-913-635-450-478,Patent Application,yes,0,0,3,3,0,C12Q1/52;;G01N33/523;;G01N33/57438;;G01N33/66;;G01N33/6893;;G01N33/92;;G01N2333/91188;;G01N2800/085,G01N33/52;;C12Q1/00;;G01N33/545,,0,0,,,,DISCONTINUED
6,US,A1,US 2015/0241433 A1,085-283-994-609-097,2015-08-27,2015,US 201514684861 A,2015-04-13,US 201514684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and Formulations for Detecting, Screening and Monitoring Levels of Certain Constituents in Bodily Fluids and Method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-08),https://lens.org/085-283-994-609-097,Patent Application,yes,1,1,2,32,0,G01N33/52;;C12Q1/52;;G01N33/558;;G01N2333/91188;;G01N21/29;;G01N33/57438;;G01N33/92;;G01N33/66;;G01N2800/085;;G01N33/57438;;G01N33/92;;G01N33/66;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N2333/91188;;G01N21/29;;G01N33/54388,G01N33/574;;G01N33/543;;G01N33/545;;G01N33/552;;G01N33/573;;G01N33/66;;G01N33/92,,2,2,092-846-322-878-032;;011-793-407-045-692,10.1016/j.aca.2010.06.019;;20678634;;17272484;;10.1373/clinchem.2006.081257,"Dungchai et al. Analytica Chimica Acta, 2010, 674:227-233.;;Chang et al. Clinical Chemistry, 2007, 53:4:686-692.",ACTIVE
7,EP,A4,EP 2884984 A4,107-321-437-679-659,2016-03-16,2016,EP 13824861 A,2013-07-30,US 201261741925 P;;US 201313837408 A;;US 2013/0052622 W,2012-07-30,THERAPEUTIC COMPOSITIONS AND METHODS,,POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2018-04-25),https://lens.org/107-321-437-679-659,Search Report,no,0,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/56;;A61K35/28;;A61K35/545;;A61K45/06;;A61P17/02;;A61P19/10;;A61P25/30;;A61P37/06,,6,5,045-781-532-813-377;;029-246-439-288-649;;057-516-538-123-340;;134-221-554-037-445;;022-190-260-808-662,18828802;;10.1111/j.1530-0277.2008.00799.x;;10.1016/s1734-1140(11)70479-0;;12700716;;10.1038/sj.npp.1300158;;23584113;;pmc3860380;;26143299;;pmc4536150;;10.1016/j.drugalcdep.2015.06.018,"CATHERINE JACQUOT ET AL: ""Effects of the Glucocorticoid Antagonist, Mifepristone, on the Consequences of Withdrawal From Long Term Alcohol Consumption"", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., vol. 32, no. 12, 1 December 2008 (2008-12-01), US, pages 2107 - 2116, XP055247584, ISSN: 0145-6008, DOI: 10.1111/j.1530-0277.2008.00799.x;;JAVIER NAVARRO-ZARAGOZA ET AL: ""PS V - 3 Glucocorticoid (GC) receptor antagonist mifepristone attenuates morphine withdrawal behaviors"", PHARMACOLOGICAL REPORTS, 13 April 2011 (2011-04-13), European Opioid Conference; Krakow, POLAND; April 13 -15, 2011, pages 253 - 254, XP055247580, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1734114011704790/1-s2.0-S1734114011704790-main.pdf?_tid=74e2833c-cb40-11e5-af9e-00000aab0f02&acdnat=1454591520_2543248385ba0cfca70f3c03bd767647> [retrieved on 20160204];;CORNELIUS G BACHMANN ET AL: ""Effect of Chronic Administration of Selective Glucocorticoid Receptor Antagonists on the Rat Hypothalamic-Pituitary-Adrenocortical Axis"", NEUROPSYCHOPHARMACOLOGY., 19 December 2002 (2002-12-19), US, XP055247533, ISSN: 0893-133X, DOI: 10.1038/sj.npp.1300158;;MARY ANN C STEPHENS ET AL: ""Stress and the HPA Axis: Role of Glucocorticoids in Alcohol Dependence"", ALCOHOL RESEARCH, 1 July 2012 (2012-07-01), Bethesda, pages 468, XP055247551, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860380/pdf/arcr-34-4-468.pdf> [retrieved on 20160204];;REYNOLDS ANNA R ET AL: ""Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis ac"", DRUG AND ALCOHOL DEPENDENCE, vol. 154, 22 June 2015 (2015-06-22), pages 100 - 104, XP029256113, ISSN: 0376-8716, DOI: 10.1016/J.DRUGALCDEP.2015.06.018;;See also references of WO 2014022340A2",ACTIVE
8,EP,B1,EP 2712317 B1,018-060-939-446-83X,2018-09-19,2018,EP 12762996 A,2012-03-28,US 201161516227 P;;US 2012/0030832 W,2011-03-31,PREVENTION OF INFECTION,,POP TEST ONCOLOGY LLC,O'BRIEN REBECCA;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON,POP TEST ONCOLOGY LLC (2018-06-06),https://lens.org/018-060-939-446-83X,Granted Patent,yes,4,0,7,7,0,A61K31/56;;A61P31/00;;A61P37/04;;A61K31/573;;A61K31/56,A61K31/56;;A61K31/00;;A61K31/04;;A61K31/57;;A61K31/573;;A61K31/58;;A61P37/04,,6,0,,,"ANTONAWICH F J ET AL: ""Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone"", NEUROSCIENCE, NEW YORK, NY, US, vol. 88, no. 1, 1 January 1999 (1999-01-01), pages 319-325, XP002476026, ISSN: 0306-4522, DOI: 10.1016/S0306-4522(98)00213-9;;N. SUGO ET AL: ""Social Stress Exacerbates Focal Cerebral Ischemia in Mice"", STROKE, vol. 33, no. 6, 1 June 2002 (2002-06-01), pages 1660-1664, XP055162738, ISSN: 0039-2499, DOI: 10.1161/01.STR.0000016967.76805.BF;;K. PRASS ET AL: ""Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1-like Immunostimulation"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 5, 2 September 2003 (2003-09-02), pages 725-736, XP055162482, ISSN: 0022-1007, DOI: 10.1084/jem.20021098;;DOMKA E. ET AL.: 'Incidence of neuromedical complications during rehabilitation after stroke' NEUROL. NEUROCHIR. POL. vol. 39, no. 4, 2005, pages 300 - 309, XP008171888;;GULDIKEN, BABURHAN ET AL.: 'Mean Platelet Volume and Peripheral Blood Count Response in Acute Ischemic Stroke.' TRAKYA UNIV TIP FAK DERG vol. 25, no. 2, 2008, pages 130 - 135, XP008172736;;ZYGUN, DAVID A. ET AL.: 'Ventilator-Associated Pneumonia in Severe Traumatic Brain Injury.' NEUROCRITICAL CARE vol. 5, 2006, pages 108 - 114, XP055092728",ACTIVE
9,US,A1,US 2012/0253312 A1,037-534-930-324-757,2012-10-04,2012,US 201213432174 A,2012-03-28,US 201213432174 A;;US 201161516227 P,2011-03-31,Prevention of Infection,The invention relates to compounds and methods for the prevention and/or treatment of infection after stroke.,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST CORTISOL LLC (2012-03-28);;POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/037-534-930-324-757,Patent Application,yes,2,1,7,7,0,A61K31/56;;A61K31/56;;A61K31/573;;A61P31/00;;A61P37/04,A61J1/14;;A61J1/00;;A61K31/56;;A61P31/00,604/403;;514/182;;206/570,0,0,,,,INACTIVE
10,US,B2,US 9114147 B2,050-695-399-994-622,2015-08-25,2015,US 201314100714 A,2013-12-09,US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST CORTISOL LLC;;POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2014-03-13);;POP TEST CORTISOL LLC (2012-02-01),https://lens.org/050-695-399-994-622,Granted Patent,yes,26,27,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K9/08;;A61K31/58;;A61K9/10;;A61K9/107;;A61K31/00;;A61K31/337;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61N5/10;;B65D75/36;;C07J17/00;;G01N33/74,,77,72,029-430-665-993-012;;025-236-889-877-681;;072-017-135-003-528;;075-604-848-120-332;;022-427-234-675-993;;027-610-441-797-691;;098-970-572-904-025;;039-764-013-605-830;;077-911-867-689-885;;004-051-499-572-775;;006-030-973-019-783;;028-006-068-536-463;;000-990-435-802-906;;070-731-131-146-498;;025-968-443-414-504;;146-449-089-963-596;;031-219-768-770-784;;028-834-962-521-841;;019-082-741-537-174;;078-818-133-871-602;;152-497-600-208-517;;010-540-968-978-319;;033-884-765-849-131;;048-310-550-318-36X;;099-883-114-833-005;;028-428-571-584-841;;023-364-956-890-880;;046-322-433-866-098;;035-083-000-444-258;;040-582-260-914-903;;054-980-079-955-454;;192-609-714-372-280;;096-741-767-207-949;;014-065-259-226-128;;081-376-983-952-92X;;035-784-409-496-514;;019-490-428-734-203;;022-633-679-770-667;;010-671-218-365-329;;008-292-323-806-999;;026-234-020-245-765;;016-114-899-296-280;;084-085-138-348-898;;019-711-514-953-919;;011-287-801-985-920;;037-480-189-672-490;;085-543-600-111-869;;046-778-406-329-065;;099-369-779-864-138;;007-571-797-644-640;;015-454-506-279-186;;051-377-782-627-959;;002-098-985-648-398;;080-562-942-546-792;;014-163-707-036-635;;035-869-118-228-758;;008-917-378-114-698;;102-621-078-333-789;;045-570-917-520-663;;018-251-894-793-513;;025-901-082-859-148;;090-455-915-702-488;;013-888-136-576-823;;029-321-866-606-59X;;073-896-843-757-961;;034-094-105-568-465;;028-022-503-455-028;;046-051-866-937-523;;036-429-482-067-724;;008-913-767-238-151;;087-722-794-850-841;;056-286-307-946-019,16340307;;10.4161/cbt.4.12.2354;;16236742;;10.1056/nejmra050541;;10.1111/j.1365-2265.2004.02106.x;;15355454;;15634032;;10.2165/00003088-200544010-00003;;3041279;;10.1056/nejm198808183190706;;10.1210/edrv-17-2-187;;8706631;;10.1210/er.17.2.187;;1645586;;10.1016/0960-0760(91)90312-s;;10.1177/070674379804300307;;9561317;;pmc1188541;;8297920;;10.2165/11587620-000000000-00000;;21175239;;10.1038/nbt1085-889;;10.1136/jnnp.23.1.56;;14399272;;pmc495331;;10.1037/t04100-000;;10.1097/00005053-198409000-00002;;6470694;;10.1177/070674378503000312;;2986814;;10.1016/0002-9343(84)90312-7;;6711582;;1984391;;10.7326/0003-4819-114-2-143;;8490591;;10.1007/bf01874090;;15268748;;10.1111/j.1474-9728.2004.00103.x;;16300484;;10.1111/j.1474-9726.2005.00178.x;;10.1016/j.biopsych.2003.12.021;;15110738;;7961563;;20859106;;10.1097/01.pra.0000388624.91039.a3;;10.1097/med.0b013e32833de61c;;20717020;;pmc2957510;;10.1016/j.schres.2010.07.012;;20692814;;10553730;;10.1176/ajp.156.11.1686;;10764142;;10.1038/sj.leu.2401743;;10.1210/jcem.86.8.7740;;11502780;;10.1210/jc.86.8.3568;;16782211;;10.1016/j.bbr.2006.03.039;;19888560;;10.1007/s12325-009-0070-1;;10.1016/0076-6879(81)73054-4;;7300683;;14680969;;10.1016/j.pep.2003.09.003;;14522905;;15378086;;10.1038/sj.onc.1207946;;8855227;;pmc38202;;10.1073/pnas.93.20.10614;;pmc20056;;9122163;;10.1073/pnas.94.6.2150;;10.1016/0092-8674(89)90237-7;;2644044;;10.1210/edrv-11-2-201;;2194782;;10.1146/annurev.bi.63.070194.002315;;10.1146/annurev.biochem.63.1.451;;7979245;;7857868;;10.1016/0960-0760(94)00155-f;;10.1182/blood-2004-03-0901;;15242869;;14630803;;pmc3311914;;10.1182/blood-2003-09-3064;;10.1073/pnas.0307618100;;14711994;;pmc321758;;10.1073/pnas.0530291100;;pmc153034;;12629218;;10.1158/0008-5472.can-05-2018;;16322242;;16230395;;10.1158/0008-5472.can-05-1343;;9212098;;10.1038/nm0797-730;;21818591;;10.1007/s10549-011-1689-6;;10.1016/j.steroids.2011.03.001;;21414337;;pmc3514452;;10.1158/0008-5472.can-11-0362;;21868756;;10.4161/cbt.5.8.2875;;16775428;;10706096;;14996737;;10.1158/0008-5472.can-03-2546;;15590693;;10.1074/jbc.m411200200;;10.1089/scd.2011.0477;;21973238;;pmc3376467;;18053085;;pmc3823477;;10.1111/j.1582-4934.2007.00177.x;;18269582;;10.1111/j.1365-2559.2007.02953.x;;10.1097/pai.0b013e3181c10180;;19875955;;21336598;;10.1007/s10549-011-1394-5;;20739888;;10.1097/cco.0b013e32833ea80c;;15862824;;10.1016/j.steroids.2005.02.006;;23045254;;10.1038/nrrheum.2012.166;;20448266;;10.1177/1091581810366486;;23303060;;pmc3672002;;10.1038/npp.2012.253;;10392950;;10.1016/s1051-0443(99)70117-x;;14607754;;17035596;;10.1124/mol.106.029629;;10404077;;10.1002/(sici)1097-0215(19990812)82:4<599::aid-ijc21>3.0.co;2-r;;10511017;;10.1097/00006842-199909000-00011;;10.1016/j.canlet.2010.10.020;;21078539;;17016446;;10.1038/sj.onc.1209991;;10.1007/s12253-009-9154-0;;19253003;;10.1016/j.cell.2013.11.012;;24315100;;pmc3932525,"Herr et al (Cancer Biology & Therapy 4:12, 1415-1416, 2005).;;Turk Rhen, PhD., et al. Antiinflammatory Action of Glucocorticoids-New Mechanisms for Old Drugs, JA. NEJM 2005; 353: 1711-23.;;Mah, et al., Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency, Clinical Endocrinology (2004) 61, 367-375.;;Crock, et al. Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids, Clin. Pharmacokinet (2005) 44, 61-98.;;Gold, et al. Clinical and Biomedical Manifest, New England J. Med. 319, 413-420, 1988.;;Florian Holsboer and Nicholas Barden, Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation, Endocrine Reviews 1996, 1vol. 7, 187-205.;;Beverley E. Pearson Murphy, Steroids and Depression, Steroid Biochem. and Mol. Biol. 1991, 38, 537-559.;;Avrameas, S., et al. Coupling of enzymes to Antibodies and Antigens, Scand. J. Immunol., vol. 8 Suppl. 7:7-23 (1978).;;Murphy, et al. Neuroendocrine Responses to Inhibitors of Steroid Biosynthesis in Patients With Major Depression Resistant to Antidepressant Therapy, Can. J. Psych. 43, 279-286, 1998.;;Murphy, et al., Possible Use of Glucocorticoid Receptor Antagonists in the Treatment of Major Depression: Preliminary Results Using RU 486, J. Psychiat. Neurosci. 18, 209-213, 1993.;;Connolly, K.R., et al., If at First You Don't Succeed, Drugs. 2011; 71: 43-64.;;Rodwell, et al., Linker Technology: Antibody-Mediated Delivery Systems, Biotech., 3:889-894 (1984).;;Max Hamilton, A rating scale for depression, J. Neurol. Neurosurg. Psychiat. 1960, 23, 56-62.;;W. Coryell, M.D., et al. The Clinical and Neuroendocrine Features of Psychotic Depression (1984) J. Nerv. Ment. Dis. 172:521.;;Stephen N. Gerson, M.D., Cushing Disease Presenting as Atypical Psychosis Followed by Sudden Death, Can. J. Psychiatry 30:223-224 Apr. 1985.;;Saad, et al. Occult Cushing's Disease Presenting with Acute Psychosis, American Journal of Med. 76:759-766, 1984.;;Aart-Jan Van Der Lely, et al. Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (1991) Annals of Internal Med. 114:143.;;A.J. Van Der Lely, Aspects of medical therapy of Neuroendocrine Disorders, vol. 15, Pharmacy World & Science 15:89-90; 1992.;;Stephen K. Butcher and Janet M. Lord, Stress Responses and innate Immunity: aging as a Contributory Factor (2004) Aging Cell, pp. 151-160.;;Butcher, et al. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and Immunity (2005), Aging Cell 5, pp. 319-324).;;Lindley, et al. Basal and dexamethasone suppressed salivary cortisol concentrations in a community sample of patients with postraumatic stress disorder, Biol. Psychiatry 2004; 55: 940-5.;;Daniel S. G. Umbricht, et al., Clozapine and Weight Gain, J Clin. Psychiatry 1994; 55: 157-160.;;Khan, et al. The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review J Psychiatr Pract. 2010;16: 289-96.;;Pornpoj Pramyothin and Lalita Khaodhair, Metabolic Syndrome with the Atypical Antipsychotics, Curr Opin Endocrinol Diabetes Obes. 2010; 17: 460-466.;;Rummel-Kluge, et al. Head-to-Head comparisons of metabolic side effects of second generation antipsychotics in the treatment of Schizophrenia: A systematic review and meta-analysis Schizophr Res. 2010; 123: 225-33.;;Allison, et al. Antipsychotic-Induced Weight Gain: A comprehensive Research Synthesis, Am J Psychiatry 156:1686-1696 (Nov. 1999).;;AE Frankel, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias, Leukemia 14:576 (2000).;;Chu, et al., Successful Long-Term Treatment of Refractory Cushing's Disease with High-dose Mifepristone (RU 486) J. Clin. Endocrinol. Metab. 2001; 86,3568-3573.;;Beebe, et al., The efficacy of Mifepristone in the reduction and prevention of Olanzapine-induced weight gain in rats Behav. Brain Res. 2006; 171, 225-229.;;Gross, et al., Mifepristone Treatment of Olanzapine-Induced Weight Gain in Healthy Men, Adv Ther. 2009; 26: 959-69.;;Dominick Deluca, ""Immunofluorescence Analysis"", in Antibody As a Tool, Marchalonis, et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982.;;G. Galfre and C. Milstein, Preparation of Monoclonal Antibodies: Strategies and Procedures, Meth. Enzymol., 73:3-46 (1981.;;J. Urieto, et al. Expression and purification of the recombinant diphtheria fusion Toxin DT388IL3 for phase I clinical trials, Protein Expression and Purification 33: 123-133 (2004).;;S. Singh, et al., ""Identification of a cancer stem cell in human brain tumors,"" Cancer Res. 63:5821-5828 (2003).;;S. Singh et al. ""Cancer Stem Cells in Nervous System Tumors"", Oncogene 23:7267-7273 (2004).;;M. Schena, et al. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes (1996) Proc. Natd. Acad. Sci. 93:10614-10619.;;R. Heller, et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays, (1997) Pro. Natl. Acad. Sci. 94:2150-2155.;;Jean-Marie Gasc and Etienne-Emile Bauilieu, Immunocytochemical localization of steroid hormone receptors: Anti-receptor antibodies, Clark, C. R. (Ellis Horwood Ltd., Chichester, England), pp. 233-250.;;Beato, Miguel, Gene Regulation by Steroid Hormones (1989) Cell vol. 56, 335-344.;;Carson-Jurica, et al. Steroid Receptor Family: Structure and Functions, Endocr. Rev. 11, 201-220; 1990.;;Hinrich Gronemeyer, Nuclear Hormone Receptors as transcriptional Activators, Steroid Hormone Action, ed. Parker, M. G. (Oxford University Press, New York), pp. 94-117.;;Ming-Jer Tsai and Bert W. O'Malley, Molecular Mechanisms of Action of Steroid/Thyroid Receptor SuperFamily Members (1994) Annu. Rev. Biochem. 63, 451-486.;;G Akner, et al., Subcellular Distribution of the Glucocorticoid Receptor and Evidence for its Association with Microtubules J. Steroid Biochem. Mol. Biol. 52, 1-16, (1995).;;Cox et al., Characterization of Acute lymphoblastic leukemia progenitor cells, Blood 104(19): 2919-2925 (2004).;;Matsui, et al., ""Characterization of clonogenic multiple myeloma cells,"" Blood 103(6): 2332, 2004.;;Kondo, et al. Persistence of a small subpopulation of cancer stem-like cells in the C6 Glioma cell line Proc. Natl. Acad. Sci. USA 101:781-786 (2004).;;Muhammad Al-Hajj, et al. Prospective identification of Tumorigenic Breast Cancer Cells, Proc. Natl. Acad. Sci. USA 100:3983-3988 (2003).;;Collins, et al., ""Prospective identification of Tumorigenic Prostate Cancer Stem Cells,"" Cancer Res 65 (23):10946-10951 (2005).;;Fang, et al., ""A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas,"" Cancer Res 65(20): 9328-9337 (2005).;;Dominique Bonnet & John E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med 3:730-737, 1997.;;Myriam Vilasco, et al., Glucocorticoid Receptor and Breast Cancer, Breast Cancer Res Treat(2011)130:1-10.;;Donita Africader, Molecular Mechanisms of Steroid Receptor-mediated actions by Synthetic Progestins Used in HRT and Contraception, Steroids 76 (2011) 636-652.;;Deng Pan, et al. Activation of Glucocorticoid Receptor is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer, Cancer Res 2011;71:6360-6370.;;Diana Pang, et al. Dexamethasone Decreases Xenograft Response to Paclitaxel Through Inhibition of Tumor Cell Apoptosis, Cancer biology & Therapy 5:8, 933-940, Aug. 2006.;;Timothy J. Moran, et al., The Glucocorticoid Receptor Mediates a Survival Signal in Human Mammary Epithelial Cells, Cancer Res. 2000;60:867-872.;;Wei Wu, et al., Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells, Cancer Res 2004;64:1757-1764.;;Wei Wu, et al., Glucocorticoid receptor-induced MAPK Phosphatase-1 (MPK-1) Expression Inhibits Paclitaxel-associated MAPK Activation and contributes to Breast Cancer Cell Survival, vol. 280, No. 6, Issue of Feb. 11, pp. 4117-4124, 2005.;;Nathan Moore, et al., Slow-Cycling Therapy-Resistant Cancer Cells, Stem Cells and Development, vol. 00, No. 00, 2011.;;Paraskevi Moutsatsou, et al., The Glucocorticoid Receptor Signalling in Breast Cancer, J. Cell. Mol. Med. vol. 12, No. 1, 2008 pp. 145-163.;;H-C Lien, et al., Differential Expression of Glucocorticoid Receptor in Carcinomas of the Human Digestive System, Histopathology, 2008, 52, 314-324.;;Buxant, F. et al. Estrogen Receptor, Progesterone Receptor, and Glucocorticoid Receptor expression in normal beast tissue, breast in situ carcinoma, and invasive breast cancer, Appl Immunohistochem Mol Morphol, May 2010; 18 (3):254-7.;;Courtin A., Glucocorticoid Receptor Activity Discriminates between progesterone and medroxyprogesterone acetate effects in breast cells, Breast Cancer Res Treat, Jan. 2012;131(1):49-63, Epub Feb. 19, 2011.;;Tessel MA, Steroid Receptor and MicroRNA Regulation in Cancer, Curr. Opin Oncol. Nov. 2010;22(6):592-7.;;Zhou, et al, The human glucocorticoid receptor: One gene, multiple proteins and diverse responses, Steroids, 2005 70:407-417.;;Baschant, U, et al. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat. Rev. Rheumatol. 2012, 8:645-655.;;Vrzal, et al, Comparative effects of microtubules disruption on glucocorticoid receptor functions in proliferating nad quiescent cells. Int. J. Toxicol. 2010, 29:326:335.;;Anacker, C. et al. Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. Neuropsychopharmacology, 2013, 38:872-883.;;Solomon, et al, Chemoembolization of Hepatocellular Carcinoma with cisplatin, Doxorubicin, Mitomycin-C, Ethiodol, and Polyvinyl Alcohol: prospective Evaluation of Response and survival in a U. S. Population, J. Vasc Interv Radiol. Jun. 1999;10(6):793-8.;;Lauten, et al., Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia, (Journal of Hematology vol. 88(11): Nov. 2003.;;Cuzzocrea, et al., Estrogen Receptor antagonist Fulvestrant (ICI 182,780) Inhibits the Anti-Inflammatory Effect of Glucocorticoids, (Mol Pharmacol 71:132-144, 2007.;;Ikeda et al. Adult T-Cell Leukemia Cells Over-express the Multidrug-Resistnce-Protein (MRP) and Lung-Resistance-Protein (LRP) Genes (Int. J. Cancer: 82, 599-604 (1999).;;Wolkowitz, et al., Treatment of Depression with Antiglucocorticoid Drugs, Psychosomatic medicine 61:698-711 (1999).;;Kassi, et al. Glucocorticoid receptor signaling and prostate cancer, Cancer Letters 302 (2011)1-10.;;Yemelyanov, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate, Oncogene (2007)26, 1885-1896.;;Bekasi et al. Overexpression of Glucocorticoid Receptor in Human Pancreatic Cancer and in Xenografts. An immunohistochemical Study, Pathol. Oncol. Res. (2009) 15:561-566.;;Arora, et al., Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade, Cell 155, 1309-1322, Dec. 5, 2013.;;Written Opinion of PCT/US2012/023630 dated Nov. 30, 2012.",ACTIVE
11,US,A1,US 2014/0107086 A1,068-547-809-607-963,2014-04-17,2014,US 201314100714 A,2013-12-09,US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2014-03-13);;POP TEST CORTISOL LLC (2012-02-01),https://lens.org/068-547-809-607-963,Patent Application,yes,2,1,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/58;;A61K31/337;;B65D75/36,514/171;;206/532,1,1,029-430-665-993-012,16340307;;10.4161/cbt.4.12.2354,"Herr et al (Cancer Biology & Therapy 4:12, 1415-1416, 2005)",ACTIVE
12,EP,A4,EP 3316881 A4,131-585-855-364-819,2019-05-29,2019,EP 16898785 A,2016-04-11,US 201514802060 A;;US 2016/0026876 W,2015-07-17,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/131-585-855-364-819,Search Report,no,2,0,2,43,0,A61K45/06;;A61K31/167;;A61K31/4439;;A61K31/473;;A61K31/496;;A61K31/573;;A61K31/575;;A61K31/58;;A61K31/585,A61K31/357;;A61K31/395;;A61K31/4439;;A61K31/575;;A61K45/06;;A61P31/00;;A61P35/00,,2,1,110-065-681-613-625,pmc3782148;;24002508;;10.1200/jco.2013.50.1684,"RATHKOPF DANA E ET AL: ""Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer"", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 31, no. 28, 1 October 2013 (2013-10-01), pages 3525 - 3530, XP008166079, ISSN: 0732-183X, [retrieved on 20130903], DOI: 10.1200/JCO.2013.50.1684;;See also references of WO 2017180086A1",PENDING
13,US,B2,US 8986677 B2,140-344-447-694-762,2015-03-24,2015,US 201313837408 A,2013-03-15,US 201313837408 A;;US 201261741925 P,2012-07-30,Therapeutic compositions and methods,"This invention relates to the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention of addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc.",POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST CORTISOL LLC (2013-04-17);;POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/140-344-447-694-762,Granted Patent,yes,3,15,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/74;;A61K31/565;;A61K31/58;;A61K35/12;;A61K35/28;;A61K35/545;;A61K45/06,424/93.7;;424/78.08,4,2,136-362-228-591-549;;028-524-829-127-059,16434782;;10.2146/ajhp050264;;10.1016/s0024-3205(02)02336-6;;12493567,"PubChem Compound. Datasheet [online].PubChem Compound.Copyright 2009.National Center for Biotechnology Information.U.S. National Library of Medicine [retrieved on Dec. 9, 2013]. Retrieved from the Internet: .;;Dopheide, J.A. 2006.Recognizing and treating depression in children and adolescents. Clinical Reviews. American Journal of Health-System Pharmacists 63:233-243. specif. pp. 233-234.;;Waye K.P. et al. 2003. Effect of nighttime low frequency noise on the cortisol response to awakening and subjective sleep quality. Life Sciences 72: 863-875. specif. pp. 864-865, 867-868.;;ICN Pharmaceuticals. Jan. 2001.Corti-Cote, Cortisol Solid Phase Component System. Product Manual. pp. 1-11. specif. pp. 1-2 and 5.",ACTIVE
14,US,B2,US 9642866 B2,188-728-677-010-48X,2017-05-09,2017,US 201615095248 A,2016-04-11,US 201615095248 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2016-04-01),https://lens.org/188-728-677-010-48X,Granted Patent,yes,6,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,9,6,012-100-414-117-262;;026-297-014-916-946;;133-014-962-417-772;;057-546-013-547-180;;093-431-353-619-932;;037-199-529-897-764,pmc2671735;;19412444;;10.1038/sj.npp.1300226;;12838270;;18656950;;pmc3056881;;10.1021/ac800892h;;10.1093/jpepsy/jsh022;;15131138;;22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072,"Gallagher et al. (Neuropsychiatric Disease and Treatment 2006:2(1) 33-42).;;Elzinger et al. Neuropsychopharmacology (2003) 28, 1656-1665).;;Nilsson (Institutetionen for fydik, kemi och biologi, 2009).;;Yehuda et al2. Neuron Review (2007).;;Stevens et al. (Anal Chem. Sep. 1, 2008; 80(17): 6747-6751).;;Kazak et al. (J. pediatric Psychology 29(3); 211-219, 2004.;;Yehuda et al. http://primarypsychiatry.com/neuroendocrine-alterations-in-posttraumatic-stress-disorder/.;;Min, KJ et al, Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), Mar. 2012, 309-319, 90(3), 10,1007/s00109-011-0821-8. Epub Oct. 29, 2011, abstract.;;Peeters, BW et al. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocortocoid receptor unclear translocation in the AtT20 cell line. Ann. NY Acad. Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.",ACTIVE
15,CN,A,CN 109394770 A,192-856-344-942-028,2019-03-01,2019,CN 201811267478 A,2013-07-30,US 201261741925 P;;US 201313837408 A;;CN 201380051001 A,2012-07-30,Therapeutic compositions and methods,"The invention relates the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of Cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/192-856-344-942-028,Patent Application,no,1,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/58;;A61K35/28;;A61K35/545;;A61K45/06;;A61P25/22;;A61P25/30;;A61P25/36,,0,0,,,,DISCONTINUED
16,JP,A,JP 2018127492 A,190-319-669-027-964,2018-08-16,2018,JP 2018093828 A,2018-05-15,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"PROBLEM TO BE SOLVED: To provide a system that is beneficial for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist.SOLUTION: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG34517. A rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol acidity or disordered circadian rhythms as a method for screening GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.SELECTED DRAWING: Figure 1",POP TEST ONCOLOGY LLC,RANDICE LISA ALTSCHUL;;NEIL DAVID THEISE;;MYRON RAPKIN;;REBECCA O'BRIEN,,https://lens.org/190-319-669-027-964,Patent Application,no,4,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/567;;A61K45/00;;A61P25/20;;G01N33/53,,1,1,051-377-782-627-959,14996737;;10.1158/0008-5472.can-03-2546,"W. WU ET AL.: ""Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibit"", CANCER RESEARCH, vol. 64, JPN6015009438, 1 March 2004 (2004-03-01), pages 1757 - 1764, XP003025131, ISSN: 0003996180, DOI: 10.1158/0008-5472.CAN-03-2546",PENDING
17,JP,A,JP 2017025082 A,008-376-871-951-271,2017-02-02,2017,JP 2016175756 A,2016-09-08,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"PROBLEM TO BE SOLVED: To provide a system that is beneficial for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist.SOLUTION: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG34517. A rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol acidity or disordered circadian rhythms as a method for screening GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.SELECTED DRAWING: Figure 1",POP TEST ONCOLOGY LLC,RANDICE LISA ALTSCHUL;;NEIL DAVID THEISE;;MYRON RAPKIN;;REBECCA O'BRIEN,,https://lens.org/008-376-871-951-271,Patent Application,no,3,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/36;;A61K31/337;;A61K31/357;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P35/00;;A61P43/00,,1,1,051-377-782-627-959,14996737;;10.1158/0008-5472.can-03-2546,"W. WU ET AL.: ""Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibit"", CANCER RESEARCH, vol. 64, JPN6015009438, 1 March 2004 (2004-03-01), pages 1757 - 1764, XP003025131, ISSN: 0003720207, DOI: 10.1158/0008-5472.CAN-03-2546",PENDING
18,US,B2,US 10076528 B2,080-814-356-721-20X,2018-09-18,2018,US 201715854053 A,2017-12-26,US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC;;POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/080-814-356-721-20X,Granted Patent,yes,8,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61K45/06,,5,3,093-431-353-619-932;;037-199-529-897-764;;061-516-257-294-56X,22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072;;26089723;;10.3747/co.22.2517;;pmc4462534,"ChemoCare 2002.;;Goodmanand Gilman (1996 1225-1233 9th Edition.;;Min, KJ et al, Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), Mar. 2012, 309-319, 90(3), 10,1007/s00109-011-0821-8. Epub Oct. 29, 2011, abstract.;;Peeters, BW et al. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocortocoid receptor unclear translocation in the AtT20 cell line. Ann. NY Acad. Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.;;Narod, S.A., Have we given up on a cure for ovarian cancer? Current Oncology, vol. 22, No. 2, Jun. 2015, e139-e141.",ACTIVE
19,US,A1,US 2017/0211125 A1,002-570-905-387-754,2017-07-27,2017,US 201715481782 A,2017-04-07,US 201715481782 A;;US 201615388697 A;;US 201615155803 A;;US 201514684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and Formulations for Detecting, Screening and Monitoring Levels of Certain Constituents in Bodily Fluids and Method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/002-570-905-387-754,Patent Application,yes,1,0,8,32,0,G01N21/29;;G01N33/558;;G01N33/57438;;G01N33/66;;G01N33/92;;C12Q1/52;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N21/78;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N2021/752;;G01N21/29;;G01N33/57438;;G01N33/66;;G01N33/92;;G01N33/54388;;G01N33/52;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/523;;G01N33/98,C12Q1/62;;C12Q1/54;;C12Q1/60;;G01N33/52;;G01N33/98,,0,0,,,,ACTIVE
20,JP,A,JP 2015232024 A,064-480-189-483-744,2015-12-24,2015,JP 2015163180 A,2015-08-20,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"PROBLEM TO BE SOLVED: To provide a system that is beneficial for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist.SOLUTION: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG34517. A rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol acidity or disordered circadian rhythms as a method for screening GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LLC,RANDICE LISA ALTSCHUL;;NEIL DAVID THEISE;;MYRON RAPKIN;;REBECCA O'BRIEN,,https://lens.org/064-480-189-483-744,Patent Application,no,3,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/337;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P43/00,,0,0,,,,ACTIVE
21,EP,A1,EP 3316881 A1,077-878-116-255-013,2018-05-09,2018,EP 16898785 A,2016-04-11,US 201514802060 A;;US 2016/0026876 W,2015-07-17,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/077-878-116-255-013,Patent Application,yes,0,0,2,43,0,A61K45/06;;A61K31/167;;A61K31/4439;;A61K31/473;;A61K31/496;;A61K31/573;;A61K31/575;;A61K31/58;;A61K31/585,A61K31/357;;A61K31/395;;A61P31/00;;A61P35/00,,0,0,,,,PENDING
22,EP,A4,EP 2705366 A4,100-549-411-039-65X,2015-01-14,2015,EP 12779902 A,2012-05-04,US 201161518344 P;;US 2012/0036453 W,2011-05-04,DIAGNOSTIC DEVICE,,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/100-549-411-039-65X,Search Report,no,1,0,6,6,0,G01N33/558;;G01N21/8483;;G01N2021/8494;;G01N21/6486;;Y02A50/30;;G01N33/525;;G01N21/8483;;G01N2021/8494;;Y02A50/30;;G01N33/54388;;G01N21/6486,G01N33/558;;G01N21/64;;G01N21/84,,0,0,,,,ACTIVE
23,US,B2,US 10231982 B2,140-006-575-894-02X,2019-03-19,2019,US 201816050155 A,2018-07-31,US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/140-006-575-894-02X,Granted Patent,yes,1,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K31/58;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,0,0,,,,ACTIVE
24,WO,A3,WO 2014/022340 A3,167-569-701-252-087,2014-04-10,2014,US 2013/0052622 W,2013-07-30,US 201261741925 P;;US 201313837408 A,2012-07-30,THERAPEUTIC COMPOSTIONS AND METHODS,"This invention relates the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of Cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/167-569-701-252-087,Search Report,yes,3,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/56;;A61K35/28;;A61K35/545;;A61K45/06;;A61P17/02;;A61P19/08;;A61P19/10;;A61P25/30;;A61P37/06;;C12N5/0735;;C12N5/074;;C12N5/0789,,3,3,037-199-529-897-764;;094-188-044-195-186;;085-468-231-571-116,19120154;;10.1196/annals.1410.072;;15542767;;10.1196/annals.1316.073;;10.1001/archsurg.1994.01420360013001;;7986150,"PEETERS ET AL: ""DIFFERENTIAL EFFECTS OF THE NEW GLUCOCORTICOID RECEPTOR ANTAGONIST ORG 34517 ANDRU486 (MIFEPRISTONE) ON GLUCOCORTICOID RECEPTOR NUCLEAR TRANSLOCATION IN THE ATT20 CELL LINE"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1148, December 2008 (2008-12-01), pages 536 - 541, XP002726583;;KOBAYASHI T. ET AL.: ""Modulators of G protein-activated inwardly rectifying K+ channels: potentially therapeutic agents for addictive drug users"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1025, October 2004 (2004-10-01), pages 590 - 594, XP055182377;;ALEX C. CECH: ""GLUCOCORTICOID RECEPTOR BLOCKADE REVERSES POSTINJURY MACROPHAGE SUPPRESSION"", ARCHIVES OF SURGERY, vol. 129, no. 12, December 1994 (1994-12-01), pages 1227 - 1232, XP002080523",PENDING
25,EP,A1,EP 2699245 A1,027-498-715-382-868,2014-02-26,2014,EP 12774862 A,2012-04-16,US 201161517343 P;;US 2012/0033731 W,2011-04-18,HAIR LOSS TREATMENT,,POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/027-498-715-382-868,Patent Application,yes,0,0,4,4,0,A61K8/63;;A61K8/63;;A61K31/00;;A61K31/00;;A61K31/58;;A61K31/58;;A61K2800/782;;A61K2800/782;;A61P17/00;;A61P17/10;;A61P17/14;;A61P31/00;;A61Q7/00;;A61Q7/00,A61K31/58;;A61K8/63;;A61K31/00;;A61P17/00;;A61P17/14;;A61Q5/12;;A61Q7/00,,0,0,,,,DISCONTINUED
26,US,A1,US 2021/0361675 A1,051-762-484-195-642,2021-11-25,2021,US 202117392264 A,2021-08-03,US 202117392264 A;;US 201916691971 A;;US 201916251299 A;;US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIAN REBECCA,,https://lens.org/051-762-484-195-642,Patent Application,yes,0,2,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,0,0,,,,ACTIVE
27,US,B2,US 9366674 B2,063-863-303-321-880,2016-06-14,2016,US 201514684861 A,2015-04-13,US 201514684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-08),https://lens.org/063-863-303-321-880,Granted Patent,yes,1,1,2,32,0,G01N33/52;;C12Q1/52;;G01N33/558;;G01N2333/91188;;G01N21/29;;G01N33/57438;;G01N33/92;;G01N33/66;;G01N2800/085;;G01N33/57438;;G01N33/92;;G01N33/66;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N2333/91188;;G01N21/29;;G01N33/54388,G01N33/574;;C12Q1/52;;G01N21/29;;G01N33/52;;G01N33/558;;G01N33/66;;G01N33/92,,2,2,092-846-322-878-032;;011-793-407-045-692,10.1016/j.aca.2010.06.019;;20678634;;17272484;;10.1373/clinchem.2006.081257,"Dungchai et al. Analytica Chimica Acta, 2010, 674:227-233.;;Chang et al. Clinical Chemistry, 2007, 53:4:686-692.",ACTIVE
28,US,A1,US 2012/0201747 A1,063-586-225-563-303,2012-08-09,2012,US 201213364651 A,2012-02-02,US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2014-03-10);;POP TEST CORTISOL LLC (2012-02-01),https://lens.org/063-586-225-563-303,Patent Application,yes,2,22,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61J1/05;;A61K31/58;;A61K31/665;;A61K31/704;;A61K31/7068;;A61K31/7076;;A61K33/24;;A61K38/12;;A61K38/50;;A61K51/00;;A61N5/00;;A61P5/00;;A61P25/18;;A61P25/24;;A61P35/00;;A61P35/02;;B82Y5/00;;C07J17/00;;C40B30/04;;G01N33/53;;G01N33/566,424/1.11;;514/174;;514/171;;514/49;;424/649;;514/110;;514/48;;514/19.2;;514/34;;514/170;;424/94.6;;540/116;;436/501;;435/7.9;;506/9;;422/430;;600/1;;604/403;;977/773;;977/915,5,4,029-321-866-606-59X;;073-896-843-757-961;;034-094-105-568-465;;028-022-503-455-028,10392950;;10.1016/s1051-0443(99)70117-x;;14607754;;17035596;;10.1124/mol.106.029629;;10404077;;10.1002/(sici)1097-0215(19990812)82:4<599::aid-ijc21>3.0.co;2-r,"Solomon et al. J Vasc Interv Radiol. 1999 Jun;10(6):793-8;;Lauten et al. (journal of hematology vol. 88(11):november 2003);;Cuzzocrea et al (Mol Pharmacol 71:132-144, 2007);;Ikeda et al. (Int. J. Cancer: 82, 599-604 (1999).;;http://www.udel.edu/chem/C465/senior/fall98/Cancer2/methods.html (2004) 4 pages",ACTIVE
29,US,B2,US 8865693 B2,082-750-886-586-036,2014-10-21,2014,US 201213432174 A,2012-03-28,US 201213432174 A;;US 201161516227 P,2011-03-31,Prevention of infection,The invention relates to compounds and methods for the prevention and/or treatment of infection after stroke.,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST CORTISOL LLC (2012-03-28);;POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/082-750-886-586-036,Granted Patent,yes,4,2,7,7,0,A61K31/56;;A61K31/56;;A61K31/573;;A61P31/00;;A61P37/04,A61K31/56;;A61K31/33;;A61K31/573,514/183;;514/182,0,0,,,,INACTIVE
30,WO,A3,WO 2012/106514 A3,126-220-652-110-154,2013-01-31,2013,US 2012/0023630 W,2012-02-02,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates to a low cost rapid response diagnostic system to determine Cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal Cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in Cortisol levels in response to treatment.",POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/126-220-652-110-154,Search Report,yes,3,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,C07J1/00;;G01N33/74;;G01N33/52;;G01N33/53;;G01N33/58,,1,1,046-051-866-937-523,10511017;;10.1097/00006842-199909000-00011,"WOLKOWITZ, O.M. ET AL.: ""Treatment of depression with antiglucocortic oid drugs."", PSYCHOSOMATIC MEDICINE, vol. 61, 1999, pages 698 - 711, XP008170055",PENDING
31,US,A1,US 2017/0202859 A1,183-302-807-374-91X,2017-07-20,2017,US 201715478368 A,2017-04-04,US 201715478368 A;;US 201615095248 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161519323 P;;US 201161518248 P;;US 201161465703 P;;US 201161463212 P;;US 201161462492 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/183-302-807-374-91X,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58,,0,0,,,,ACTIVE
32,US,B2,US 10537586 B2,062-278-843-413-678,2020-01-21,2020,US 201916251299 A,2019-01-18,US 201916251299 A;;US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/062-278-843-413-678,Granted Patent,yes,9,6,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,6,3,093-431-353-619-932;;037-199-529-897-764;;061-516-257-294-56X,22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072;;26089723;;10.3747/co.22.2517;;pmc4462534,"Goodman and Gilman (ninth edition, 1996, 1225-1232.;;Min, KJ et al, Glucocorticold receptor antagonist sensitizes TRAIL-induced apoptosis in renal cardinoma cells through up-regulation of DRS and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), Mar. 2012, 309-319, 90(3), 10, 1007s00109-011-0821-8 Epub Oct. 29, 2011, abstract.;;Peeters, BW et al. Differential effects of new glucocorticoid receptor antagonist ORG 34517 and ru486 (mifepristone) on glucocortocold receptor unclear translocation in the AIT20 cell line. Ann NY Acad Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.;;Narod, S.A., Have we given up on a cure for ovarian cancer? Current Oncology, vol. 22, No. 2, Jun. 2015, e139-e141.;;ChemoCare 2002.;;Goodman and Gilman (1996 1225-1233 9th Edition.",ACTIVE
33,US,A1,US 2012/0263660 A1,076-833-125-438-449,2012-10-18,2012,US 201213447345 A,2012-04-16,US 201213447345 A;;US 201161517343 P,2011-04-18,Hair Loss Treatment,This invention relates to the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or treatment of stress induced hair loss.,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST CORTISOL LLC (2012-04-13);;POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/076-833-125-438-449,Patent Application,yes,4,9,4,4,0,A61K8/63;;A61K8/63;;A61K31/00;;A61K31/00;;A61K31/58;;A61K31/58;;A61K2800/782;;A61K2800/782;;A61P17/00;;A61P17/10;;A61P17/14;;A61P31/00;;A61Q7/00;;A61Q7/00,A61K31/58;;A61K8/63;;A61K8/66;;A61K8/67;;A61K8/92;;A61K8/97;;A61K31/704;;A61K36/886;;A61K38/43;;A61P17/00;;A61P17/10;;A61P17/14;;A61P31/00;;A61Q1/12;;A61Q3/02;;A61Q5/02;;A61Q5/04;;A61Q5/06;;A61Q5/10;;A61Q5/12;;A61Q9/02;;A61Q9/04;;A61Q15/00;;A61Q17/04;;A61Q19/00;;A61Q19/02;;A61Q19/04;;A61Q19/10;;B65D69/00,424/59;;514/172;;424/69;;424/61;;424/65;;424/62;;514/174;;8/405;;424/94.1;;424/63;;424/744;;514/33;;206/570,0,0,,,,DISCONTINUED
34,US,B2,US 8889427 B2,114-407-861-346-811,2014-11-18,2014,US 201213463956 A,2012-05-04,US 201213463956 A;;US 201161518344 P,2011-05-04,Diagnostic device,"The invention provides for rapid response analysis through lateral flow chromatographic assays of specific antigens present in human or animal fluids, or in agricultural, microbial or biological products, with an audio and visual result of the analysis and when needed, an electronic surge to provide heat for rapid results. A lateral flow device for conducting the analysis includes a plurality of components, and a method for making the device forms components of the device on an elongate, ribbon-like substrate of dielectric material, then folds the substrate into shorter lengths which are then secured together to establish a multiple-layered, self-sustaining structure.",ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2012-05-03),https://lens.org/114-407-861-346-811,Granted Patent,yes,24,1,6,6,0,G01N33/558;;G01N21/8483;;G01N2021/8494;;G01N21/6486;;Y02A50/30;;G01N33/525;;G01N21/8483;;G01N2021/8494;;Y02A50/30;;G01N33/54388;;G01N21/6486,G01N33/558;;G01N21/64;;G01N21/84;;G01N33/52,436/514,9,5,040-582-260-914-903;;007-356-231-902-653;;017-402-213-772-16X;;159-337-591-879-942;;020-095-322-220-402,10.1016/0076-6879(81)73054-4;;7300683;;15734566;;10.1016/j.ijfoodmicro.2004.07.021;;10.1021/jf021020i;;12797729;;10.1016/0021-9673(95)01274-5;;10.1016/s0021-9673(96)00486-4,"Deluca, et al.""Immunofluorescence Analysis"" in antibody as a Tool, Marchalonism et al. eds. John Wiley & Sons, Itd. pp. 189-231 (1982).;;Galfre, et al., Meth Enzymol, 73:3-46 (1981).;;Aurameas, et al. Scand. J. Immunol. vol. 8 Suppl. 7:7-23.;;Rodwell, et al. Biotech., 3:889-894(1984).;;Burns,, ed., Immunochemical Protocols, 3rd ed Humana Press (2005) pp. 27, 28, 41, 42, 71, 72, 97, 98, 123, 124, 127, 128, 135, 136, 207, 208, 209.;;Sun Xiulan, et al Preparation of Gold Labeled Antibody Probe and its use in Immunochromatography Assay for detection of aflatoxim B1, Internatioanl Journal of Food Microbiology 99 (2005) 185-194.;;J.K.Lee, et al. J. Agric Food Chem. 2003, 51, 3695-3703.;;J.F. Lawrence, et al., J. Chromatography (1996) 732, 277-281.;;J.F. Lawrence, et al. J. Chromatography (1996) 752-147-154.",INACTIVE
35,US,A1,US 2021/0008080 A1,123-101-949-435-872,2021-01-14,2021,US 201916691971 A,2019-11-22,US 201916691971 A;;US 201916251299 A;;US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/123-101-949-435-872,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61K9/00;;A61K45/06;;A61K51/00;;A61N5/10,,0,0,,,,ACTIVE
36,EP,A4,EP 2712317 A4,139-821-871-503-367,2015-03-04,2015,EP 12762996 A,2012-03-28,US 201161516227 P;;US 2012/0030832 W,2011-03-31,PREVENTION OF INFECTION,,POP TEST CORTISOL LLC;;O'BRIEN REBECCA,O'BRIEN REBECCA;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON,POP TEST ONCOLOGY LLC (2018-06-06),https://lens.org/139-821-871-503-367,Search Report,no,1,0,7,7,0,A61K31/56;;A61K31/56;;A61K31/573;;A61P31/00;;A61P37/04,A61K31/56;;A61K31/00;;A61K31/04;;A61K31/57;;A61K31/573;;A61K31/58;;A61P37/04,,4,3,116-374-221-772-50X;;018-475-262-809-567;;063-320-387-942-981,10051210;;10.1016/s0306-4522(98)00213-9;;12053008;;10.1161/01.str.0000016967.76805.bf;;12939340;;pmc2194193;;10.1084/jem.20021098,"ANTONAWICH F J ET AL: ""Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone"", NEUROSCIENCE, NEW YORK, NY, US, vol. 88, no. 1, 1 January 1999 (1999-01-01), pages 319 - 325, XP002476026, ISSN: 0306-4522, DOI: 10.1016/S0306-4522(98)00213-9;;N. SUGO ET AL: ""Social Stress Exacerbates Focal Cerebral Ischemia in Mice"", STROKE, vol. 33, no. 6, 1 June 2002 (2002-06-01), pages 1660 - 1664, XP055162738, ISSN: 0039-2499, DOI: 10.1161/01.STR.0000016967.76805.BF;;K. PRASS ET AL: ""Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1-like Immunostimulation"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 5, 2 September 2003 (2003-09-02), pages 725 - 736, XP055162482, ISSN: 0022-1007, DOI: 10.1084/jem.20021098;;See also references of WO 2012135274A1",ACTIVE
37,US,A1,US 2012/0245552 A1,143-426-202-206-335,2012-09-27,2012,US 201213425964 A,2012-03-21,US 201213425964 A;;US 201161465704 P;;US 201161516035 P;;US 201161516970 P,2011-03-23,Combination Therapy,This invention relates to compositions and methods for treating GC-responsive conditions and for reducing and preventing side-effects of GC treatment in patients.,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST CORTISOL LLC (2012-03-21);;POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/143-426-202-206-335,Patent Application,yes,1,2,4,4,0,A61K45/06;;A61K45/06;;A61K31/573;;A61K31/573;;A61P1/00;;A61P1/18;;A61P5/00;;A61P7/00;;A61P9/00;;A61P13/00;;A61P13/10;;A61P13/12;;A61P19/00;;A61P19/04;;A61P21/00;;A61P25/00;;A61P27/00;;A61P29/00,A61J1/05;;A61J1/00;;A61K31/573;;A61P1/00;;A61P1/18;;A61P5/00;;A61P7/00;;A61P9/00;;A61P13/00;;A61P13/10;;A61P13/12;;A61P19/00;;A61P19/04;;A61P21/00;;A61P25/00;;A61P27/00;;A61P29/00,604/403;;514/171;;206/438;;206/570,1,1,037-199-529-897-764,19120154;;10.1196/annals.1410.072,"Peeters, BWMM et al. Differential Effects of the New Glucocorticoid Receptor ORG34517 and RU486 (Mifepristone) on Glucocorticoid Receptor Nuclear Translocation in the AtT20 Cell Line. Ann. NY Acad Sci. 1148:536-541 (2008).",DISCONTINUED
38,EP,A4,EP 2671086 A4,012-604-791-423-838,2014-09-03,2014,EP 12742639 A,2012-02-02,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P;;US 2012/0023630 W,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,,POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2018-01-17),https://lens.org/012-604-791-423-838,Search Report,no,0,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,G01N33/74;;A61P35/00;;C07J1/00;;G01N33/52;;G01N33/53;;G01N33/58,,1,1,037-199-529-897-764,19120154;;10.1196/annals.1410.072,"PEETERS B W ET AL: ""Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1148, 1 December 2008 (2008-12-01), pages 536 - 541, XP002726583, ISSN: 0077-8923, [retrieved on 20081211], DOI: 10.1196/ANNALS.1410.072",ACTIVE
39,US,B2,US 9861643 B2,037-655-242-630-719,2018-01-09,2018,US 201715471123 A,2017-03-28,US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161519323 P;;US 201161518248 P;;US 201161465703 P;;US 201161463212 P;;US 201161462492 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/037-655-242-630-719,Granted Patent,yes,8,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61K45/06,,3,3,007-882-274-947-050;;093-431-353-619-932;;037-199-529-897-764,26089714;;pmc4462525;;10.3747/co.22.2457;;22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072,"Narod (Current Oncology, vol. 22, No. 3, Jun. 2015).;;Min, KJ et al, Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), Mar. 2012, 309-319, 90(3), 10,1007/s00109-011-0821-8. Epub Oct. 29, 2011, abstract.;;Peeters, BW et al. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocortocoid receptor unclear translocation in the AtT20 cell line. Ann. NY Acad. Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.",ACTIVE
40,US,A1,US 2015/0366881 A1,070-621-940-878-114,2015-12-24,2015,US 201514801939 A,2015-07-17,US 201514801939 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/070-621-940-878-114,Patent Application,yes,0,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K9/00;;A61K31/58;;A61K31/337,,0,0,,,,ACTIVE
41,US,B2,US 8658128 B2,145-889-037-749-099,2014-02-25,2014,US 201213364651 A,2012-02-02,US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2014-03-10);;POP TEST CORTISOL LLC (2012-02-01),https://lens.org/145-889-037-749-099,Granted Patent,yes,24,51,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K51/00;;A61K31/58;;A61K33/24;;A61K38/46,424/1.11;;424/649;;424/94.6;;514/174;;514/171,68,64,029-321-866-606-59X;;073-896-843-757-961;;034-094-105-568-465;;028-022-503-455-028;;046-051-866-937-523;;025-236-889-877-681;;072-017-135-003-528;;075-604-848-120-332;;022-427-234-675-993;;027-610-441-797-691;;098-970-572-904-025;;039-764-013-605-830;;077-911-867-689-885;;004-051-499-572-775;;006-030-973-019-783;;028-006-068-536-463;;000-990-435-802-906;;070-731-131-146-498;;146-449-089-963-596;;028-834-962-521-841;;019-082-741-537-174;;078-818-133-871-602;;152-497-600-208-517;;010-540-968-978-319;;033-884-765-849-131;;048-310-550-318-36X;;099-883-114-833-005;;028-428-571-584-841;;023-364-956-890-880;;046-322-433-866-098;;035-083-000-444-258;;040-582-260-914-903;;054-980-079-955-454;;192-609-714-372-280;;096-741-767-207-949;;014-065-259-226-128;;081-376-983-952-92X;;035-784-409-496-514;;022-633-679-770-667;;010-671-218-365-329;;008-292-323-806-999;;016-114-899-296-280;;084-085-138-348-898;;019-711-514-953-919;;011-287-801-985-920;;085-543-600-111-869;;046-778-406-329-065;;099-369-779-864-138;;007-571-797-644-640;;015-454-506-279-186;;051-377-782-627-959;;002-098-985-648-398;;080-562-942-546-792;;014-163-707-036-635;;035-869-118-228-758;;008-917-378-114-698;;102-621-078-333-789;;045-570-917-520-663;;018-251-894-793-513;;025-901-082-859-148;;090-455-915-702-488;;013-888-136-576-823;;085-543-600-111-869;;088-946-508-144-700,10392950;;10.1016/s1051-0443(99)70117-x;;14607754;;17035596;;10.1124/mol.106.029629;;10404077;;10.1002/(sici)1097-0215(19990812)82:4<599::aid-ijc21>3.0.co;2-r;;10511017;;10.1097/00006842-199909000-00011;;16236742;;10.1056/nejmra050541;;10.1111/j.1365-2265.2004.02106.x;;15355454;;15634032;;10.2165/00003088-200544010-00003;;3041279;;10.1056/nejm198808183190706;;10.1210/edrv-17-2-187;;8706631;;10.1210/er.17.2.187;;1645586;;10.1016/0960-0760(91)90312-s;;10.1177/070674379804300307;;9561317;;pmc1188541;;8297920;;10.2165/11587620-000000000-00000;;21175239;;10.1038/nbt1085-889;;10.1136/jnnp.23.1.56;;14399272;;pmc495331;;10.1037/t04100-000;;10.1097/00005053-198409000-00002;;6470694;;10.1177/070674378503000312;;2986814;;1984391;;10.7326/0003-4819-114-2-143;;15268748;;10.1111/j.1474-9728.2004.00103.x;;16300484;;10.1111/j.1474-9726.2005.00178.x;;10.1016/j.biopsych.2003.12.021;;15110738;;7961563;;20859106;;10.1097/01.pra.0000388624.91039.a3;;10.1097/med.0b013e32833de61c;;20717020;;pmc2957510;;10.1016/j.schres.2010.07.012;;20692814;;10553730;;10.1176/ajp.156.11.1686;;10764142;;10.1038/sj.leu.2401743;;10.1210/jcem.86.8.7740;;11502780;;10.1210/jc.86.8.3568;;16782211;;10.1016/j.bbr.2006.03.039;;19888560;;10.1007/s12325-009-0070-1;;10.1016/0076-6879(81)73054-4;;7300683;;14680969;;10.1016/j.pep.2003.09.003;;14522905;;15378086;;10.1038/sj.onc.1207946;;8855227;;pmc38202;;10.1073/pnas.93.20.10614;;pmc20056;;9122163;;10.1073/pnas.94.6.2150;;10.1016/0092-8674(89)90237-7;;2644044;;10.1146/annurev.bi.63.070194.002315;;10.1146/annurev.biochem.63.1.451;;7979245;;7857868;;10.1016/0960-0760(94)00155-f;;10.1182/blood-2004-03-0901;;15242869;;10.1073/pnas.0307618100;;14711994;;pmc321758;;10.1073/pnas.0530291100;;pmc153034;;12629218;;10.1158/0008-5472.can-05-2018;;16322242;;16230395;;10.1158/0008-5472.can-05-1343;;21818591;;10.1007/s10549-011-1689-6;;10.1016/j.steroids.2011.03.001;;21414337;;pmc3514452;;10.1158/0008-5472.can-11-0362;;21868756;;10.4161/cbt.5.8.2875;;16775428;;10706096;;14996737;;10.1158/0008-5472.can-03-2546;;15590693;;10.1074/jbc.m411200200;;10.1089/scd.2011.0477;;21973238;;pmc3376467;;18053085;;pmc3823477;;10.1111/j.1582-4934.2007.00177.x;;18269582;;10.1111/j.1365-2559.2007.02953.x;;10.1097/pai.0b013e3181c10180;;19875955;;21336598;;10.1007/s10549-011-1394-5;;20739888;;10.1097/cco.0b013e32833ea80c;;15862824;;10.1016/j.steroids.2005.02.006;;23045254;;10.1038/nrrheum.2012.166;;20448266;;10.1177/1091581810366486;;23303060;;pmc3672002;;10.1038/npp.2012.253;;21818591;;10.1007/s10549-011-1689-6;;22578718;;10.1016/j.molmed.2012.04.005,"Solomon et al. J Vasc Interv Radiol. Jun. 1999;10(6):793-8.;;Lauten et al. (journal of hematology vol. 88(11):Nov. 2003).;;Cuzzocrea et al (Mol Pharmacol 71:132-144, 2007).;;Ikeda et al. (Int. J. Cancer: 82, 599-604 (1999).;;http://www.udel.edu/chem/C465/senior/fall98/Cancer2/methods.html (2004) 4 pages.;;Wolkowitz, O.M., Treatment of Depression with Antiglucocorticoid Drugs. Psychosomatic Medicine. 61:698-711 (1999).;;PCT/US2012/023630 Written Opinion, Nov. 30, 2012.;;Turk Rhen, PhD., et al. Antiinflammatory Action of Glucocorticoids-New Mechanisms for Old Drugs, Ja. NEJM 2005; 353: 1711-23.;;Mah, et al., Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency, Clinical Endocrinology (2004) 61, 367-375.;;Crock, et al. Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids, Clin. Pharmacokinet (2005) 44, 61-98.;;Gold, et al. Clinical and Biomedical Manifest, New England J. Med. 319, 413-420, 1988.;;Florian Holsboer and Nicholas Barden, Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation, Endocrine Reviews 1996, 1vol. 7, 187-205.;;Beverley E. Pearson Murphy, Steroids and Depression, Steroid Biochem. and Mol. Biol. 1991, 38, 537-559.;;Avrameas, S., et al. Coupling of enzymes to Antibodies and Antigens, Scand. J. Immunol., vol. 8 Suppl. 7:7-23 (1978).;;Murphy, et al. Neuroendocrine Responses to Inhibitors of Steroid Biosynthesis in Patients With Major Depression Resistant to Antidepressant Therapy, Can. J. Psych. 43, 279-286, 1998.;;Murphy, et al., Possible Use of Glucocorticoid Receptor Antagonists in the Treatment of Major Depression: Preliminary Results Using RU 486, J. Psychiat. Neurosci. 18, 209-213, 1993.;;Connolly, K.R., et al., If at First You Don't Succeed, Drugs. 2011; 71: 43-64.;;Rodwell, et al., Linker Technology: Antibody-Mediated Delivery Systems, Biotech., 3:889-894 (1984).;;Max Hamilton, A rating scale for depression, J. Neurol. Neurosurg. Psychiat. 1960, 23, 56-62.;;W. Coryell, M.D., et al. The Clinical and Neuroendocrine Features of Psychotic Depression (1984) J. Nerv. Ment. Dis. 172:521.;;Stephen N. Gerson, M.D., Cushing Disease Presenting as Atypical Psychosis Followed by Sudden Death, Can. J. Psychiatry 30:223-224 Apr. 1985.;;Aart-Jan Van Der Lely, et al. Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (1991) Annals of Internal Med. 114:143.;;Stephen K. Butcher and Janet M. Lord, Stress Responses and innate Immunity: aging as a Contributory Factor (2004) Aging Cell, pp. 151-160.;;Butcher, et al. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and Immunity (2005), Aging Cell 5, pp. 319-324).;;Lindley, et al. Basal and dexamethasone suppressed salivary cortisol concentrations in a community sample of patients with postraumatic stress disorder, Biol. Psychiatry 2004; 55: 940-5.;;Daniel S. G. Umbricht, et al., Clozapine and Weight Gain, J Clin. Psychiatry 1994; 55: 157-160.;;Khan, et al. The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review J Psychiatr Pract. 2010;16: 289-96.;;Pornpoj Pramyothin and Lalita Khaodhair, Metabolic Syndrome with the Atypical Antipsychotics, Curr Opin Endocrinol Diabetes Obes. 2010; 17: 460-466.;;Rummel-Kluge, et al. Head-to-Head comparisons of metabolic side effects of second generation antipsychotics in the treatment of Schizophrenia: A systematic review and meta-analysis Schizophr Res. 2010; 123: 225-33.;;Allison, et al. Antipsychotic-Induced Weight Gain: A comprehensive Research Synthesis, Am J Psychiatry 156:1686-1696 (Nov. 1999).;;AE Frankel, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias, Leukemia 14:576 (2000).;;Chu, et al., Successful Long-Term Treatment of Refractory Cushing's Disease with High-dose Mifepristone (RU 486) J. Clin. Endocrinol. Metab. 2001; 86, 3568-3573.;;Beebe, et al., The efficacy of Mifepristone in the reduction and prevention of Olanzapine-induced weight gain in rats Behav. Brain Res. 2006; 171, 225-229.;;Gross, et al., Mifepristone Treatment of Olanzapine-Induced Weight Gain in Healthy Men, Adv Ther. 2009; 26:959-69.;;Dominick Deluca, ""Immunofluorescence Analysis"", in Antibody As a Tool, Marchalonis, et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982.;;G. Galfre and C. Milstein, Preparation of Monoclonal Antibodies: Strategies and Procedures, Meth. Enzymol., 73:3-46 (1981.;;J. Urieto, et al. Expression and purification of the recombinant diphtheria fusion Toxin DT388IL3 for phase I clinical trials, Protein Expression and Purification 33: 123-133 (2004).;;S. Singh, et al., ""Identification of a cancer stem cell in human brain tumors,"" Cancer Res. 63:5821-5828 (2003).;;S. Singh et al. ""Cancer Stem Cells in Nervous System Tumors"", Oncogene 23:7267-7273 (2004).;;M. Schena, et al. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes (1996) Proc. Natd. Acad. Sci. 93:10614-10619.;;R. Heller, et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays, (1997) Pro. Natl. Acad. Sci. 94:2150-2155.;;Beato, Miguel, Gene Regulation by Steroid Hormones (1989) Cell vol. 56, 335-344.;;Ming-Jer Tsai and Bert W. O'Malley, Molecular Mechanisms of Action of Steroid/Thyroid Receptor SuperFamily Members (1994) Annu. Rev. Biochem. 63, 451-486.;;G Akner, et al., Subcellular Distribution of the Glucocorticoid Receptor and Evidence for its Association with Microtubules J. Steroid Biochem. Mol. Biol. 52, 1-16, (1995).;;Cox et al., Characterization of Acute lymphoblastic leukemia progenitor cells, Blood 104(19): 2919-2925 (2004).;;Kondo, et al. Persistence of a small subpopulation of cancer stem-like cells in the C6 Glioma cell line Proc. Natl. Acad. Sci. USA 101:781-786 (2004).;;Muhammad Al-Hajj, et al. Prospective identification of Tumorigenic Breast Cancer Cells, Proc. Natl. Acad. Sci. USA 100:3983-3988 (2003).;;Collins, et al., ""Prospective Identification of Tumorigenic Prostate Cancer Stem Cells,"" Cancer Res 65(23):10946-10951 (2005).;;Fang, et al., ""A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas,"" Cancer Res 65(20): 9328-9337 (2005).;;Myriam Vilasco, et al., Glucocorticoid Receptor and Breast Cancer, Breast Cancer Res Treat(2011)130:1-10.;;Donita Africader, Molecular Mechanisms of Steroid Receptor-mediated actions by Synthetic Progestins Used in HRT and Contraception, Steroids 76 (2011) 636-652.;;Deng Pan, et al. Activation of Glucocorticoid Receptor is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer, Cancer Res 2011;71:6360-6370.;;Diana Pang, et al. Dexamethasone Decreases Xenograft Response to Paclitaxel Through Inhibition of Tumor Cell Apoptosis, Cancer biology & Therapy 5:8, 933-940, Aug. 2006.;;Timothy J. Moran, et al., The Glucocorticoid Receptor Mediates a Survival Signal in Human Mammary Epithelial Cells, Cancer Res. 2000;60:867-872.;;Wei Wu, et al., Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells, Cancer Res 2004;64:1757-1764.;;Wei Wu, et al., Glucocorticoid receptor-induced MAPK Phosphatase-1 (MPK-1) Expression Inhibits Paclitaxel-associated MAPK Activation and contributes to Breast Cancer Cell Survival, vol. 280, No. 6, Issue of Feb. 11, pp. 4117-4124, 2005.;;Nathan Moore, et al., Slow-Cycling Therapy-Resistant Cancer Cells, Stem Cells and Development, vol. 00, No. 00, 2011.;;Paraskevi Moutsatsou, et al., The Glucocorticoid Receptor Signalling in Breast Cancer, J. Cell. Mol. Med. vol. 12, No. 1, 2008 pp. 145-163.;;H-C Lien, et al., Differential Expression of Glucocorticoid Receptor in Carcinomas of the Human Digestive System, Histopathology, 2008, 52, 314-324.;;Buxant, F. et al. Estrogen Receptor, Progesterone Receptor, and Glucocorticoid Receptor expression in normal beast tissue, breast in situ carcinoma, and invasive breast cancer, Appl Immunohistochem Mol Morphol, May 2010; 18(3):254-7.;;Courtin A., Glucocorticoid Receptor Activity Discriminates between progesterone and medroxyprogesterone acetate effects in breast cells, Breast Cancer Res Treat, Jan. 2012;131(1):49-63, Epub Feb. 19, 2011.;;Tessel MA, Steroid Receptor and MicroRNA Regulation in Cancer, Curr. Opin Oncol. Nov. 2010;22(6):592-7.;;Zhou, J. et al. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids, 2005, 70:407-417.;;Baschant, U. et al. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat. Rev. Rheumatol. 2012, 8:645-655.;;Vrzal, R. et al. Comparative effects of microtubules disruption on glucocorticoid receptor functions in proliferating and quiescent cells. Int. J. Toxicol. 2010, 29:326-335.;;Anacker, C. et al. Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. Neuropsychopharmacology. 2013, 38:872-883.;;Vilasco, M. et al. Glucocorticoid receptor and breast cancer. Breast Cancer Res. Treat. 2011, 130:1-10.;;Moutsatsou, P. et al. Glucocorticoid receptor signaling in bone cells. Trends Mol. Med. 2012, 18:348-359.",ACTIVE
42,EP,A1,EP 3395347 A1,192-773-239-688-968,2018-10-31,2018,EP 18175779 A,2013-07-30,US 201261741925 P;;US 201313837408 A;;EP 13824861 A;;US 2013/0052622 W,2012-07-30,THERAPEUTIC COMPOSITIONS FOR TREATING ADDICTION,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention of addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc.
",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/192-773-239-688-968,Patent Application,yes,12,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/58;;A61K35/28;;A61K35/545;;A61K45/06;;A61P25/36,,37,31,029-246-439-288-649;;037-199-529-897-764;;025-236-889-877-681;;035-784-409-496-514;;019-490-428-734-203;;022-633-679-770-667;;010-671-218-365-329;;003-208-707-292-88X;;024-188-874-869-363;;049-759-168-776-163;;016-420-757-875-004;;155-397-001-403-661;;082-220-201-284-919;;126-109-329-996-893;;155-397-001-403-661;;018-953-278-576-570;;108-475-590-069-580;;001-884-727-265-660;;088-903-320-289-510;;004-077-820-380-629;;117-917-505-944-451;;059-261-751-454-502;;104-971-501-025-592;;071-535-527-040-313;;114-868-541-492-803;;079-248-305-753-026;;136-585-974-103-867;;049-511-830-248-64X;;084-593-952-947-714;;023-406-300-972-157;;036-784-657-029-073,10.1016/s1734-1140(11)70479-0;;19120154;;10.1196/annals.1410.072;;16236742;;10.1056/nejmra050541;;10.1016/0092-8674(89)90237-7;;2644044;;10.1210/edrv-11-2-201;;2194782;;10.1146/annurev.bi.63.070194.002315;;10.1146/annurev.biochem.63.1.451;;7979245;;7857868;;10.1016/0960-0760(94)00155-f;;10.1016/0092-8674(92)90317-6;;1381289;;12077603;;10.1038/nature00870;;10.1016/j.cell.2004.11.011;;15620358;;19252477;;10.1038/nature07864;;pmc2667910;;10.1038/nature05142;;16929302;;17667917;;10.1038/cr.2007.61;;16227970;;10.1038/nature04277;;10.1038/nature05142;;16929302;;18371431;;10.1016/j.stem.2007.12.013;;16990582;;10.1634/stemcells.2006-0377;;12634411;;10.1634/stemcells.21-2-152;;18941782;;10.1007/s00441-008-0696-3;;18615777;;10.1002/term.107;;18065397;;pmc3311226;;10.1634/stemcells.2007-0439;;10.1089/clo.2007.0027;;18154518;;10.1046/j.1365-2141.2003.04284.x;;12694261;;10.1089/scd.2009.0177;;19619003;;10.1007/978-3-642-77925-1;;10.1002/pen.20600;;16359251;;10.1586/17434440.3.1.29;;10.1055/s-0037-1613389;;12624643;;10656542;;10.1106/emcm-k7qc-gwgx-1k4v;;10.1177/088532820001400303;;7948588;;10.1016/0142-9612(94)90164-3;;17257666;;10.1016/j.biomaterials.2007.01.002,"JAVIER NAVARRO-ZARAGOZA ET AL: ""PS V - 3 Glucocorticoid (GC) receptor antagonist mifepristone attenuates morphine withdrawal behaviors"", PHARMACOLOGICAL REPORTS, 13 April 2011 (2011-04-13), European Opioid Conference; Krakow, POLAND; April 13 -15, 2011, pages 253 - 254, XP055247580, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1734114011704790/1-s2.0-S1734114011704790-main.pdf?_tid=74e2833c-cb40-11e5-af9e-00000aab0f02&acdnat=1454591520_2543248385ba0cfca70f3c03bd767647> [retrieved on 20160204];;PEETERS B W ET AL: ""Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1148, 1 December 2008 (2008-12-01), pages 536 - 541, XP002726583, ISSN: 0077-8923, [retrieved on 20081211], DOI: 10.1196/ANNALS.1410.072;;RHEN T; CIDLOWSKI JA, NEJM, vol. 353, 2005, pages 1711 - 23;;GASC, J. -M.; BAULIEU, E. E.: ""Steroid Hormone Receptors: Their Intracellular Localisation"", 1987, ELLIS HORWOOD LTD., pages: 233 - 250;;BEATO, M., CELL, vol. 56, 1989, pages 335 - 344;;CARSON-JURICA, M. A.; SCHRADER, W. T.; O'MALLEY, B. W., ENDOCR. REV., vol. 11, 1990, pages 201 - 220;;GRONEMEYER, H.: ""Steroid Hormone Action"", 1993, OXFORD UNIVERSITY PRESS, pages: 94 - 117;;TSAI, M. J.; O'MALLEY, B. W., ANNU. REV. BIOCHEM., vol. 63, 1994, pages 451 - 486;;AKNER, G.; WIKSTROM, A. C.; GUSTAFSSON, J. A., J. STEROID BIOCHEM. MOL. BIOL., vol. 52, 1995, pages 1 - 16;;T.W. GREEN: ""Protective Groups in Organic Synthesis"", 1981, WILEY;;GENNARO ET AL., REMINGTON'S PHARMACEUTICAL SCIENCES;;MATSUI ET AL.: ""Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture"", CELL, vol. 70, 1992, pages 841 - 847, XP024245512, DOI: doi:10.1016/0092-8674(92)90317-6;;JIANG ET AL.: ""Pluripotency of mesenchymal stem cells derived from adult marrow"", NATURE, vol. 418, 2002, pages 41 - 49, XP002559664, DOI: doi:10.1038/nature00870;;KANATSU-SHINOHARA ET AL.: ""Generation of pluripotent stem cells from neonatal mouse testis"", CELL, vol. 119, 2004, pages 1001 - 1012, XP002985005, DOI: doi:10.1016/j.cell.2004.11.011;;KAJI ET AL.: ""Virus-free induction of pluripotency and subsequent excision of reprogramming factors"", NATURE, 1 March 2009 (2009-03-01);;KLIMANSKAYA I; CHUNG Y; BECKER S; LU S J; LANZA R: ""Human embryonic stem cell lines derived from single blastomeres"", NATURE, vol. 444, 2006, pages 512, XP055307055, DOI: doi:10.1038/nature05366;;LEI ET AL.: ""Xeno-free derivation and culture of human embryonic stem cells: current status, problems and challenges"", CELL RESEARCH, vol. 17, 2007, pages 682 - 688;;CHUNG Y; KLIMANSKAYA I; BECKER S ET AL.: ""Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres"", NATURE, vol. 439, 2006, pages 216 - 219, XP007901044, DOI: doi:10.1038/nature04277;;KLIMANSKAYA I; CHUNG Y; BECKER S ET AL.: ""Human embryonic stem cell lines derived from single blastomeres"", NATURE, vol. 444, 2006, pages 481 - 485, XP009076989, DOI: doi:10.1038/nature05142;;CHUNG Y; KLIMANSKAYA I; BECKER S ET AL.: ""Human embryonic stem cell lines generated without embryo destruction"", CELL STEM CELL, vol. 2, 2008, pages 113 - 117;;ZHANG X; STOJKOVIC P; PRZYBORSKI S ET AL.: ""Derivation of human embryonic stem cells from developing and arrested embryos"", STEM CELLS, vol. 24, 2006, pages 2669 - 2676, XP002471258, DOI: doi:10.1634/stemcells.2006-0377;;LIN ET AL.: ""Multilineage potential of homozygous stem cells derived from metaphase II oocytes"", STEM CELLS, vol. 21, no. 2, 2003, pages 152 - 61, XP002243096, DOI: doi:10.1634/stemcells.21-2-152;;CHRIS H. JO ET AL.: ""Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion"", CELL TISSUE RES, vol. 334, 2008, pages 423 - 433, XP019716547;;WINSTON COSTA PEREIRA ET AL.: ""Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation"", J TISSUE ENG REGEN MED, vol. 2, 2008, pages 394 - 399;;TROYER; WEISS: ""Concise Review: Wharton's Jelly-Derived Cells Are a primitive Stromal Cell Population"", STEM CELLS, vol. 26, 2008, pages 591 - 599, XP055059242, DOI: doi:10.1634/stemcells.2007-0439;;KIM ET AL.: ""Ex vivo characteristics of human amniotic membrane-derived stem cells"", CLONING STEM CELLS, vol. 9, no. 4, 2007, pages 581 - 94, XP002465150, DOI: doi:10.1089/clo.2007.0027;;WEXLER ET AL.: ""Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not"", HAEMOPOIESIS AND LEUCOCYTES BRITISH JOURNAL OF HAEMATOLOGY, vol. 121, no. 2, April 2003 (2003-04-01), pages 368 - 374, XP008160364, DOI: doi:10.1046/j.1365-2141.2003.04284.x;;TA ET AL.: ""Long- term Expansion and Pluripotent Marker Array Analysis of Wharton's Jelly-Derived Mesenchymal Stem Cells"", STEM CELLS DEV., 20 July 2009 (2009-07-20);;BAILEY, J E.: ""Biochemical Engineering Fundamentals, 2nd ed."", 1986, MCGRAW-HILL, INC., ISBN: 0-07-003212-2;;JACKSON A T.; JACKSON A T.: ""Verfahrenstechnik in der Biotechnologie"", 1993, SPRINGER, ISBN: 3540561900;;""Remington's Pharmaceutical Sciences, 20th ed."", 2000, LIPPINCOTT, WILLIAMS & WILKINS;;TANAKA, S.; TAKIGAWA, T.; ICHIHARA, S.; NAKAMURA, T.: ""Mechanical properties of the bioabsorbable polyglycolic acid-collagen nerve guide tube"", POLYMER ENGINEERING & SCIENCE, vol. 46, 2006, pages 1461 - 1467, XP002535269, DOI: doi:10.1002/PEN.20600;;RAJESH VASITA; DHIRENDRA S KATTI: ""Growth factor delivery systems for tissue engineering: a materials perspective"", EXPERT REVIEWS IN MEDICAL DEVICES, vol. 3, no. 1, 2006, pages 29 - 47;;WONG C; INMAN E; SPAETHE R; HELGERSON S, THROMB. HAEMOST., vol. 89, no. 3, 2003, pages 573 - 582;;PANDIT A S; WILSON D J; FELDMAN D S: ""Fibrin scaffold as an effective vehicle for the delivery of acidic growth factor (FGF-1"", J. BIOMATERIALS APPLICATIONS, vol. 14, no. 3, 2000, pages 229 - 242;;DEBLOIS COTE M F; DOILLON C J: ""Heparin-fibroblast growth factor fibrin complex: in vitro and in vivo applications to collagen based materials"", BIOMATERIALS, vol. 15, no. 9, 1994, pages 665 - 672, XP002460505, DOI: doi:10.1016/0142-9612(94)90164-3;;LUONG-VAN ET AL.: ""In vitro biocompatibility and bioactivity of microencapsulated heparan sulphate"", BIOMATERIALS, vol. 28, 2007, pages 2127 - 2136, XP005876557, DOI: doi:10.1016/j.biomaterials.2007.01.002",DISCONTINUED
43,WO,A1,WO 2017/180108 A1,052-238-576-955-747,2017-10-19,2017,US 2016/0027108 W,2016-04-12,US 2016/0027108 W,2016-04-12,"DEVICES AND FORMULATIONS FOR DETECTING, SCREENING AND MONITORING LEVELS OF CERTAIN CONSTITUENTS IN BODILY FLUIDS AND METHOD","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/052-238-576-955-747,Patent Application,yes,4,0,3,3,0,C12Q1/52;;G01N33/523;;G01N33/57438;;G01N33/66;;G01N33/6893;;G01N33/92;;G01N2333/91188;;G01N2800/085,G01N33/52;;C12Q1/00;;G01N33/545,,3,0,,,"PAVLOV CH. S. ET AL.: ""Nealkogolnaya zhirovaya bolezn pecheni v klinike vnutrennikh organov"", RMZH 2010, pages 1742, XP055566972;;GURYANOVA L. N. ET AL.: ""Diagnosticheskoe znachenie laboratornykh metodov issledovaniya"", THE DIAGNOSTIC VALUE OF LABORATORY RESEARCH METHODS LEARNING TOOLKIT = ДИАГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ ЛАБОРАТОРНЫХ МЕТОДОВ ИССЛЕДОВАНИЯ УЧЕБНО МЕТОДИЧЕСКОЕ ПОСОБИЕ, 2008, Saransk, pages 39 , 41, 57, 58, XP009513125;;See also references of EP 3455627A4",PENDING
44,WO,A1,WO 2012/129305 A1,076-633-103-779-027,2012-09-27,2012,US 2012/0029940 W,2012-03-21,US 201161516970 P;;US 201161465704 P;;US 201161516035 P,2011-03-23,COMBINATION THERAPY,This invention relates to compositions and methods for treating GC-responsive conditions and for reducing and preventing side-effects of GC treatment in patients.,POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/076-633-103-779-027,Patent Application,yes,3,16,4,4,0,A61K45/06;;A61K45/06;;A61K31/573;;A61K31/573;;A61P1/00;;A61P1/18;;A61P5/00;;A61P7/00;;A61P9/00;;A61P13/00;;A61P13/10;;A61P13/12;;A61P19/00;;A61P19/04;;A61P21/00;;A61P25/00;;A61P27/00;;A61P29/00,A61K45/06;;A61K31/573;;A61K31/58,,2,0,,,"MASHKOVSKIY M.D.: ""Lekarstvennye sredstva."", POSOBIE DLYA VRACHEI, M., 000 ''NOVAYA VOLNA'', vol. 2, 2001, pages 25 - 29, XP008171357;;See also references of EP 2701744A4",PENDING
45,EP,A1,EP 3434274 A1,062-356-678-305-833,2019-01-30,2019,EP 18194019 A,2012-03-28,US 201161516227 P;;EP 12762996 A;;US 2012/0030832 W,2011-03-31,PREVENTION OF INFECTION,The invention relates to a composition comprising the glucocorticoid receptor antagonist ORG 34517 for use in reducing infarct severity and improving long term outcome after ischemic stroke of for use in improving long term outcome secondary to CNS injury in a patient in need thereof.,POP TEST ONCOLOGY LLC,O'BRIEN REBECCA;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON,,https://lens.org/062-356-678-305-833,Patent Application,yes,3,0,7,7,0,A61K31/56;;A61K31/56;;A61K31/573;;A61P31/00;;A61P37/04,A61K31/56;;A61K31/00;;A61K31/04;;A61K31/57;;A61K31/573;;A61K31/58;;A61P37/04,,5,3,116-374-221-772-50X;;018-475-262-809-567;;063-320-387-942-981,10051210;;10.1016/s0306-4522(98)00213-9;;12053008;;10.1161/01.str.0000016967.76805.bf;;12939340;;pmc2194193;;10.1084/jem.20021098,"ANTONAWICH F J ET AL: ""Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone"", NEUROSCIENCE, NEW YORK, NY, US, vol. 88, no. 1, 1 January 1999 (1999-01-01), pages 319 - 325, XP002476026, ISSN: 0306-4522, DOI: 10.1016/S0306-4522(98)00213-9;;N. SUGO ET AL: ""Social Stress Exacerbates Focal Cerebral Ischemia in Mice"", STROKE, vol. 33, no. 6, 1 June 2002 (2002-06-01), pages 1660 - 1664, XP055162738, ISSN: 0039-2499, DOI: 10.1161/01.STR.0000016967.76805.BF;;K. PRASS ET AL: ""Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1-like Immunostimulation"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 5, 2 September 2003 (2003-09-02), pages 725 - 736, XP055162482, ISSN: 0022-1007, DOI: 10.1084/jem.20021098;;T.W. GREEN: ""Protective Groups in Organic Synthesis"", 1981, WILEY;;GENNARO ET AL., REMINGTON'S PHARMACEUTICAL SCIENCES, 2005",DISCONTINUED
46,US,A1,US 2017/0232005 A1,198-395-733-194-894,2017-08-17,2017,US 201715471123 A,2017-03-28,US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161519323 P;;US 201161518248 P;;US 201161465703 P;;US 201161463212 P;;US 201161462492 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/198-395-733-194-894,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K45/06;;A61K31/58,,0,0,,,,ACTIVE
47,EP,A4,EP 2699245 A4,003-643-924-520-574,2014-12-10,2014,EP 12774862 A,2012-04-16,US 201161517343 P;;US 2012/0033731 W,2011-04-18,HAIR LOSS TREATMENT,,POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/003-643-924-520-574,Search Report,no,3,0,4,4,0,A61K8/63;;A61K8/63;;A61K31/00;;A61K31/00;;A61K31/58;;A61K31/58;;A61K2800/782;;A61K2800/782;;A61P17/00;;A61P17/10;;A61P17/14;;A61P31/00;;A61Q7/00;;A61Q7/00,A61K31/58;;A61K8/63;;A61K31/00;;A61P17/00;;A61P17/14;;A61Q5/12;;A61Q7/00,,1,0,,,See also references of WO 2012145258A1,DISCONTINUED
48,US,B2,US 9314473 B2,020-270-112-315-003,2016-04-19,2016,US 201514802060 A,2015-07-17,US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/020-270-112-315-003,Granted Patent,yes,3,29,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00,,2,0,,,Chemocare 2002.;;Goodmanand Gilman (1996 1225-1233 9th Edition.,ACTIVE
49,WO,A1,WO 2012/151465 A1,052-846-978-578-621,2012-11-08,2012,US 2012/0036453 W,2012-05-04,US 201161518344 P,2011-05-04,DIAGNOSTIC DEVICE,"The invention provides for rapid response analysis through lateral flow chromatographic assays of specific antigens present in human or animal fluids, or in agricultural, microbial or biological products, with an audio and visual result of the analysis and when needed, an electronic surge to provide heat for rapid results. A lateral flow device for conducting the analysis includes a plurality of components, and a method for making the device forms components of the device on an elongate, ribbon-like substrate of dielectric material, then folds the substrate into shorter lengths which are then secured together to establish a multiple-layered, self-sustaining structure.",POP TEST LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/052-846-978-578-621,Patent Application,yes,17,7,6,6,0,G01N33/558;;G01N21/8483;;G01N2021/8494;;G01N21/6486;;Y02A50/30;;G01N33/525;;G01N21/8483;;G01N2021/8494;;Y02A50/30;;G01N33/54388;;G01N21/6486,G01N33/53;;G01N27/02;;G01N33/543;;G01N33/558,,14,7,040-582-260-914-903;;085-660-472-186-059;;020-026-345-586-213;;106-753-778-592-300;;017-402-213-772-16X;;056-485-674-479-610;;007-356-231-902-653,10.1016/0076-6879(81)73054-4;;7300683;;10.1385/1592598730;;25291284;;10.1016/0167-5699(83)90123-8;;1172191;;10.1038/256495a0;;10.1021/jf021020i;;12797729;;10.1134/s0003683811060032;;15734566;;10.1016/j.ijfoodmicro.2004.07.021,"DELUCA ET AL.: ""Antibody As a Tool"", 1982, JOHN WILEY & SONS, LTD., article ""Immunofluorescence Analysis"", pages: 189 - 231;;GALFRE ET AL., METH. ENZYMOL., vol. 73, 1981, pages 3 - 46;;AURAMEAS ET AL., SCAND. J. IMMUNOL., vol. 8, no. 7, 1978, pages 7 - 23;;RODWELL ET AL., BIOTECH, vol. 3, 1984, pages 889 - 894;;BURNS: ""Immunochemical Protocols"", 2005, HUMANA PRESS;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;J. K. LEE ET AL., J. AGRIC. FOOD CHEM., vol. 51, 2003, pages 3695 - 3703;;J. F. LAWRENCE ET AL., J. CHROMATOGRAPHY, vol. 732, 1996, pages 277 - 281;;J. F. LAWRENCE ET AL., J. CHROMATOGRAPHY, vol. 752, 1996, pages 147 - 154;;N. A. BYZOVA; E. A. ZVEREVA; A. V. ZHERDEV; B. B. DZANTIEV: ""Immunochromatographic Technique for Express Determination of Ampicillin in Milk and Dairy Products"", PRIKLADNAYA BIOKHIMIYA I MIKROBIOLOGIYA, vol. 47, no. 6, 2011, pages 685 - 693;;SUN XIULAN; ZHAO XIAOLIAN; TANG JIAN; JUN ZHOU; F.S. CHU: ""Preparation of gold-labeled antibody probe and its use in immunochromatography assay for detection of aflatoxin B 1"", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, vol. 99, 2005, pages 185 - 194;;See also references of EP 2705366A4",PENDING
50,EP,B1,EP 2671086 B1,050-786-199-142-680,2018-04-25,2018,EP 12742639 A,2012-02-02,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P;;US 2012/0023630 W,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2018-01-17),https://lens.org/050-786-199-142-680,Granted Patent,yes,3,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,G01N33/74;;A61P35/00;;C07J1/00;;G01N33/52;;G01N33/53;;G01N33/58,,2,0,,,"PEETERS B W ET AL: ""Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1148, 1 December 2008 (2008-12-01), pages 536-541, XP002726583, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1410.072 [retrieved on 2008-12-11];;WOLKOWITZ, O.M. ET AL.: 'Treatment of depression with antiglucocortic oid drugs.' PSYCHOSOMATIC MEDICINE vol. 61, 1999, pages 698 - 711, XP008170055",ACTIVE
51,EP,A1,EP 2701744 A1,078-380-228-517-75X,2014-03-05,2014,EP 12760977 A,2012-03-21,US 201161465704 P;;US 201161516035 P;;US 201161516970 P;;US 2012/0029940 W,2011-03-23,COMBINATION THERAPY,,POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/078-380-228-517-75X,Patent Application,yes,0,0,4,4,0,A61K45/06;;A61K45/06;;A61K31/573;;A61K31/573;;A61P1/00;;A61P1/18;;A61P5/00;;A61P7/00;;A61P9/00;;A61P13/00;;A61P13/10;;A61P13/12;;A61P19/00;;A61P19/04;;A61P21/00;;A61P25/00;;A61P27/00;;A61P29/00,A61K45/06;;A61K31/573;;A61K31/58,,0,0,,,,DISCONTINUED
52,US,B2,US 9295680 B2,085-611-650-322-172,2016-03-29,2016,US 201514801939 A,2015-07-17,US 201514801939 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/085-611-650-322-172,Granted Patent,yes,2,1,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/58;;A61K9/00;;A61K31/00;;A61K31/337,,2,0,,,Goodmanand Gilman (1996 1225-1233 9th Edition.;;Chemocare 2002.,ACTIVE
53,CN,A,CN 104822381 A,142-615-604-331-290,2015-08-05,2015,CN 201380051001 A,2013-07-30,US 2013/0052622 W;;US 201261741925 P;;US 201313837408 A,2012-07-30,Therapeutic compositions and methods,"This invention relates the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of Cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/142-615-604-331-290,Patent Application,no,2,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/56;;A61K35/28;;A61K35/545;;A61K45/06;;A61P17/02;;A61P19/08;;A61P19/10;;A61P25/30;;A61P37/06;;C12N5/0735;;C12N5/074;;C12N5/0789,,2,0,,,"CATHERINE JACQUOT等: ""“Effects of the Glucocorticoid Antagonist, Mifepristone, on the Consequences of Withdrawal From Long Term Alcohol Consumption"", 《ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH》;;JAVIER NAVARRO-ZARAGOZA等: ""Glucocorticoid (GC) receptor antagonist mifepristone attenuates morphine withdrawal behaviors"", 《PHARMACOLOGICAL REPORTS》",ACTIVE
54,US,A1,US 2018/0360852 A1,191-868-883-802-253,2018-12-20,2018,US 201816050155 A,2018-07-31,US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/191-868-883-802-253,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,0,0,,,,ACTIVE
55,US,B2,US 11116775 B2,027-374-184-685-960,2021-09-14,2021,US 201916691971 A,2019-11-22,US 201916691971 A;;US 201916251299 A;;US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/027-374-184-685-960,Granted Patent,yes,7,4,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,5,3,093-431-353-619-932;;037-199-529-897-764;;061-516-257-294-56X,22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072;;26089723;;10.3747/co.22.2517;;pmc4462534,"Min, KJ et al., Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal cardinoma cells through up-regulation of DRS and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med (Berl), Mar. 2012, 309-319, 90(3), 10, 1007s00109-0821-8 Epub Oct. 29, 2011, abstract.;;Peeters, BW et al., Differential effects of new glucocorticoid receptor antagonist ORG 34517 and ru486 (mifepristone) on glucocortocold receptor unclear translocation in the AIT20 cell line. Ann NY Acad Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.;;Narod, S.A., Have we given up on a cure for ovarian cancer? Current Oncology, vol. 22, No. 2, Jun. 2015, e139-3141.;;ChemoCare 2002.;;Goodman and Gilman (1996 1225-1233 9th Edition).",ACTIVE
56,US,A1,US 2018/0117066 A1,070-787-944-886-795,2018-05-03,2018,US 201715854053 A,2017-12-26,US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/070-787-944-886-795,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61K45/06,,0,0,,,,ACTIVE
57,US,B2,US 10058563 B2,080-969-366-035-760,2018-08-28,2018,US 201715478368 A,2017-04-04,US 201715478368 A;;US 201615095248 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161519323 P;;US 201161518248 P;;US 201161465703 P;;US 201161463212 P;;US 201161462492 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/080-969-366-035-760,Granted Patent,yes,6,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58,,9,7,093-431-353-619-932;;037-199-529-897-764;;026-297-014-916-946;;012-100-414-117-262;;057-546-013-547-180;;133-014-962-417-772;;005-160-630-285-958,22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072;;10.1038/sj.npp.1300226;;12838270;;pmc2671735;;19412444;;10.1093/jpepsy/jsh022;;15131138;;18656950;;pmc3056881;;10.1021/ac800892h;;10.1016/j.neuron.2007.09.006;;17920012,"Min, KJ et al, Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), Mar. 2012, 309-319, 90(3), 10,1007/s00109-011-0821-8. Epub Oct. 29, 2011, abstract.;;Deeters, BW et al, Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocortocoid receptor unclear translocation in the AtT20 cell line. Ann. NY Acad. Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.;;Elzinga, B.M., Higher cortisol levels following exposure to traumatic reminders in abuse-related PTSD, Neuropsychopharmacology, 2003:38, 1656-1665.;;Gallagher, P. et al, Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications, Neuropsychiatric Disease and Treatment, 2006:2(1), 33-42.;;Kazak, A.E. et al, Posttraumatic stress disorder (PTSD) and Posttraumatic stress symptoms (PTSS) in families of adolescent childhood cancer survivors, Journal of Pediatric Psychology, 2004, 29(3), 211-219.;;Nilsson, E.C., Salivary cortisol and post traumatic stress symptoms, Chemical and Biotechniques Department of Physics, Chemistry and Biology, Linkoping University, 2009, 1-22.;;Stevens, R.C. et al, Detection of cortisol in saliva with a flow-filtered, portable surface plasmon resonance biosensor system, Anal. Chem. Sep. 1, 2008, 80:17, 6747-6751.;;Yehuda, R. et al, Response variation following trauma: A translational neuroscience approach to understanding PTSD, Neuron 56, Oct. 4, 2007, 19032.;;Yehuda, R., Neuroendocrine alterations in posttraumatic stress disorde, Primary Psychiatry (http://primarypsychiatry.com/author/primaryp/), Feb. 1, 2002, 1-13.",ACTIVE
58,WO,A2,WO 2012/106514 A2,095-197-995-159-579,2012-08-09,2012,US 2012/0023630 W,2012-02-02,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates to a low cost rapid response diagnostic system to determine Cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal Cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in Cortisol levels in response to treatment.",POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/095-197-995-159-579,Patent Application,yes,10,8,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,G01N33/74;;C07J1/00;;G01N33/52;;G01N33/53;;G01N33/58,,58,46,025-236-889-877-681;;072-017-135-003-528;;075-604-848-120-332;;022-427-234-675-993;;027-610-441-797-691;;098-970-572-904-025;;098-970-572-904-025;;039-764-013-605-830;;077-911-867-689-885;;004-051-499-572-775;;077-911-867-689-885;;028-006-068-536-463;;000-990-435-802-906;;070-731-131-146-498;;025-968-443-414-504;;146-449-089-963-596;;031-219-768-770-784;;028-834-962-521-841;;019-082-741-537-174;;078-818-133-871-602;;152-497-600-208-517;;010-540-968-978-319;;033-884-765-849-131;;048-310-550-318-36X;;099-883-114-833-005;;023-364-956-890-880;;046-322-433-866-098;;035-083-000-444-258;;040-582-260-914-903;;014-065-259-226-128;;081-376-983-952-92X;;035-784-409-496-514;;019-490-428-734-203;;022-633-679-770-667;;010-671-218-365-329;;037-480-189-672-490;;008-292-323-806-999;;016-114-899-296-280;;084-085-138-348-898;;019-711-514-953-919;;011-287-801-985-920;;039-376-070-403-51X;;096-741-767-207-949;;192-609-714-372-280;;028-428-571-584-841;;054-980-079-955-454,16236742;;10.1056/nejmra050541;;10.1111/j.1365-2265.2004.02106.x;;15355454;;15634032;;10.2165/00003088-200544010-00003;;3041279;;10.1056/nejm198808183190706;;10.1210/edrv-17-2-187;;8706631;;10.1210/er.17.2.187;;1645586;;10.1016/0960-0760(91)90312-s;;1645586;;10.1016/0960-0760(91)90312-s;;10.1177/070674379804300307;;9561317;;pmc1188541;;8297920;;10.2165/11587620-000000000-00000;;21175239;;pmc1188541;;8297920;;10.1136/jnnp.23.1.56;;14399272;;pmc495331;;10.1037/t04100-000;;10.1097/00005053-198409000-00002;;6470694;;10.1177/070674378503000312;;2986814;;10.1016/0002-9343(84)90312-7;;6711582;;1984391;;10.7326/0003-4819-114-2-143;;8490591;;10.1007/bf01874090;;15268748;;10.1111/j.1474-9728.2004.00103.x;;16300484;;10.1111/j.1474-9726.2005.00178.x;;10.1016/j.biopsych.2003.12.021;;15110738;;7961563;;20859106;;10.1097/01.pra.0000388624.91039.a3;;10.1097/med.0b013e32833de61c;;20717020;;pmc2957510;;10.1016/j.schres.2010.07.012;;20692814;;10553730;;10.1176/ajp.156.11.1686;;10.1210/jcem.86.8.7740;;11502780;;10.1210/jc.86.8.3568;;16782211;;10.1016/j.bbr.2006.03.039;;19888560;;10.1007/s12325-009-0070-1;;10.1016/0076-6879(81)73054-4;;7300683;;8855227;;pmc38202;;10.1073/pnas.93.20.10614;;pmc20056;;9122163;;10.1073/pnas.94.6.2150;;10.1016/0092-8674(89)90237-7;;2644044;;10.1210/edrv-11-2-201;;2194782;;10.1146/annurev.bi.63.070194.002315;;10.1146/annurev.biochem.63.1.451;;7979245;;7857868;;10.1016/0960-0760(94)00155-f;;9212098;;10.1038/nm0797-730;;10.1182/blood-2004-03-0901;;15242869;;10.1073/pnas.0307618100;;14711994;;pmc321758;;10.1073/pnas.0530291100;;pmc153034;;12629218;;10.1158/0008-5472.can-05-2018;;16322242;;16230395;;10.1158/0008-5472.can-05-1343;;10.1038/nature03128;;15549107;;15378086;;10.1038/sj.onc.1207946;;14522905;;10764142;;10.1038/sj.leu.2401743;;14680969;;10.1016/j.pep.2003.09.003,"RHEN T; CIDLOWSKI JA, NEJM, vol. 353, 2005, pages 1711 - 1723;;MAH ET AL., CLINICAL ENDOCRINOLOGY, vol. 61, 2004, pages 367 - 375;;CZOCK ET AL., CLIN. PHARMACOKINET, vol. 44, 2005, pages 61 - 98;;GOLD P.W. ET AL.: ""Clinical and biochemical manifestations of depression: relation to neurobiology of stress"", NEW ENGLAND J. MED., vol. 319, 1988, pages 413 - 420;;HOLSBOER, F.; BARDEN, N., ENDOCRINE REVIEWS, vol. 17, 1996, pages 187 - 205;;MURPHY, B.E.P., J. OF STEROID BIOCHEM. AND MOL. BIOL., vol. 38, 1991, pages 537 - 559;;MURPHY, B.E.P., STEROIDS AND DEPRESSION. J. STEROID BIOCHEM & MOL. BIOL., vol. 38, 1991, pages 537 - 558;;MURPHY, B.E.P., CAN. J. PSYCH., vol. 43, 1998, pages 279 - 286;;MURPHY, B.E.P., J. PSYCHIAT. NEUROSC., vol. 18, 1993, pages 209 - 213;;NEMEROFF, C., REMERON SCIENTIFIC EXPERT MEETING, BUDAPEST, 29 March 2001 (2001-03-29);;CONNOLLY KR, DRUGS, vol. 71, 2011, pages 43 - 64;;MURPHY, B.E.P. ET AL., J. PSYCHIAT. NEUROSC, vol. 18, 1993, pages 209 - 213;;HAMILTON, M: ""A rating scale for depression"", J. NEUROL. NEUROSURG. PSYCHIAT., vol. 23, 1960, pages 56 - 62;;CORYELL, J. NERV. MENT. DIS., vol. 172, 1984, pages 521;;GERSON, CAN. J. PSYCHIATRY, vol. 30, 1985, pages 223 - 224;;SAAD, AM. J. MED., vol. 76, 1984, pages 759 - 766;;VAN DER LELY, ANN. INTERN. MED., vol. 114, 1991, pages 143;;VAN DER LELY, PHARMACY WORLD & SCIENCE, vol. 15, 1993, pages 89 - 90;;BUTCHER; LORD, AGING CELL, 2004, pages 151 - 160;;BUTCHER ET AL., AGING CELL, vol. 5, 2005, pages 319 - 324;;""Diagnostic and statistical manual of mental disorders: DSM-IV"", 1994, AMERICAN PSYCHIATRIC ASSOCIATION;;LINDLEY SE ET AL.: ""Basal and dexamethasone suppressed salivary cortisol concentrations in a community sample of patients with posttraumatic stress disorder"", BIOL. PSYCHIATRY, vol. 55, 2004, pages 940 - 5;;UMBRICHT ET AL., J CLIN. PSYCHIATRY, vol. 55, 1994, pages 157 - 160;;KHAN AY ET AL., J PSYCHIATR PRACT., vol. 16, 2010, pages 289 - 296;;PRAMYOTHIN P; KHAODHIAR L., CURR OPIN ENDOCRINOL DIABETES OBES., vol. 17, 2010, pages 460 - 466;;RUMMEL-KLUGE C ET AL., SCHIZOPHR RES., vol. 123, 2010, pages 225 - 233;;ALLISON ET AL., AM J PSYCHIATRY, vol. 156, 1999, pages 1686 - 1696;;RUMMEL-KLUGE C ET AL., SCHIZOPHR RES, vol. 123, 2010, pages 225 - 233;;CHU ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 86, 2001, pages 3568 - 3573;;BEEBE ET AL., BEHAV. BRAIN RES., vol. 171, 2006, pages 225 - 229;;GROSS ET AL., ADV THER., vol. 26, 2009, pages 959 - 969;;DELUCA ET AL.: ""Antibody As a Tool"", 1982, JOHN WILEY & SONS, LTD., article ""Immunofluorescence Analysis"", pages: 189 - 231;;GALFRE ET AL., METH. ENZYMOL., vol. 73, 1981, pages 3 - 46;;AURAMEAS ET AL., SCAND. J. IMMUNOL., vol. 8, no. 7, 1978, pages 7 - 23;;RODWELL ET AL., BIOTECH., vol. 3, 1984, pages 889 - 894;;D. P. SITES ET AL.: ""Basic and Clinical Immunology"", 1982, LANGE MEDICAL PUBLICATIONS OF LOS ALTOS;;SCHENA ET AL., PROC. NATD. ACAD. SCI., vol. 93, 1996, pages 10614 - 10619;;HELLER ET AL., PROC. NATL. ACAD. SCI., vol. 94, 1997, pages 2150 - 2155;;GASC, J. -M.; BAULIEU, E. E: ""Steroid Hormone Receptors: Their Intracellular Localisation"", 1987, ELLIS HORWOOD LTD., pages: 233 - 250;;BEATO, M., CELL, vol. 56, 1989, pages 335 - 344;;CARSON-JURICA, M. A.; SCHRADER, W. T.; O'MALLEY, B. W., ENDOCR. REV., vol. 11, 1990, pages 201 - 220;;GRONEMEYER, H.: ""Steroid Hormone Action"", 1993, OXFORD UNIVERSITY PRESS, pages: 94 - 117;;TSAI, M. J.; O'MALLEY, B. W., ANNU. REV. BIOCHEM., vol. 63, 1994, pages 451 - 486;;AKNER, G.; WIKSTROM, A. C.; GUSTAFSSON, J. A., J. STEROID BIOCHEM. MOL. BIOL., vol. 52, 1995, pages 1 - 16;;T.W. GREEN: ""Protective Groups in Organic Synthesis"", 1981, WILEY;;NAT MED, vol. 3, 1997, pages 730 - 737;;COX ET AL., BLOOD, vol. 104, no. 19, 2004, pages 2919 - 2925;;KONDO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 781 - 786;;AL-HAJJ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 3983 - 3988;;COLLINS ET AL.: ""Prospective Identification of Tumorigenic Prostate Cancer Stem Cells"", CANCER RES, vol. 65, no. 23, 2005, pages 10946 - 10951, XP008128778, DOI: doi:10.1158/0008-5472.CAN-05-2018;;FANG ET AL.: ""A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas"", CANCER RES, vol. 65, no. 20, 2005, pages 9328 - 9337, XP002550851, DOI: doi:10.1158/0008-5472.CAN-05-1343;;SINGH ET AL.: ""Identification of human brain tumor initiating cell"", NATURE, vol. 432, 2004, pages 396 - 401;;SINGH ET AL.: ""Cancer stem cells in nervous system tumors"", ONCOGENE, vol. 23, 2004, pages 7267 - 7273, XP002489599, DOI: doi:10.1038/sj.onc.1207946;;SINGH ET AL.: ""Identification of a cancer stem cell in human brain tumors"", CANCER RES., vol. 63, 2003, pages 5821 - 5828;;FRANKEL ET AL.: ""Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias"", LEUKEMIA, vol. 14, 2000, pages 576, XP009150271;;URIETO ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 33, 2004, pages 123 - 133;;""Physician's Desk Reference"", 2006;;See also references of EP 2671086A4",PENDING
59,EP,A2,EP 2884984 A2,158-156-821-847-382,2015-06-24,2015,EP 13824861 A,2013-07-30,US 201261741925 P;;US 201313837408 A;;US 2013/0052622 W,2012-07-30,GLUCOCORTICOID RECEPTOR ANTAGONIST IN THE TREATMENT OF ADDICTION,,POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2018-04-25),https://lens.org/158-156-821-847-382,Patent Application,yes,0,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/56;;A61K35/28;;A61K35/545;;A61K45/06;;A61P17/02;;A61P19/10;;A61P25/30;;A61P37/06,,0,0,,,,ACTIVE
60,US,B2,US 11364252 B2,191-068-599-535-578,2022-06-21,2022,US 202117392264 A,2021-08-03,US 202117392264 A;;US 201916691971 A;;US 201916251299 A;;US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/191-068-599-535-578,Granted Patent,yes,1,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,1,1,059-786-196-998-819,15148141;;10.1001/archneur.61.5.661,Arvanitakis et al. (Arch Neurol.; 61:661-666).,ACTIVE
61,US,A1,US 2017/0281652 A1,021-411-140-660-587,2017-10-05,2017,US 201715628179 A,2017-06-20,US 201715628179 A;;US 201414570338 A;;US 201313837408 A;;US 201261741925 P,2012-07-30,Therapeutic Compositions and Methods,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/021-411-140-660-587,Patent Application,yes,2,12,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/58;;A61K31/565;;A61K35/12;;A61K35/28;;A61K35/545;;A61K45/06,,5,4,017-091-519-798-658;;019-167-027-903-790;;008-455-294-780-147;;127-792-369-495-300,18567959;;10.1151/spp021113;;pmc2851054;;10.2174/157015911795016949;;pmc3137186;;21886593;;12954743;;10.1056/nejmoa022164;;16684876;;pmc1458620;;10.1073/pnas.0602661103,"Kosten, T.R. et al. 2002. The neurobiology of opioid dependence: implications for treatment. Research reviews- the neurobiology of opioid dependence. Science & Practice Perspectives, pp. 13-20. specif. pp. 13, 20;;Tien, L.-T. et al. 2011 March. Involvement of u-opioid receptor in methamphetamine-induced behavioral sensitization. Current Neuropharmacology 9: 215-218. specif. pg. 215;;Fudala, P.J. et al. 2003. Office-based treatment of opiate addiction with a sublingual-tablet formation of buprenorphine and naloxone. The New England Journal of Medicine 349(10): 949-958. specif. pg. 949;;Yao, L. et al. 2006. Adenosine A2a blockade prevents synergy between u-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. PNAS 103(20): 7877-7882. specif. pg. 7877;;Gilpin, N.W. et al. 2008.Neurobiology of alcohol dependence. The Scripps Research Institute. manuscript # 19510. pp. 185-195. specif. pp. 186, 188, 189",DISCONTINUED
62,US,A1,US 2019/0151335 A1,018-560-405-336-637,2019-05-23,2019,US 201916251299 A,2019-01-18,US 201916251299 A;;US 201816050155 A;;US 201715854053 A;;US 201715471123 A;;US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/018-560-405-336-637,Patent Application,yes,2,6,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,1,0,,,"Goodman and Gilman (ninth edition, 1996, 1225-1232",ACTIVE
63,EP,B1,EP 2884984 B1,053-164-502-630-840,2018-06-06,2018,EP 13824861 A,2013-07-30,US 201261741925 P;;US 201313837408 A;;US 2013/0052622 W,2012-07-30,GLUCOCORTICOID RECEPTOR ANTAGONIST IN THE TREATMENT OF ADDICTION,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2018-04-25),https://lens.org/053-164-502-630-840,Granted Patent,yes,3,0,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/56;;A61K35/28;;A61K35/545;;A61K45/06;;A61P17/02;;A61P19/10;;A61P25/30;;A61P37/06,,8,0,,,"CATHERINE JACQUOT ET AL: ""Effects of the Glucocorticoid Antagonist, Mifepristone, on the Consequences of Withdrawal From Long Term Alcohol Consumption"", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., vol. 32, no. 12, 1 December 2008 (2008-12-01), pages 2107-2116, XP055247584, US ISSN: 0145-6008, DOI: 10.1111/j.1530-0277.2008.00799.x;;Javier Navarro-Zaragoza ET AL: ""PS V - 3 Glucocorticoid (GC) receptor antagonist mifepristone attenuates morphine withdrawal behaviors"", Pharmacological Reports, 13 April 2011 (2011-04-13), pages 253-254, XP055247580, European Opioid Conference; Krakow, POLAND; April 13 -15, 2011 Retrieved from the Internet: URL:http://ac.els-cdn.com/S173411401170479 0/1-s2.0-S1734114011704790-main.pdf?_tid=7 4e2833c-cb40-11e5-af9e-00000aab0f02&acdnat =1454591520_2543248385ba0cfca70f3c03bd7676 47 [retrieved on 2016-02-04];;CORNELIUS G BACHMANN ET AL: ""Effect of Chronic Administration of Selective Glucocorticoid Receptor Antagonists on the Rat Hypothalamic-Pituitary-Adrenocortical Axis"", NEUROPSYCHOPHARMACOLOGY., 19 December 2002 (2002-12-19), XP055247533, US ISSN: 0893-133X, DOI: 10.1038/sj.npp.1300158;;Mary Ann C Stephens ET AL: ""Stress and the HPA Axis: Role of Glucocorticoids in Alcohol Dependence"", Alcohol Research, 1 July 2012 (2012-07-01), page 468, XP055247551, Bethesda Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl es/PMC3860380/pdf/arcr-34-4-468.pdf [retrieved on 2016-02-04];;REYNOLDS ANNA R ET AL: ""Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis ac"", DRUG AND ALCOHOL DEPENDENCE, vol. 154, 22 June 2015 (2015-06-22), pages 100-104, XP029256113, ISSN: 0376-8716, DOI: 10.1016/J.DRUGALCDEP.2015.06.018;;PEETERS ET AL: 'DIFFERENTIAL EFFECTS OF THE NEW GLUCOCORTICOID RECEPTOR ANTAGONIST ORG 34517 ANDRU486 (MIFEPRISTONE) ON GLUCOCORTICOID RECEPTOR NUCLEAR TRANSLOCATION IN THE ATT20 CELL LINE' ANNALS OF THE NEW YORK ACADEMY OF SCIENCES vol. 1148, December 2008, pages 536 - 541, XP002726583 & DATABASE PUBMED [Online] 'Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line' Database accession no. 19120154;;KOBAYASHI T. ET AL.: 'Modulators of G protein-activated inwardly rectifying K+ channels: potentially therapeutic agents for addictive drug users' ANNALS OF THE NEW YORK ACADEMY OF SCIENCES vol. 1025, October 2004, pages 590 - 594, XP055182377;;ALEX C. CECH: 'GLUCOCORTICOID RECEPTOR BLOCKADE REVERSES POSTINJURY MACROPHAGE SUPPRESSION' ARCHIVES OF SURGERY vol. 129, no. 12, December 1994, pages 1227 - 1232, XP002080523 & DATABASE PUBMED [Online] 'Glucocorticoid receptor blockade reverses postinjury macrophage suppression' Database accession no. 7986150",ACTIVE
64,US,B2,US 9562256 B2,073-752-285-106-140,2017-02-07,2017,US 201615155803 A,2016-05-16,US 201615155803 A;;US 201514684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2016-05-11),https://lens.org/073-752-285-106-140,Granted Patent,yes,1,0,8,32,0,G01N21/29;;G01N33/558;;G01N33/57438;;G01N33/66;;G01N33/92;;C12Q1/52;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N21/78;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N2021/752;;G01N21/29;;G01N33/57438;;G01N33/66;;G01N33/92;;G01N33/54388;;G01N33/52;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/523;;G01N33/98,G01N21/78;;C12Q1/52;;G01N21/29;;G01N21/75;;G01N33/52;;G01N33/558;;G01N33/574;;G01N33/66;;G01N33/92,,1,0,,,"Pollock et al. 2012, vol. 4, Issue 152, pp. 1-10.",ACTIVE
65,US,B1,US 9320747 B1,116-243-830-806-795,2016-04-26,2016,US 201514982139 A,2015-12-29,US 201514982139 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-12-17),https://lens.org/116-243-830-806-795,Granted Patent,yes,2,19,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/58;;A61K31/337;;A61K31/45,,0,0,,,,ACTIVE
66,US,B2,US 9636351 B2,121-644-220-215-208,2017-05-02,2017,US 201615095293 A,2016-04-11,US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and method for diagnosis and treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2016-04-01),https://lens.org/121-644-220-215-208,Granted Patent,yes,8,2,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,5,3,150-165-351-200-771;;093-431-353-619-932;;037-199-529-897-764,pmc1887817;;17554405;;22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072,"Chang S. vol. 9 Suppl. 2 2007 Reviews in Urology S13-S18.;;Chemocare 2002.;;Goodmanand Gilman (1996 1225-1233 9th Edition.;;Min, KJ et al, Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), Mar. 2012, 309-319, 90(3), 10,1007/s00109-011-0821-8. Epub Oct. 29, 2011, abstract.;;Peeters, BW et al. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocortocoid receptor unclear translocation in the AtT20 cell line. Ann. NY Acad. Sci., Dec. 2008, 536-541, doi: 10, 1196/annals, 1410.072, abstract.",ACTIVE
67,US,A1,US 2016/0113948 A1,143-841-683-967-159,2016-04-28,2016,US 201514982139 A,2015-12-29,US 201514982139 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-12-17),https://lens.org/143-841-683-967-159,Patent Application,yes,0,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,A61K31/58;;A61K31/337,,0,0,,,,ACTIVE
68,WO,A1,WO 2017/180086 A1,030-614-789-507-938,2017-10-19,2017,US 2016/0026876 W,2016-04-11,US 2016/0026876 W,2016-04-11,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/030-614-789-507-938,Patent Application,yes,6,2,1,43,0,A61K31/585;;A61K31/167;;A61K31/473;;A61K31/496;;A61K31/573;;A61K31/58;;A61P31/00;;A61P35/00,A61K31/357;;A61K31/395;;A61P31/00;;A61P35/00,,3,2,093-431-353-619-932;;037-199-529-897-764,22008998;;10.1007/s00109-011-0821-8;;19120154;;10.1196/annals.1410.072,"MIN KJ ET AL.: ""Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down- regulation of c-FLIP(L) and Bcl-2"", J.MOL.MED., vol. 90, no. 3, March 2012 (2012-03-01), Berl, pages 309 - 19, XP035024445, DOI: doi:10.1007/s00109-011-0821-8;;PEETERS BW ET AL.: ""Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU 486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line"", ANN N Y ACAD.SCI., vol. 1148, December 2008 (2008-12-01), pages 536 - 41, XP002726583;;See also references of EP 3316881A4",PENDING
69,EP,A4,EP 3455627 A4,012-800-757-666-287,2020-10-21,2020,EP 16898797 A,2016-04-12,US 2016/0027108 W,2016-04-12,"DEVICES AND FORMULATIONS FOR DETECTING, SCREENING AND MONITORING LEVELS OF CERTAIN CONSTITUENTS IN BODILY FLUIDS AND METHOD",,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/012-800-757-666-287,Search Report,no,1,0,3,3,0,C12Q1/52;;G01N33/523;;G01N33/57438;;G01N33/66;;G01N33/6893;;G01N33/92;;G01N2333/91188;;G01N2800/085,G01N33/52;;C12Q1/00;;G01N33/545,,1,0,,,See also references of WO 2017180108A1,DISCONTINUED
70,WO,A1,WO 2012/135274 A1,024-941-152-971-451,2012-10-04,2012,US 2012/0030832 W,2012-03-28,US 201161516227 P,2011-03-31,PREVENTION OF INFECTION,The invention relates to compounds and methods for the prevention and/or treatment of infection after stroke.,POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/024-941-152-971-451,Patent Application,no,6,5,7,7,0,A61K31/56;;A61P31/00;;A61P37/04;;A61K31/573;;A61K31/56,A61K31/56;;A61K31/00;;A61K31/04;;A61K31/57;;A61K31/58,,8,5,008-918-674-799-315;;007-296-712-160-177;;116-374-221-772-50X;;018-475-262-809-567;;063-320-387-942-981,16096935;;17099256;;10.1385/ncc:5:2:108;;10051210;;10.1016/s0306-4522(98)00213-9;;12053008;;10.1161/01.str.0000016967.76805.bf;;12939340;;pmc2194193;;10.1084/jem.20021098,"DOMKA E. ET AL.: ""Incidence of neuromedical complications during rehabilitation after stroke"", NEUROL. NEUROCHIR. POL., vol. 39, no. 4, 2005, pages 300 - 309, XP008171888;;GULDIKEN, BABURHAN ET AL.: ""Mean Platelet Volume and Peripheral Blood Count Response in Acute Ischemic Stroke."", TRAKYA UNIV TIP FAK DERG, vol. 25, no. 2, 2008, pages 130 - 135, XP008172736;;ZYGUN, DAVID A. ET AL.: ""Ventilator-Associated Pneumonia in Severe Traumatic Brain Injury."", NEUROCRITICAL CARE, vol. 5, 2006, pages 108 - 114, XP055092728;;ANTONAWICH F.J. ET AL.: ""Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone"", NEUROSCIENCE, vol. 88, no. 1, 1 January 1999 (1999-01-01), pages 319 - 325, XP002476026, DOI: doi:10.1016/S0306-4522(98)00213-9;;N. SUGO ET AL.: ""Social Stress Exacerbates Focal Cerebral Ischemia in Mice"", STROKE, vol. 33, no. 6, 1 June 2002 (2002-06-01), pages 1660 - 1664, XP055162738, DOI: doi:10.1161/01.STR.0000016967.76805.BF;;K. PRASS ET AL.: ""Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1-like Immunostimulation"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 5, 2 September 2003 (2003-09-02), pages 725 - 736, XP055162482, DOI: doi:10.1084/jem.20021098;;T.W. GREEN: ""Protective Groups in Organic Synthesis"", 1981, WILEY;;GENNARO ET AL., REMINGTON'S PHARMACEUTICAL SCIENCES, 2005",PENDING
71,US,A1,US 2017/0153227 A1,181-644-906-271-665,2017-06-01,2017,US 201615388697 A,2016-12-22,US 201615388697 A;;US 201615155803 A;;US 201514684861 A;;US 201314684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and Formulations for Detecting, Screening and Monitoring Levels of Certain Constituents in Bodily Fluids and Method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/181-644-906-271-665,Patent Application,yes,1,0,8,32,0,G01N21/29;;G01N33/558;;G01N33/57438;;G01N33/66;;G01N33/92;;C12Q1/52;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N21/78;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N2021/752;;G01N21/29;;G01N33/57438;;G01N33/66;;G01N33/92;;G01N33/54388;;G01N33/52;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/523;;G01N33/98,G01N33/52;;G01N21/29;;G01N21/78,,0,0,,,,ACTIVE
72,EP,B1,EP 2705366 B1,006-980-442-192-21X,2017-07-12,2017,EP 12779902 A,2012-05-04,US 201161518344 P;;US 2012/0036453 W,2011-05-04,DIAGNOSTIC DEVICE,,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/006-980-442-192-21X,Granted Patent,yes,8,0,6,6,0,G01N33/558;;G01N21/8483;;G01N2021/8494;;G01N21/6486;;Y02A50/30;;G01N33/525;;G01N21/8483;;G01N2021/8494;;Y02A50/30;;G01N33/54388;;G01N21/6486,G01N33/558;;G01N21/64;;G01N21/84,,0,0,,,,ACTIVE
73,EP,A4,EP 2701744 A4,085-970-402-528-15X,2014-08-20,2014,EP 12760977 A,2012-03-21,US 201161465704 P;;US 201161516035 P;;US 201161516970 P;;US 2012/0029940 W,2011-03-23,COMBINATION THERAPY,,POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/085-970-402-528-15X,Search Report,no,4,0,4,4,0,A61K45/06;;A61K45/06;;A61K31/573;;A61K31/573;;A61P1/00;;A61P1/18;;A61P5/00;;A61P7/00;;A61P9/00;;A61P13/00;;A61P13/10;;A61P13/12;;A61P19/00;;A61P19/04;;A61P21/00;;A61P25/00;;A61P27/00;;A61P29/00,A61K45/06;;A61K31/573;;A61K31/58,,6,4,099-440-781-829-98X;;012-128-760-011-414;;018-370-221-872-286;;037-199-529-897-764,10.1210/endo-119-1-375;;2424746;;10.1080/08916930500285550;;16373258;;10.1124/mol.63.5.1012;;12695529;;19120154;;10.1196/annals.1410.072,"KONAGAYA M ET AL: ""Blockade of glucocorticoid receptor binding and inhibition of dexamethasone-induced muscle atrophy in the rat by RU38486, a potent glucocorticoid antagonist."", ENDOCRINOLOGY, vol. 119, no. 1, July 1986 (1986-07-01), pages 375 - 380, XP009178827, ISSN: 0013-7227;;NORDMARK G ET AL: ""Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus"", AUTOIMMUNITY, vol. 38, no. 7, November 2005 (2005-11-01), pages 531 - 540, XP009178828, ISSN: 0891-6934;;DATABASE WPI Week 200537, Derwent World Patents Index; AN 2005-359571, XP002726581;;HONER CHRISTIAN ET AL: ""Glucocorticoid receptor antagonism by cyproterone acetate and RU486."", MOLECULAR PHARMACOLOGY, vol. 63, no. 5, May 2003 (2003-05-01), pages 1012 - 1020, XP002726582, ISSN: 0026-895X;;PEETERS B W M M ET AL: ""Differential Effects of the New Glucocorticoid Receptor Antagonist ORG 345177 and RU486 (Mifepristone) on Glucocorticoid Receptor Nuclear Translocation in the AtT20 Cell Line"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2008, & 9TH SYMPOSIUM ON CATECHOLAMINES AND OTHER NEUROTRANSMITTERE IN STRESS; BETHESDA, MD, USA; JUNE 16 -21, 2007, pages 536 - 541, XP002726583, ISSN: 0077-8923;;See also references of WO 2012129305A1",DISCONTINUED
74,EP,A1,EP 2705366 A1,101-080-873-390-074,2014-03-12,2014,EP 12779902 A,2012-05-04,US 201161518344 P;;US 2012/0036453 W,2011-05-04,DIAGNOSTIC DEVICE,,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/101-080-873-390-074,Patent Application,yes,0,0,6,6,0,G01N33/558;;G01N21/8483;;G01N2021/8494;;G01N21/6486;;Y02A50/30;;G01N33/525;;G01N21/8483;;G01N2021/8494;;Y02A50/30;;G01N33/54388;;G01N21/6486,G01N33/558;;G01N21/64;;G01N21/84,,0,0,,,,ACTIVE
75,US,A1,US 2016/0257989 A1,116-390-386-280-618,2016-09-08,2016,US 201615155803 A,2016-05-16,US 201615155803 A;;US 201514684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and Formulations for Detecting, Screening and Monitoring Levels of Certain Constituents in Bodily Fluids and Method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-ladencarrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2016-05-11),https://lens.org/116-390-386-280-618,Patent Application,yes,1,1,8,32,0,G01N21/29;;G01N33/558;;G01N33/57438;;G01N33/66;;G01N33/92;;C12Q1/52;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N21/78;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N2021/752;;G01N21/29;;G01N33/57438;;G01N33/66;;G01N33/92;;G01N33/54388;;G01N33/52;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/523;;G01N33/98,C12Q1/52;;G01N21/78,,1,0,,,"Pollock et al. 2012, vol. 4, Issue 152, pages 1-10.",ACTIVE
76,US,A1,US 2016/0279149 A1,134-627-090-407-70X,2016-09-29,2016,US 201615095293 A,2016-04-11,US 201615095293 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2016-04-01),https://lens.org/134-627-090-407-70X,Patent Application,yes,0,2,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K45/06;;B65D75/00;;B65D75/36,,0,0,,,,ACTIVE
77,US,A1,US 2014/0030233 A1,178-578-022-120-545,2014-01-30,2014,US 201313837408 A,2013-03-15,US 201313837408 A;;US 201261741925 P,2012-07-30,Therapeutic Compositions and Methods,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST CORTISOL LLC (2013-04-17);;POP TEST ONCOLOGY LLC (2015-03-31),https://lens.org/178-578-022-120-545,Patent Application,yes,1,3,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K31/565;;A61K31/58;;A61K35/12;;A61K35/28;;A61K35/545;;A61K45/06,424/93.7;;514/174;;514/179;;514/171,0,0,,,,ACTIVE
78,WO,A1,WO 2012/145258 A1,006-811-265-323-778,2012-10-26,2012,US 2012/0033731 W,2012-04-16,US 201161517343 P,2011-04-18,HAIR LOSS TREATMENT,This invention relates to the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or treatment of stress induced hair loss.,POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/006-811-265-323-778,Patent Application,yes,5,0,4,4,0,A61K8/63;;A61K8/63;;A61K31/00;;A61K31/00;;A61K31/58;;A61K31/58;;A61K2800/782;;A61K2800/782;;A61P17/00;;A61P17/10;;A61P17/14;;A61P31/00;;A61Q7/00;;A61Q7/00,A61K31/58;;A61P17/00;;A61P17/14;;A61Q5/12;;A61Q7/00,,2,0,,,"RUSSCHER HENDRIK.: ""Glucocorticoid Receptor Variants Modulate the Sensitivity to Cortisol."", 7 June 2006 (2006-06-07), XP055137965, Retrieved from the Internet <URL:http://www.repub.eur.nl/res/pub/7790/060607_Russcher-H.pdf>;;See also references of EP 2699245A4",PENDING
79,WO,A2,WO 2014/022340 A2,083-005-085-106-30X,2014-02-06,2014,US 2013/0052622 W,2013-07-30,US 201261741925 P;;US 201313837408 A,2012-07-30,THERAPEUTIC COMPOSTIONS AND METHODS,"This invention relates the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of Cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.",POP TEST CORTISOL LLC;;ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/083-005-085-106-30X,Patent Application,yes,11,1,13,13,0,A61P25/36;;A61K31/58;;A61K45/06;;A61K31/58;;A61K31/565;;A61K45/06;;A61K35/12;;A61P25/36;;A61K35/28;;A61K35/545,A61K35/28;;A61K35/545,,36,30,025-236-889-877-681;;035-784-409-496-514;;019-490-428-734-203;;022-633-679-770-667;;010-671-218-365-329;;003-208-707-292-88X;;024-188-874-869-363;;049-759-168-776-163;;016-420-757-875-004;;029-746-254-619-342;;155-397-001-403-661;;082-220-201-284-919;;126-109-329-996-893;;155-397-001-403-661;;018-953-278-576-570;;108-475-590-069-580;;001-884-727-265-660;;088-903-320-289-510;;004-077-820-380-629;;117-917-505-944-451;;059-261-751-454-502;;104-971-501-025-592;;071-535-527-040-313;;114-868-541-492-803;;079-248-305-753-026;;136-585-974-103-867;;049-511-830-248-64X;;084-593-952-947-714;;023-406-300-972-157;;036-784-657-029-073,16236742;;10.1056/nejmra050541;;10.1016/0092-8674(89)90237-7;;2644044;;10.1210/edrv-11-2-201;;2194782;;10.1146/annurev.bi.63.070194.002315;;10.1146/annurev.biochem.63.1.451;;7979245;;7857868;;10.1016/0960-0760(94)00155-f;;10.1016/0092-8674(92)90317-6;;1381289;;12077603;;10.1038/nature00870;;10.1016/j.cell.2004.11.011;;15620358;;19252477;;10.1038/nature07864;;pmc2667910;;10.1016/j.stem.2007.05.012;;18371333;;10.1038/nature05142;;16929302;;17667917;;10.1038/cr.2007.61;;16227970;;10.1038/nature04277;;10.1038/nature05142;;16929302;;18371431;;10.1016/j.stem.2007.12.013;;16990582;;10.1634/stemcells.2006-0377;;12634411;;10.1634/stemcells.21-2-152;;18941782;;10.1007/s00441-008-0696-3;;18615777;;10.1002/term.107;;18065397;;pmc3311226;;10.1634/stemcells.2007-0439;;10.1089/clo.2007.0027;;18154518;;10.1046/j.1365-2141.2003.04284.x;;12694261;;10.1089/scd.2009.0177;;19619003;;10.1007/978-3-642-77925-1;;10.1002/pen.20600;;16359251;;10.1586/17434440.3.1.29;;10.1055/s-0037-1613389;;12624643;;10656542;;10.1106/emcm-k7qc-gwgx-1k4v;;10.1177/088532820001400303;;7948588;;10.1016/0142-9612(94)90164-3;;17257666;;10.1016/j.biomaterials.2007.01.002,"RHEN T; CIDLOWSKI JA, NEJM, vol. 353, 2005, pages 1711 - 23;;GASC, J. -M.; BAULIEU, E. E.: ""Steroid Hormone Receptors: Their Intracellular Localisation"", 1987, ELLIS HORWOOD LTD., pages: 233 - 250;;BEATO, M., CELL, vol. 56, 1989, pages 335 - 344;;CARSON-JURICA, M. A.; SCHRADER, W. T.; O'MALLEY, B. W., ENDOCR. REV., vol. 11, 1990, pages 201 - 220;;GRONEMEYER, H.: ""Steroid Hormone Action"", 1993, OXFORD UNIVERSITY PRESS, pages: 94 - 117;;TSAI, M. J.; O'MALLEY, B. W., ANNU. REV. BIOCHEM., vol. 63, 1994, pages 451 - 486;;AKNER, G.; WIKSTROM, A. C.; GUSTAFSSON, J. A., J. STEROID BIOCHEM. MOL. BIOL., vol. 52, 1995, pages 1 - 16;;T.W. GREEN: ""Protective Groups in Organic Synthesis"", 1981, WILEY;;MATSUI ET AL.: ""Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture"", CELL, vol. 70, 1992, pages 841 - 847, XP024245512, DOI: doi:10.1016/0092-8674(92)90317-6;;JIANG ET AL.: ""Pluripotency of mesenchymal stem cells derived from adult marrow"", NATURE, vol. 418, 2002, pages 41 - 49, XP002559664, DOI: doi:10.1038/nature00870;;KANATSU-SHINOHARA ET AL.: ""Generation of pluripotent stem cells from neonatal mouse testis"", CELL, vol. 119, 2004, pages 1001 - 1012, XP002985005, DOI: doi:10.1016/j.cell.2004.11.011;;KAJI ET AL.: ""Virus-free induction of pluripotency and subsequent excision of reprogramming factors"", NATURE, 1 March 2009 (2009-03-01);;SHINYA YAMANAKA: ""Cell Stem Cell"", 1 July 2007, ELSEVIER INC, article ""Strategies and New Developments in the Generation of Patient-Specific Pluripotent Stem Cells"";;KLIMANSKAYA I; CHUNG Y; BECKER S; LU S J; LANZA R: ""Human embryonic stem cell lines derived from single blastomeres"", NATURE, vol. 444, 2006, pages 512, XP055307055, DOI: doi:10.1038/nature05366;;LEI ET AL.: ""Xeno-free derivation and culture of human embryonic stem cells: current status, problems and challenges"", CELL RESEARCH, vol. 17, 2007, pages 682 - 688;;CHUNG Y; KLIMANSKAYA I; BECKER S ET AL.: ""Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres"", NATURE, vol. 439, 2006, pages 216 - 219, XP007901044, DOI: doi:10.1038/nature04277;;KLIMANSKAYA I; CHUNG Y; BECKER S ET AL.: ""Human embryonic stem cell lines derived from single blastomeres"", NATURE, vol. 444, 2006, pages 481 - 485, XP009076989, DOI: doi:10.1038/nature05142;;CHUNG Y; KLIMANSKAYA I; BECKER S ET AL.: ""Human embryonic stem cell lines generated without embryo destruction"", CELL STEM CELL, vol. 2, 2008, pages 113 - 117;;ZHANG X; STOJKOVIC P; PRZYBORSKI S ET AL.: ""Derivation of human embryonic stem cells from developing and arrested embryos"", STEM CELLS, vol. 24, 2006, pages 2669 - 2676, XP002471258, DOI: doi:10.1634/stemcells.2006-0377;;LIN ET AL.: ""Multilineage potential of homozygous stem cells derived from metaphase II oocytes"", STEM CELLS, vol. 21, no. 2, 2003, pages 152 - 61, XP002243096, DOI: doi:10.1634/stemcells.21-2-152;;CHRIS H. JO ET AL.: ""Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion"", CELL TISSUE RES, vol. 334, 2008, pages 423 - 433, XP019716547;;WINSTON COSTA PEREIRA ET AL.: ""Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation"", J TISSUE ENG REGEN MED, vol. 2, 2008, pages 394 - 399;;TROYER; WEISS: ""Concise Review: Wharton's Jelly-Derived Cells Are a primitive Stromal Cell Population"", STEM CELLS, vol. 26, 2008, pages 591 - 599, XP055059242, DOI: doi:10.1634/stemcells.2007-0439;;KIM ET AL.: ""Ex vivo characteristics of human amniotic membrane-derived stem cells"", CLONING STEM CELLS, vol. 9, no. 4, 2007, pages 581 - 94, XP002465150, DOI: doi:10.1089/clo.2007.0027;;WEXLER ET AL.: ""Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. HAEMOPOIESIS AND LEUCOCYTES"", BRITISH JOURNAL OF HAEMATOLOGY, vol. 121, no. 2, April 2003 (2003-04-01), pages 368 - 374;;TA ET AL.: ""Long-term Expansion and Pluripotent Marker Array Analysis of Wharton's Jelly-Derived Mesenchymal Stem Cells"", STEM CELLS DEV, 20 July 2009 (2009-07-20);;BAILEY, J E.: ""Biochemical Engineering Fundamentals"", 1986, MCGRAW-HILL, INC.;;JACKSON A T.; JACKSON A T.: ""Verfahrenstechnik in der Biotechnologie"", 1993, SPRINGER;;""Remington's Pharmaceutical Sciences"", 2000, LIPPINCOTT, WILLIAMS & WILKINS;;TANAKA, S.; TAKIGAWA, T.; ICHIHARA, S.; NAKAMURA, T.: ""Mechanical properties of the bioabsorbable polyglycolic acid-collagen nerve guide tube"", POLYMER ENGINEERING & SCIENCE, vol. 46, 2006, pages 1461 - 1467, XP002535269, DOI: doi:10.1002/PEN.20600;;RAJESH VASITA; DHIRENDRA S KATTI: ""Growth factor delivery systems for tissue engineering: a materials perspective"", EXPERT REVIEWS IN MEDICAL DEVICES, vol. 3, no. 1, 2006, pages 29 - 47;;WONG C; INMAN E; SPAETHE R; HELGERSON S, THROMB. HAEMOST., vol. 89, no. 3, 2003, pages 573 - 582;;PANDIT A S; WILSON D J; FELDMAN D S: ""Fibrin scaffold as an effective vehicle for the delivery of acidic growth factor (FGF-1"", J. BIOMATERIALS APPLICATIONS, vol. 14, no. 3, 2000, pages 229 - 242;;DEBLOIS COTE M F.; DOILLON C J.: ""Heparin-fibroblast growth factor fibrin complex: in vitro and in vivo applications to collagen based materials"", BIOMATERIALS, vol. 15, no. 9, 1994, pages 665 - 672, XP002460505, DOI: doi:10.1016/0142-9612(94)90164-3;;LUONG-VAN ET AL.: ""In vitro biocompatibility and bioactivity of microencapsulated heparan sulphate"", BIOMATERIALS, vol. 28, 2007, pages 2127 - 2136, XP005876557, DOI: doi:10.1016/j.biomaterials.2007.01.002;;See also references of EP 2884984A4",PENDING
80,US,B2,US 9957547 B2,170-873-740-358-727,2018-05-01,2018,US 201715481782 A,2017-04-07,US 201715481782 A;;US 201615388697 A;;US 201615155803 A;;US 201514684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/170-873-740-358-727,Granted Patent,yes,12,0,8,32,0,G01N21/29;;G01N33/558;;G01N33/57438;;G01N33/66;;G01N33/92;;C12Q1/52;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N21/78;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N2021/752;;G01N21/29;;G01N33/57438;;G01N33/66;;G01N33/92;;G01N33/54388;;G01N33/52;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/523;;G01N33/98,G01N33/574;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/52;;G01N33/98,,7,6,011-793-407-045-692;;092-846-322-878-032;;090-767-439-476-784;;043-121-403-819-67X;;014-417-498-830-724;;084-943-987-603-564,17272484;;10.1373/clinchem.2006.081257;;10.1016/j.aca.2010.06.019;;20678634;;10488919;;10.1093/jat/23.5.333;;1311645;;10.1093/clinchem/38.2.298;;pmc3624093;;22993296;;10.1126/scitranslmed.3003981;;10.3390/s20400127,"Chang, Yoosoo et al, Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease, Clinical Chemistry 53:4, 2007, 686-692.;;Dungchai, Wijitar et al. Use of Multiple Colorimetric Indicators for Paper-Based Microfluidic Devices, Analytica Chimica Acta 674, 2010, 227-233.;;Jones, A.W. et al. Storage of Specimens at 4 Degrees C or Addition of Sodium Fluoride (1 Percent) Prevents Formation of Ethanol in Urine Inoculated with Candida Albicans, Journal of Analytical Toxicology, vol. 23, Sep. 1999, 333-336.;;Leary, N.O. et al, Improving Accuracy of Glucose Oxidase Procedure for Glucose Determinations on Discrete Analyzers, Clinical Chemistry, 38:2, 1992, 298-302.;;Pollock, Nira R. et al, A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing, Biomedical Engineering, 4:152, Sep. 19, 2012, 1-10.;;Ugwu, Sydney O. et al, The Effect of Buffers on Protein Conformational Stability, Pharmaceutical Technology, Mar. 2004, 86-113.;;Zhu, Jianzhong et al, Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian Blue Layer, Sensors 2, 2002, 127-136.",ACTIVE
81,US,A1,US 2015/0366882 A1,187-855-412-699-627,2015-12-24,2015,US 201514802060 A,2015-07-17,US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/187-855-412-699-627,Patent Application,yes,0,10,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K45/06;;B65D75/00;;B65D75/36,,0,0,,,,ACTIVE
82,US,A1,US 2016/0279148 A1,020-513-452-049-921,2016-09-29,2016,US 201615095248 A,2016-04-11,US 201615095248 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161462492 P;;US 201161463212 P;;US 201161465703 P;;US 201161518248 P;;US 201161519323 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2016-04-01),https://lens.org/020-513-452-049-921,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K9/00;;A61K31/58;;A61K31/337;;A61K51/00;;A61N5/10;;G01N33/74,,0,0,,,,ACTIVE
83,US,A1,US 2018/0325920 A1,025-567-264-928-131,2018-11-15,2018,US 201816035896 A,2018-07-16,US 201816035896 A;;US 201715478368 A;;US 201615095248 A;;US 201514802060 A;;US 201314100714 A;;US 201213364651 A;;US 201161519323 P;;US 201161518248 P;;US 201161465703 P;;US 201161463212 P;;US 201161462492 P,2011-02-03,System and Method for Diagnosis and Treatment,"This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (2015-07-15),https://lens.org/025-567-264-928-131,Patent Application,yes,0,0,21,43,0,A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K31/58;;A61K45/06;;A61K31/58;;A61K45/06;;B65D75/002;;B65D75/36;;A61J1/10;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/337;;C07J17/00;;A61K38/09;;A61K9/0053;;A61N2005/1091;;A61N2005/1098;;B65D75/367;;A61K9/0019;;A61K51/00;;G01N33/743;;G01N2333/575;;G01N2800/56,A61K31/58;;A61J1/10;;A61K9/00;;A61K9/08;;A61K9/10;;A61K9/107;;A61K31/337;;A61K38/09;;A61K45/06;;A61K47/10;;A61K47/26;;A61K47/34;;A61K47/42;;A61K47/44;;A61K51/00;;A61N5/10;;B65D75/00;;B65D75/36;;C07J17/00;;G01N33/74,,0,0,,,,DISCONTINUED
84,EP,A2,EP 2671086 A2,164-719-516-786-548,2013-12-11,2013,EP 12742639 A,2012-02-02,US 201161463212 P;;US 201161462492 P;;US 201161518248 P;;US 201161465703 P;;US 201161519323 P;;US 2012/0023630 W,2011-02-03,SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT,,POP TEST CORTISOL LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ONCOLOGY LLC (2018-01-17),https://lens.org/164-719-516-786-548,Patent Application,yes,0,0,19,43,0,A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;A61P1/16;;A61P11/00;;A61P13/08;;A61P15/00;;A61P25/00;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P35/00;;A61P35/02;;A61P3/08;;A61P43/00;;A61P5/00;;A61K31/00;;A61K31/337;;A61K45/06;;C07J17/00;;G01N33/743;;G01N2800/04;;G01N2800/304;;G01N2800/52;;G01N2800/7004;;A61N5/1001;;A61K47/10;;A61K47/26;;A61K47/34;;A61K9/08;;A61K9/10;;A61K9/107;;A61K47/42;;A61K47/44;;A61K31/58;;B65D75/367;;A61K9/0019,G01N33/74;;A61P35/00;;C07J1/00;;G01N33/52;;G01N33/53;;G01N33/58,,0,0,,,,ACTIVE
85,US,B1,US 9651545 B1,190-409-011-627-655,2017-05-16,2017,US 201615388697 A,2016-12-22,US 201615388697 A;;US 201615155803 A;;US 201514684861 A;;US 201314684861 A;;US 201313836679 A;;US 201213606299 A;;US 201113278306 A;;US 45552810 P;;US 45553110 P;;US 45553210 P;;US 201161462890 P,2010-10-23,"Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method","A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/190-409-011-627-655,Granted Patent,yes,11,0,8,32,0,G01N21/29;;G01N33/558;;G01N33/57438;;G01N33/66;;G01N33/92;;C12Q1/52;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N33/52;;C12Q1/52;;G01N21/78;;G01N2333/91188;;C12Y206/01001;;C12Y206/01002;;G01N2800/085;;G01N2021/752;;G01N21/29;;G01N33/57438;;G01N33/66;;G01N33/92;;G01N33/54388;;G01N33/52;;C12Q1/54;;C12Q1/60;;C12Q1/62;;G01N33/523;;G01N33/98,G01N21/78;;G01N21/29;;G01N21/75;;G01N33/52,,7,6,011-793-407-045-692;;092-846-322-878-032;;090-767-439-476-784;;043-121-403-819-67X;;014-417-498-830-724;;084-943-987-603-564,17272484;;10.1373/clinchem.2006.081257;;10.1016/j.aca.2010.06.019;;20678634;;10488919;;10.1093/jat/23.5.333;;1311645;;10.1093/clinchem/38.2.298;;pmc3624093;;22993296;;10.1126/scitranslmed.3003981;;10.3390/s20400127,"Chang, Yoosoo et al, Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease, Clinical Chemistry 53:4, 2007, 686-692.;;Dungchai, Wijitar et al. Use of Multiple Colorimetric Indicators for Paper-Based Microfluidic Devices, Analytica Chimica Acta 674, 2010, 227-233.;;Jones, A.W. et al. Storage of Specimens at 4 Degrees C or Addition of Sodium Fluoride (1 Percent) Prevents Formation of Ethanol in Urine Inoculated with Candida Albicans, Journal of Analytical Toxicology, vol. 23, Sep. 1999, 333-336.;;Leary, N.O. et al, Improving Accuracy of Glucose Oxidase Procedure for Glucose Determinations on Discrete Analyzers, Clinical Chemistry, 38:2, 1992, 298-302.;;Pollock, Nira R. et al, A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing, Biomedical Engineering, 4:152, Sep. 19, 2012, 1-10.;;Ugwu, Sydney O. et al, The Effect of Buffers on Protein Conformational Stability, Pharmaceutical Technology, Mar. 2004, 86-113.;;Zhu, Jianzhong et al, Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian Blue Layer, Sensors 2, 2002, 127-136.",ACTIVE
86,US,A1,US 2012/0282636 A1,199-386-204-525-960,2012-11-08,2012,US 201213463956 A,2012-05-04,US 201213463956 A;;US 201161518344 P,2011-05-04,Diagnostic Device,"The invention provides for rapid response analysis through lateral flow chromatographic assays of specific antigens present in human or animal fluids, or in agricultural, microbial or biological products, with an audio and visual result of the analysis and when needed, an electronic surge to provide heat for rapid results. A lateral flow device for conducting the analysis includes a plurality of components, and a method for making the device forms components of the device on an elongate, ribbon-like substrate of dielectric material, then folds the substrate into shorter lengths which are then secured together to establish a multiple-layered, self-sustaining structure.",ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA;;POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2012-05-03),https://lens.org/199-386-204-525-960,Patent Application,yes,11,23,6,6,0,G01N33/558;;G01N21/8483;;G01N2021/8494;;G01N21/6486;;Y02A50/30;;G01N33/525;;G01N21/8483;;G01N2021/8494;;Y02A50/30;;G01N33/54388;;G01N21/6486,C12M1/42;;G01N21/76;;G01N33/558,435/7.92;;435/287.2;;435/287.8;;436/501;;422/69;;422/52,0,0,,,,INACTIVE
87,EP,A1,EP 3643355 A1,144-476-201-683-369,2020-04-29,2020,EP 19214446 A,2015-05-04,US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P;;EP 15803922 A;;US 2015/0029042 W,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,"This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
",POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/144-476-201-683-369,Patent Application,yes,63,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M37/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61J1/00;;A61K9/00;;A61K9/52;;A61K31/485;;A61K31/56;;A61K31/58;;A61K45/06;;A61P25/00;;A61P25/30;;G16H20/13;;G16Z99/00,,27,16,015-540-247-449-427;;042-757-454-082-310;;074-944-999-297-287;;033-710-967-568-610;;033-271-950-020-219;;078-268-154-838-349;;045-245-065-721-895;;019-444-785-471-23X;;040-651-091-410-435;;027-865-154-389-542;;056-400-940-126-055;;003-370-630-789-585;;156-847-182-016-32X;;100-692-997-533-285;;012-431-558-746-697;;102-808-039-029-83X,10.1177/193229680900300121;;20046663;;pmc2769845;;15790850;;10.1126/science.1109128;;10.1038/35104535;;11713525;;10.1038/nature03456;;15846341;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;12071849;;pmc1222666;;10.1042/bj20011727;;7613863;;10.1016/s0969-2126(01)00164-2;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1063/1.1763252;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/0956-5663(96)82336-0;;8828165;;10.1021/nl903377u;;20102189;;10.1021/ja0163164;;11525685;;19203203;;10.1021/nl803904b;;10.1063/1.3160542;;17218431;;10.1152/japplphysiol.00105.2006,"MOORE, J. DIABETES SCI. TECHNOL., vol. 3, 2009, pages 180 - 183;;SNOW SCIENCE, vol. 307, 2005, pages 1942 - 1945;;HAGLEITNER ET AL., NATURE, vol. 414, 2001, pages 293 - 296;;YUSA ET AL., NATURE, vol. 343, 2005, pages 1001 - 1005;;""The Biomedical Engineering Handbook"", vol. I, 2000, CRC PRESS LLC, pages: V-1 - 51,9;;MORRISON ET AL.: ""Biomedical Nanostructures"", 2008, JOHN WILEY & SONS, INC., article ""Clinical Applications of Micro- and Nanoscale Biosensors"";;MATTLEY ET AL.: ""Proc. SPIE Advances in Fluorescence Sensing Technology II"", vol. 2388, 1995, article ""Blood characterization using UV/VIS spectroscopy"", pages: 462 - 470;;HONES ET AL., DIABETES TECHN & THERAP, vol. 10, no. 1, pages S 10 - S26;;HERMANIDESDEVRIES, DIABETOLOGIA, vol. 53, 2010, pages 593 - 596;;NIELSEN ET AL., J. DIABETES SCI. TECHNOL., vol. 2, 2008, pages 1066 - 1074;;WADUM ET AL., BIOCHEM. J., vol. 365, 2002, pages 165 - 172;;RAGHAVANBJORKMAN, STRUCTURE, vol. 3, 1995, pages 331 - 333;;FAN ET AL., ANAL. CHIM. ACTA, vol. 620, 2008, pages 8 - 26;;LAVRIK ET AL., REV. SCI. INST, vol. 75, no. 4, 2004, pages 2229 - 2253;;VASHIST J, NANOTECH ONLINE, vol. 3, 2007;;YANG ET AL., IEEE SENSORS, 2006;;DURICKNEGULESCU, BIOSENS. BIOELECTRON, vol. 16, 2001, pages 587 - 592;;SCHMIDT ET AL., BIOSENSORS BIOELECTRONICS, vol. 11, 1996, pages 1139 - 1145;;T.W. GREEN: ""Protective Groups in Organic Synthesis"", 1981, WILEY;;""Martindale's The Extra Pharmacopoeia"", 1996, THE PHARMACEUTICAL PRESS;;""Physician's Desk Reference"", 2005;;QI ET AL., NANO LETT., vol. 10, 2010, pages 524 - 528;;CHEN T ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 8630 - 8631;;YANG ET AL., NATURE NANOTECHNOL., vol. 4, 2009, pages 34 - 39;;YANG ET AL., NANO LETT., vol. 9, 2009, pages 1201 - 1205;;WACHARASINDHUT ET AL., APPL. PHYS. LETT., vol. 95, 2009, pages 014103;;BUDGETT ET AL., J. APPL. PHYSIOL., vol. 102, 2007, pages 1658 - 1663",PENDING
88,US,B2,US 10245323 B2,140-771-095-633-128,2019-04-02,2019,US 201815987462 A,2018-05-23,US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/140-771-095-633-128,Granted Patent,yes,62,1,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61K45/06;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61M5/14;;A61M31/00;;G16H20/10;;G16H20/13;;G16H40/63;;G16Z99/00,,36,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102: 1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620(1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10(2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Supplementary European Search Report for related European Patent Application No. EP15803922 dated Dec. 22, 2017.",ACTIVE
89,EP,A4,EP 3758778 A4,074-211-756-056-712,2022-01-26,2022,EP 19761669 A,2019-02-27,US 201862636196 P;;US 201862650165 P;;US 201862655367 P;;US 201862723071 P;;US 2019/0019744 W,2018-02-28,MEDICAL DEVICES AND USES THEREOF,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/074-211-756-056-712,Search Report,no,6,0,4,4,0,A61M2230/201;;A61M2205/3561;;A61M5/14244;;A61M2210/1071;;A61M2230/20;;A61M2205/502;;A61M2205/3303;;A61M2205/3368;;A61M2205/3324;;A61M2205/3306;;A61M5/427;;A61M5/46;;A61M1/3489;;A61M2209/088;;A61B2034/2055;;A61B5/021;;A61B5/14546;;A61B5/4845;;A61B5/4866;;A61M5/14244;;A61M5/14276;;A61M2202/0413;;A61M2202/0415;;A61M2205/18;;A61M2205/3584;;A61M2205/50;;G01N33/57438;;A61M1/3489;;A61M2210/1071;;A61M2210/1082;;A61M1/3623;;A61M1/3486;;A61M1/1601;;C12M3/06;;C12M23/44;;C12M3/065;;C12M3/067;;C12M23/42;;C12M23/58;;C12M25/14,A61M5/46;;A61K9/00;;A61M1/34;;A61M5/00;;A61M5/142;;A61M5/42,,4,4,037-221-042-514-651;;067-180-274-139-694;;007-015-545-989-215;;028-266-461-874-814,10.1016/s0168-8278(99)80078-6;;10068112;;10.1263/jbb.99.311;;16233796;;10.3727/000000006783982296;;16826801;;29210278;;10.1021/acsami.7b13727,"FLENDRIG LEONARD M ET AL: ""Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific [alpha]-GST detection to monitor hepatocyte viability"", JOURNAL OF HEPATOLOGY, vol. 30, no. 2, 1 January 1999 (1999-01-01), pages 311 - 320, XP085006260, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(99)80078-6;;PARK J K ET AL: ""Bioartificial liver systems: current status and future perspective"", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, vol. 99, no. 4, 1 April 2005 (2005-04-01), pages 311 - 319, XP027707168, ISSN: 1389-1723, [retrieved on 20050401];;GERLACH JOERG C: ""Bioreactors for extracorporeal liver support"", CELL TRANSPLANTATION, SAGE, US, vol. 15, no. Suppl. 1, 1 January 2006 (2006-01-01), pages S91 - S103, XP009123199, ISSN: 0963-6897, DOI: 10.3727/000000006783982296;;DAMANIA APEKSHA ET AL: ""Decellularized Liver Matrix-Modified Cryogel Scaffolds as Potential Hepatocyte Carriers in Bioartificial Liver Support Systems and Implantable Liver Constructs"", APPLIED MATERIALS & INTERFACES, vol. 10, no. 1, 10 January 2018 (2018-01-10), US, pages 114 - 126, XP055872368, ISSN: 1944-8244, DOI: 10.1021/acsami.7b13727",PENDING
90,EP,B1,EP 3151906 B1,084-513-883-787-08X,2019-12-11,2019,EP 15803922 A,2015-05-04,US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P;;US 2015/0029042 W,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/084-513-883-787-08X,Granted Patent,yes,6,10,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,G16H20/13;;A61B5/00;;A61B5/01;;A61B5/145;;A61J1/00;;A61K9/00;;A61K9/52;;A61K31/485;;A61K31/56;;A61K31/58;;A61K45/06;;A61M31/00;;A61M37/00;;A61P25/00;;A61P25/30;;G16H40/63;;G16Z99/00,,0,0,,,,ACTIVE
91,EP,A1,EP 3151906 A1,194-327-074-355-251,2017-04-12,2017,EP 15803922 A,2015-05-04,US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P;;US 2015/0029042 W,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/194-327-074-355-251,Patent Application,yes,0,1,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M37/00;;A61J1/00;;A61K9/52;;A61K31/485;;A61K31/56;;A61P25/00;;A61P25/30;;G16Z99/00,,0,0,,,,ACTIVE
92,US,A1,US 2019/0374252 A1,030-568-517-623-439,2019-12-12,2019,US 201916548071 A,2019-08-22,US 201916548071 A;;US 201815758531 A;;US 2016/0050893 W;;US 201562217347 P,2015-09-11,METHOD OF USING AN INTRADERMAL APPLICATOR FOR DELIVERING A SENSOR WITHIN THE SKIN,"The present invention provides for a method and apparatus for inserting and using, dermal interstitial sensors in, for example, an analyte monitoring system. The present invention permits the proper positioning of a cannula tip and/or sensor(s) within the reticular dermis.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2018-03-09),https://lens.org/030-568-517-623-439,Patent Application,yes,0,0,8,8,0,A61B17/3468;;A61B17/3468;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/1451;;A61B5/1451;;A61B5/14532;;A61B5/14546;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B10/0045;;A61B10/0045;;A61B10/0233;;A61B10/0233;;A61B17/34;;A61B17/34;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B90/20;;A61B2010/008;;A61B2010/008;;A61B2017/3407;;A61B2034/2057;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B2560/066;;A61M37/00;;A61M37/00;;A61M37/0069,A61B17/34;;A61B5/00;;A61B5/07;;A61B5/145;;A61B34/20;;A61B90/20;;A61M37/00,,0,0,,,,ACTIVE
93,US,B2,US 10625063 B2,043-476-172-021-398,2020-04-21,2020,US 201916548414 A,2019-08-22,US 201916548414 A;;US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/043-476-172-021-398,Granted Patent,yes,62,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;A61M5/14;;G16H20/10;;G16H20/13;;G16H40/63;;G16Z99/00,,36,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102: 1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620 (1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10(2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Patent No. 9,662,392.;;Supplementary European Search Report for related European Patent Application No. EP15803922 dated Dec. 22, 2017.",ACTIVE
94,US,A1,US 2017/0106178 A1,090-177-226-742-436,2017-04-20,2017,US 201515315400 A,2015-05-04,US 201515315400 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P;;US 2015/0029042 W,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2017-01-11),https://lens.org/090-177-226-742-436,Patent Application,yes,8,6,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61K31/58;;A61K45/06;;G16Z99/00,,0,0,,,,ACTIVE
95,US,A1,US 2023/0060681 A1,115-952-740-282-452,2023-03-02,2023,US 202217977461 A,2022-10-31,US 202217977461 A;;US 202016822921 A;;US 201916548414 A;;US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/115-952-740-282-452,Patent Application,yes,4,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61B5/00;;G16H20/13;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;A61M31/00;;G16Z99/00,,0,0,,,,PENDING
96,EP,A1,EP 3758778 A1,061-135-801-693-590,2021-01-06,2021,EP 19761669 A,2019-02-27,US 201862636196 P;;US 201862650165 P;;US 201862655367 P;;US 201862723071 P;;US 2019/0019744 W,2018-02-28,MEDICAL DEVICES AND USES THEREOF,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/061-135-801-693-590,Patent Application,yes,0,0,4,4,2,A61M2230/201;;A61M2205/3561;;A61M5/14244;;A61M2210/1071;;A61M2230/20;;A61M2205/502;;A61M2205/3303;;A61M2205/3368;;A61M2205/3324;;A61M2205/3306;;A61M5/427;;A61M5/46;;A61M1/3489;;A61M2209/088;;A61B2034/2055;;A61B5/021;;A61B5/14546;;A61B5/4845;;A61B5/4866;;A61M5/14244;;A61M5/14276;;A61M2202/0413;;A61M2202/0415;;A61M2205/18;;A61M2205/3584;;A61M2205/50;;G01N33/57438;;A61M1/3489;;A61M2210/1071;;A61M2210/1082;;A61M1/3623;;A61M1/3486;;A61M1/1601;;C12M3/06;;C12M23/44;;C12M3/065;;C12M3/067;;C12M23/42;;C12M23/58;;C12M25/14,A61M5/46;;A61K9/00;;A61M5/00,,0,0,,,,PENDING
97,US,A1,US 2017/0259050 A1,013-553-358-149-638,2017-09-14,2017,US 201715494077 A,2017-04-21,US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug Device Configured for Wireless Communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/013-553-358-149-638,Patent Application,yes,0,7,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;G16Z99/00,,0,0,,,,ACTIVE
98,US,A1,US 2015/0343144 A1,055-627-673-242-704,2015-12-03,2015,US 201514703163 A,2015-05-04,US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug Device Configured for Wireless Communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/055-627-673-242-704,Patent Application,yes,13,74,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M5/172;;A61K31/58;;A61K45/06;;G16Z99/00,,0,0,,,,ACTIVE
99,US,A1,US 2020/0222677 A1,121-121-555-466-284,2020-07-16,2020,US 202016822921 A,2020-03-18,US 202016822921 A;;US 201916548414 A;;US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug Device Configured for Wireless Communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/121-121-555-466-284,Patent Application,yes,0,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;G16H20/10;;G16H20/13;;G16Z99/00,,0,0,,,,ACTIVE
100,US,A1,US 2018/0256208 A1,031-257-301-621-678,2018-09-13,2018,US 201615758531 A,2016-09-09,US 201615758531 A;;US 201562217347 P;;US 2016/0050893 W,2015-09-11,THERAPEUTIC METHOD AND DEVICE,"The present invention provides for a method and apparatus for inserting and using dermal interstitial sensors in, for example, an analyte monitoring system. The present invention permits the proper positioning of a cannula tip and/or sensor(s) within the reticular dermis.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2018-03-09),https://lens.org/031-257-301-621-678,Patent Application,yes,9,9,8,8,0,A61B17/3468;;A61B17/3468;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/1451;;A61B5/1451;;A61B5/14532;;A61B5/14546;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B10/0045;;A61B10/0045;;A61B10/0233;;A61B10/0233;;A61B17/34;;A61B17/34;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B90/20;;A61B2010/008;;A61B2010/008;;A61B2017/3407;;A61B2034/2057;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B2560/066;;A61M37/00;;A61M37/00;;A61M37/0069,A61B17/34;;A61B5/00;;A61B5/07;;A61B5/145;;A61B34/20;;A61B90/20;;A61M37/00,,2,2,074-898-308-787-603;;074-898-308-787-603,10.1109/sensor.2003.1215385;;10.1109/sensor.2003.1215385,"MURAKAMI et al.; ""A miniature confocal optical microscope with MEMS gimbal scanner""; Transducers '03; The 12th International Conference on Solid State Sensors, Actuators and Microsystems; June 8-12, 2003; pp. 587-590; IEEE.;;MURAKAMI et al.; ""A miniature confocal optical microscope with MEMS gimbal scanner""; Transducers '03; The 12th International Conference on Solid State Sensors, Actuators and Microsystems; June 8-12, 2003; pp. 587-590; IEEE.",INACTIVE
101,US,B2,US 11527315 B2,083-095-588-180-87X,2022-12-13,2022,US 202016822921 A,2020-03-18,US 202016822921 A;;US 201916548414 A;;US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/083-095-588-180-87X,Granted Patent,yes,64,1,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;A61M5/14;;G16H20/10;;G16H20/13;;G16H40/63;;G16Z99/00,,36,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102:1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123,8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008,620 (1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1):S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10 (2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Harmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, ittps://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator” Nano Lett, 2009,9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392, dated Nov. 15, 2016.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392, dated Nov. 15, 2016.;;Supplementary European Search Report for related European Patent Application No. EP15803922 dated Dec. 22, 2017.",ACTIVE
102,US,A1,US 2019/0151635 A1,090-272-092-694-12X,2019-05-23,2019,US 201916259308 A,2019-01-28,US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/090-272-092-694-12X,Patent Application,yes,0,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;G16H20/10;;G16H20/13;;G16Z99/00,,0,0,,,,ACTIVE
103,US,B2,US 9662392 B2,055-134-172-837-579,2017-05-30,2017,US 201514703163 A,2015-05-04,US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST LLC;;POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/055-134-172-837-579,Granted Patent,yes,23,7,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61K9/22;;A61K31/58;;A61K45/06;;A61M5/14;;G16Z99/00,,4,0,,,"Bernstein, et al., “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job’”, The Washington Post, Oct. 22, 2016, https://www.washingtonpost.com/investigations/how-drugs-intended-for-patients-ended-up-in-the-hands-of-illegal-users-no-one-was-doing-their-job/2016/10/22/10e79396-30a7-11e6-8ff7-7b6c1998b7a0—story.html.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.",ACTIVE
104,US,B2,US 9878138 B2,089-235-651-177-076,2018-01-30,2018,US 201515315400 A,2015-05-04,US 201515315400 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P;;US 2015/0029042 W,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2017-01-11),https://lens.org/089-235-651-177-076,Granted Patent,yes,57,20,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61K31/58;;A61K45/06;;G16Z99/00,,35,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102: 1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620 (1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10 (2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.",ACTIVE
105,US,B2,US 10441762 B2,176-094-457-897-341,2019-10-15,2019,US 201916259308 A,2019-01-28,US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/176-094-457-897-341,Granted Patent,yes,64,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;A61M5/14;;G16H20/10;;G16H20/13;;G16H40/63;;G16Z99/00,,36,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102: 1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620(1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 1050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10 (2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Patent No. 9,662,392.;;Supplementary European Search Report for related European Patent Application No. EP15803922 dated Dec. 22, 2017.",ACTIVE
106,US,B2,US 10653447 B2,174-506-190-214-454,2020-05-19,2020,US 201916548071 A,2019-08-22,US 201916548071 A;;US 201815758531 A;;US 2016/0050893 W;;US 201562217347 P,2015-09-11,Method of using an intradermal applicator for delivering a sensor within the skin,"The present invention provides for a method and apparatus for inserting and using, dermal interstitial sensors in, for example, an analyte monitoring system. The present invention permits the proper positioning of a cannula tip and/or sensor(s) within the reticular dermis.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2018-03-09),https://lens.org/174-506-190-214-454,Granted Patent,yes,39,0,8,8,0,A61B17/3468;;A61B17/3468;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/1451;;A61B5/1451;;A61B5/14532;;A61B5/14546;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B10/0045;;A61B10/0045;;A61B10/0233;;A61B10/0233;;A61B17/34;;A61B17/34;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B90/20;;A61B2010/008;;A61B2010/008;;A61B2017/3407;;A61B2034/2057;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B2560/066;;A61M37/00;;A61M37/00;;A61M37/0069,A61B5/145;;A61B5/00;;A61B5/07;;A61B10/00;;A61B10/02;;A61B17/34;;A61B34/20;;A61B90/00;;A61B90/20;;A61B90/30;;A61M37/00,,17,9,102-036-669-955-443;;033-271-950-020-219;;015-540-247-449-427;;002-266-416-749-463;;025-832-912-174-847;;066-129-492-627-899;;042-757-454-082-310;;074-944-999-297-287;;033-710-967-568-610,10.1089/dia.2008.0005;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;15790850;;10.1126/science.1109128;;10.1038/35104535;;11713525;;10.1038/nature03456;;15846341,"Mattley, Y. D., et al. “Blood characterization using UV/vis spectroscopy.” In Advances in Fluorescence Sensing Technology II, vol. 2388, pp. 462-471. International Society for Optics and Photonics, 1995.;;Lakowicz, J. R. “Advances in fluorescence sensing technology II.” In Proc. SPIE, vol. 2388, pp. 159-170. 1995.;;Hoenes, J. et al. “The technology behind glucose meters: test strips.” Diabetes Technology & Therapeutics 10, No. S1 (2008): S-10, Abstract.;;Hermanides, J., and J. H. DeVries. “Sense and nonsense in sensors.” Diabetologia 53, No. 4 (2010): 593-596.;;Moore, B. “The potential use of radio frequency identification devices for active monitoring of blood glucose levels.” Journal of diabetes science and technology 3, No. 1 (2009): 180-183.;;Nielsen, J. et al. “Clinical evaluation of a transcutaneous interrogated fluorescence lifetime-based microsensor for continuous glucose reading.” Journal of diabetes science and technology 3, No. 1 (2009): 98-109.;;Li, S. et al. “Development of novel glucose sensing fluids with potential application to microelectromechanical systems-based continuous glucose monitoring.” Journal of diabetes science and technology 2, No. 6 (2008): 1066-1074.;;Mok, W., and Li, Y. “Recent progress in nucleic acid aptamer-based biosensors and bioassays.” Sensors 8, No. 11 (2008): 7050-7084.;;Snow, E. S. et al. “Chemical detection with a single-walled carbon nanotube capacitor.” Science 307, No. 5717 (2005): 1942-1945.;;Hagleitner, C. et al. “Smart single-chip gas sensor microsystem.” Nature 414, No. 6861 (2001): 293, Abstract.;;“Electroacupuncture.” Acupuncture Today—The Leading Provider of Acupuncture and Traditional Chinese Medicine News and Research Information in the World—TCM—Find an Acupuncturist. Accessed Mar. 4, 2019. https://www.acupuncturetoday.com/abc/electroacupuncture.php.;;International Search Report for PCT Application No. PCT/US2016/050893 dated Dec. 29, 2016.;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spins in a Nonometre-Scale Device”, Nature 434, pp. 1001-1005 (Apr. 21, 2005).;;Bronzino, Joseph D. “The Biomedical Engineering Handbook”, Second Edition, Introduction and Preface (2000).;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454 (2008).;;Lakowicz, Joseph R., “Principles of Fluorescence Spectroscopy”, Second Edition, Introduction to Fluoresecense, pp. 1-2 (1999).;;“Who Standard Acupuncture Point Locations in the Western Pacific Region”, World Health Organization, Wester Pacific Region, pp. 1-21, 66, 67 (2008).",ACTIVE
107,US,B2,US 10441316 B2,191-950-309-029-123,2019-10-15,2019,US 201615758531 A,2016-09-09,US 201615758531 A;;US 201562217347 P;;US 2016/0050893 W,2015-09-11,Intradermal applicator/analyte sensor placement using fluorescence,"The present invention provides for a method and apparatus for inserting and using dermal interstitial sensors in, for example, an analyte monitoring system. The present invention permits the proper positioning of a cannula tip and/or sensor(s) within the reticular dermis.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2018-03-09),https://lens.org/191-950-309-029-123,Granted Patent,yes,40,0,8,8,0,A61B17/3468;;A61B17/3468;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/1451;;A61B5/1451;;A61B5/14532;;A61B5/14546;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B10/0045;;A61B10/0045;;A61B10/0233;;A61B10/0233;;A61B17/34;;A61B17/34;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B90/20;;A61B2010/008;;A61B2010/008;;A61B2017/3407;;A61B2034/2057;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B2560/066;;A61M37/00;;A61M37/00;;A61M37/0069,A61B5/145;;A61B5/00;;A61B5/07;;A61B10/00;;A61B10/02;;A61B17/34;;A61B34/20;;A61B90/00;;A61B90/20;;A61B90/30;;A61M37/00,,15,9,074-898-308-787-603;;102-036-669-955-443;;033-271-950-020-219;;015-540-247-449-427;;002-266-416-749-463;;025-832-912-174-847;;066-129-492-627-899;;042-757-454-082-310;;074-944-999-297-287,10.1109/sensor.2003.1215385;;10.1089/dia.2008.0005;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;15790850;;10.1126/science.1109128;;10.1038/35104535;;11713525,"Murakami et al.; “A miniature confocal optical microscope with MEMS gimbal scanner”; Transducers '03; The 12th International Conference on Solid State Sensors, Actuators and Microsystems; Jun. 8-12, 2003; pp. 587-590; IEEE.;;PCT Written Opinion of PCT/US2016/050893 dated Mar. 22, 2018.;;International Search Report of PCT/US2016/050893 dated Dec. 29, 2016.;;Mattley, Y. D., et al. “Blood characterization using UV/vis spectroscopy.” In Advances in Fluorescence Sensing Technology II, vol. 2388, pp. 462-471. International Society for Optics and Photonics, 1995.;;Lakowicz, J. R. “Advances in fluorescence sensing technology II.” In Proc. SPIE, vol. 2388, pp. 159-170. 1995.;;Hoenes, J. et al. “The technology behind glucose meters: test strips.” Diabetes Technology & Therapeutics 10, No. S1 (2008): S-10, Abstract.;;Hermanides, J., and J. H. DeVries. “Sense and nonsense in sensors.” Diabetologia 53, No. 4 (2010): 593-596.;;Moore, B. “The potential use of radio frequency identification devices for active monitoring of blood glucose levels.” Journal of diabetes science and technology 3, No. 1 (2009): 180-183.;;Nielsen, J. et al. “Clinical evaluation of a transcutaneous interrogated fluorescence lifetime-based microsensor for continuous glucose reading.” Journal of diabetes science and technology 3, No. 1 (2009): 98-109.;;Li, S. et al. “Development of novel glucose sensing fluids with potential application to microelectromechanical systems-based continuous glucose monitoring.” Journal of diabetes science and technology 2, No. 6 (2008): 1066-1074.;;Mok, W., and Li, Y. “Recent progress in nucleic acid aptamer-based biosensors and bioassays.” Sensors 8, No. 11 (2008): 7050-7084.;;Snow, E S. et al. “Chemical detection with a single-walled carbon nanotube capacitor.” Science 307, No. 5717 (2005): 1942-1945.;;Hagleitner, C. et al. “Smart single-chip gas sensor microsystem.” Nature 414, No. 6861 (2001): 293, Abstract.;;“Electroacupuncture.” Acupuncture Today—The Leading Provider of Acupuncture and Traditional Chinese Medicine News and Research Information in the World—TCM—Find an Acupuncturist. Accessed Mar. 4, 2019. https://www.acupuncturetoday.com/abc/electroacupuncture.php.;;Supplementary European Search Report for corresponding European Patent Application No. EP16845095 dated Aug. 26, 2019.",INACTIVE
108,US,A1,US 2018/0078748 A1,057-565-457-573-869,2018-03-22,2018,US 201715822778 A,2017-11-27,US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/057-565-457-573-869,Patent Application,yes,0,2,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;G16Z99/00,,0,0,,,,ACTIVE
109,US,B2,US 9878139 B2,123-645-674-205-896,2018-01-30,2018,US 201715494077 A,2017-04-21,US 201715494077 A;;US 201514703163 A;;US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC;;POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/123-645-674-205-896,Granted Patent,yes,58,12,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;G16Z99/00,,35,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102:1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620(1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10(2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhatten Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Patent No. 9,662,392.",ACTIVE
110,US,A1,US 2021/0162125 A1,004-347-364-376-77X,2021-06-03,2021,US 201916992705 A,2019-02-27,US 201916992705 A;;US 201862636196 P;;US 201862650165 P;;US 201862655367 P;;US 201862723071 P;;US 2019/0019744 W,2018-02-28,Medical Devices and Uses Thereof,"The present invention provides for a method and apparatus for inserting and using dermal interstitial sensors in, for example, an analyte monitoring system, and for injecting active pharmaceutical ingredients, a bio-artificial organ device, and detection of a protein biomarker.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/004-347-364-376-77X,Patent Application,yes,13,6,4,4,2,A61M2230/201;;A61M2205/3561;;A61M5/14244;;A61M2210/1071;;A61M2230/20;;A61M2205/502;;A61M2205/3303;;A61M2205/3368;;A61M2205/3324;;A61M2205/3306;;A61M5/427;;A61M5/46;;A61M1/3489;;A61M2209/088;;A61B2034/2055;;A61B5/021;;A61B5/14546;;A61B5/4845;;A61B5/4866;;A61M5/14244;;A61M5/14276;;A61M2202/0413;;A61M2202/0415;;A61M2205/18;;A61M2205/3584;;A61M2205/50;;G01N33/57438;;A61M1/3489;;A61M2210/1071;;A61M2210/1082;;A61M1/3623;;A61M1/3486;;A61M1/1601;;C12M3/06;;C12M23/44;;C12M3/065;;C12M3/067;;C12M23/42;;C12M23/58;;C12M25/14,A61M5/172;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/145;;A61B17/34;;A61B34/20;;A61M5/142;;G01N33/574,,3,2,146-827-175-361-343;;013-653-037-516-642,10.1088/1361-6439/ab8832;;18699201;;10.1063/1.1135623,"Ghazali, Farah Afiqa Mohd, Md Nazibul Hasan, Tariq Rehman, Marwan Nafea, Mohamed Sultan Mohamed Ali, and Kenichi Takahata. ""MEMS actuators for biomedical applications: a review."" Journal of Micromechanics and Microengineering 30, no. 7 (2020): 073001.;;Chase, C. Peter, and August O. Weilbach. ""Viking GC/MS mechanisms design and performance."" In JPL 10th Aerospace Mech. Symp. 1976.;;Rushneck, D. R., A. V. Diaz, D. W. Howarth, J. Rampacek, K. W. Olson, W. D. Dencker, P. Smith et al. ""Viking gas chromatograph–mass spectrometer."" Review of Scientific Instruments 49, no. 6 (1978): 817-834.",PENDING
111,EP,A4,EP 3367913 A4,022-471-881-313-305,2019-09-25,2019,EP 16845095 A,2016-09-09,US 201562217347 P;;US 2016/0050893 W,2015-09-11,THERAPEUTIC METHOD AND DEVICE,,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/022-471-881-313-305,Search Report,no,1,0,8,8,0,A61B17/3468;;A61B17/3468;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/1451;;A61B5/1451;;A61B5/14532;;A61B5/14546;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B10/0045;;A61B10/0045;;A61B10/0233;;A61B10/0233;;A61B17/34;;A61B17/34;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B90/20;;A61B2010/008;;A61B2010/008;;A61B2017/3407;;A61B2034/2057;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B2560/066;;A61M37/00;;A61M37/00;;A61M37/0069,A61B10/02;;A61B17/34;;A61M37/00,,1,0,,,See also references of WO 2017044702A1,ACTIVE
112,US,A1,US 2018/0271980 A1,138-409-118-725-372,2018-09-27,2018,US 201815987462 A,2018-05-23,US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/138-409-118-725-372,Patent Application,yes,0,2,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61K45/06;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61M5/14;;A61M31/00;;G16H20/10;;G16H20/13;;G16H40/63;;G16Z99/00,,0,0,,,,ACTIVE
113,WO,A1,WO 2015/187289 A1,175-089-010-997-327,2015-12-10,2015,US 2015/0029042 W,2015-05-04,US 201461997506 P;;US 201462122205 P;;US 201462124208 P;;US 201462122431 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECHNOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/175-089-010-997-327,Patent Application,yes,3,11,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M37/00;;A61J1/00;;A61K9/52;;A61K31/485;;A61K31/56;;A61P25/00;;A61P25/30;;G16Z99/00,,1,0,,,See also references of EP 3151906A4,PENDING
114,EP,B1,EP 3367913 B1,038-961-611-374-389,2020-09-02,2020,EP 16845095 A,2016-09-09,US 201562217347 P;;US 2016/0050893 W,2015-09-11,THERAPEUTIC DEVICE,,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/038-961-611-374-389,Granted Patent,yes,4,0,8,8,0,A61B17/34;;A61M37/00;;A61B10/0045;;A61B10/0233;;A61B2010/008;;A61B17/3403;;A61B5/1451;;A61B17/3468;;A61B5/14546;;A61B17/3403;;A61B5/1451;;A61B10/0045;;A61B10/0233;;A61B17/34;;A61B2010/008;;A61M37/00;;A61B17/3468;;A61B34/20;;A61B2034/2057;;A61B90/20;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/14532;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B2017/3407;;A61B2560/066;;A61M37/0069,A61B10/02;;A61B17/34;;A61M37/00,,0,0,,,,ACTIVE
115,US,A1,US 2018/0078747 A1,090-723-153-247-594,2018-03-22,2018,US 201715822625 A,2017-11-27,US 201715822625 A;;US 201615315400 A;;US 2015/0029042 W;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2017-01-11),https://lens.org/090-723-153-247-594,Patent Application,yes,0,2,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;G16Z99/00,,0,0,,,,ACTIVE
116,WO,A1,WO 2017/044702 A1,116-307-419-524-384,2017-03-16,2017,US 2016/0050893 W,2016-09-09,US 201562217347 P,2015-09-11,THERAPEUTIC METHOD AND DEVICE,"The present invention provides for a method and apparatus for inserting and using dermal interstitial sensors in, for example, an analyte monitoring system. The present invention permits the proper positioning of a cannula tip and/or sensor(s) within the reticular dermis.",POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/116-307-419-524-384,Patent Application,yes,36,5,8,8,0,A61B17/34;;A61M37/00;;A61B10/0045;;A61B10/0233;;A61B2010/008;;A61B17/3403;;A61B5/1451;;A61B17/3468;;A61B5/14546;;A61B17/3403;;A61B5/1451;;A61B10/0045;;A61B10/0233;;A61B17/34;;A61B2010/008;;A61M37/00;;A61B17/3468;;A61B34/20;;A61B2034/2057;;A61B90/20;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/14532;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B2017/3407;;A61B2560/066;;A61M37/0069,A61B10/02;;A61B17/34;;A61M37/00,,15,6,033-271-950-020-219;;015-540-247-449-427;;066-129-492-627-899;;042-757-454-082-310;;074-944-999-297-287;;033-710-967-568-610,20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1177/193229680900300121;;20046663;;pmc2769845;;10.3390/s8117050;;27873915;;pmc3787431;;15790850;;10.1126/science.1109128;;10.1038/35104535;;11713525;;10.1038/nature03456;;15846341,"MATTLEY ET AL.: ""Proc. SPIE Advances in Fluorescence Sensing Technology II"", vol. 2388, 1995, article ""Blood characterization using UV/VIS spectroscopy"", pages: 462 - 470;;HONES ET AL., DIABETES TECHN & THERAP, vol. 10, no. 1, 2008, pages S 10 - S26;;HERMANIDESDEVRIES, DIABETOLOGIA, vol. 53, 2010, pages 593 - 596;;MOORE, J. DIABETES SCI. TECHNOL., vol. 3, 2009, pages 180 - 183;;NIELSEN ET AL., J. DIABETES SCI. TECHNOL., vol. 2, 2008, pages 1066 - 1074;;MOKLI, SENSORS, vol. 8, 2008, pages 7050 - 7084;;SNOW, SCIENCE, vol. 307, 2005, pages 1942 - 1945;;HAGLEITNER ET AL., NATURE, vol. 414, 2001, pages 293 - 296;;YUSA ET AL., NATURE, vol. 343, 2005, pages 1001 - 1005;;""The Biomedical Engineering Handbook"", vol. I, 2000, CRC PRESS LLC, pages: V-1 - 51,9;;MORRISON ET AL.: ""Biomedical Nanostructures"", 2008, JOHN WILEY & SONS, INC., article ""Clinical Applications of Micro- and Nanoscale Biosensors"";;""Principles of Fluorescence Spectroscopy"", July 1999, PLENUM PUB CORP;;NOVAK, PATRICIA D. ET AL.: ""Dorland's Pocket Medical Dictionary"", 1995, W.B. SAUNDERS PUBLISHER;;""WHO STANDARD ACUPUNCTURE POINT LOCATIONS IN THE WESTERN PACIFIC REGION"", 2008, WORLD HEALTH ORGANIZATION (WHO;;ACUPUNCTURE TODAY: ELECTROACUPUNCTURE, 1 February 2004 (2004-02-01), Retrieved from the Internet <URL:www.acupuncturetoday.com/abc/electroacupuncture.php>",PENDING
117,EP,A4,EP 3151906 A4,148-286-757-165-530,2018-03-14,2018,EP 15803922 A,2015-05-04,US 201461997506 P;;US 201462122205 P;;US 201462122431 P;;US 201462124208 P;;US 2015/0029042 W,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;OBRIEN REBECCA,,https://lens.org/148-286-757-165-530,Search Report,no,3,0,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M37/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61J1/00;;A61K9/00;;A61K9/52;;A61K31/485;;A61K31/56;;A61K31/58;;A61K45/06;;A61P25/00;;A61P25/30;;G16Z99/00,,1,0,,,See also references of WO 2015187289A1,ACTIVE
118,US,B2,US 10137288 B2,188-385-566-516-961,2018-11-27,2018,US 201715822778 A,2017-11-27,US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC;;POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/188-385-566-516-961,Granted Patent,yes,62,3,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;G16Z99/00,,37,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102: 1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620 (1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors Aug. 2008, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10(2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Supplementary European Search Report for related European Patent Application No. EP15803922 dated Dec. 22, 2017.;;Supplementary European Search Report dated Dec. 22, 2017.",ACTIVE
119,EP,A1,EP 3367913 A1,014-708-189-795-259,2018-09-05,2018,EP 16845095 A,2016-09-09,US 201562217347 P;;US 2016/0050893 W,2015-09-11,THERAPEUTIC METHOD AND DEVICE,,POP TEST LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,,https://lens.org/014-708-189-795-259,Patent Application,yes,0,0,8,8,0,A61B17/3468;;A61B17/3468;;A61B5/0071;;A61B5/0077;;A61B5/076;;A61B5/14503;;A61B5/1451;;A61B5/1451;;A61B5/14532;;A61B5/14546;;A61B5/4845;;A61B5/6861;;A61B5/742;;A61B10/0045;;A61B10/0045;;A61B10/0233;;A61B10/0233;;A61B17/34;;A61B17/34;;A61B17/3403;;A61B17/3403;;A61B34/20;;A61B90/20;;A61B2010/008;;A61B2010/008;;A61B2017/3407;;A61B2034/2057;;A61B2090/304;;A61B2090/3925;;A61B2090/3933;;A61B2090/3941;;A61B2090/395;;A61B2090/3954;;A61B2090/3966;;A61B2560/066;;A61M37/00;;A61M37/00;;A61M37/0069,A61B10/02;;A61B17/34;;A61M37/00,,0,0,,,,ACTIVE
120,US,A1,US 2019/0374758 A1,187-231-068-482-932,2019-12-12,2019,US 201916548414 A,2019-08-22,US 201916548414 A;;US 201916259308 A;;US 201815987462 A;;US 201715822778 A;;US 201715494077 A;;US 201514703163 A;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST LLC (2015-04-30);;POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2015-10-22),https://lens.org/187-231-068-482-932,Patent Application,yes,0,1,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61B5/01;;A61B5/145;;A61K9/00;;A61K31/58;;A61K45/06;;G16H20/10;;G16H20/13;;G16Z99/00,,0,0,,,,ACTIVE
121,US,B2,US 10010703 B2,180-936-811-400-792,2018-07-03,2018,US 201715822625 A,2017-11-27,US 201715822625 A;;US 201615315400 A;;US 2015/0029042 W;;US 201462124208 P;;US 201462122431 P;;US 201462122205 P;;US 201461997506 P,2014-06-03,Drug device configured for wireless communication,This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.,POP TEST ABUSE DETERRENT TECH LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;ENE RAZVAN ANDREI;;RAPKIN MYRON;;O'BRIEN REBECCA,POP TEST ABUSE DETERRENT TECHNOLOGY LLC (2017-01-11),https://lens.org/180-936-811-400-792,Granted Patent,yes,62,8,24,24,0,A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/52;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;A61M2205/3553;;A61M2205/3569;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61P25/00;;A61P25/30;;Y02A90/10;;G16H20/10;;A61B5/4839;;A61B5/4845;;A61B5/4343;;A61B5/14546;;A61B5/073;;A61B2560/0214;;A61B5/14539;;A61B5/14542;;A61B5/02055;;A61B5/024;;A61B5/0816;;A61B5/0531;;A61M31/002;;G16Z99/00;;A61K31/58;;A61K45/06;;A61M2205/3523;;A61M2205/50;;A61M2205/52;;A61M2205/33;;A61M2205/3303;;A61M2205/3306;;A61M2230/201;;G16H40/63;;Y02A90/10;;G16Z99/00;;A61M5/14;;A61B5/4845;;A61M31/002;;A61M2205/3553;;A61M2205/3569;;A61M2205/8206;;A61M2205/8268;;A61M2230/005;;A61M2230/20;;A61M2230/208;;A61M2230/50;;A61M2250/00;;G16H20/13;;A61B5/002;;A61B5/0022;;A61B5/01;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/4343;;A61B5/4839;;A61B2560/0214;;A61K9/0053;;A61K9/0097;;G16H20/10;;H05K999/99,A61M31/00;;A61B5/00;;A61K31/58;;A61K45/06;;G16Z99/00,,37,22,165-066-588-839-128;;102-808-039-029-83X;;156-847-182-016-32X;;027-865-154-389-542;;019-444-785-471-23X;;074-944-999-297-287;;033-271-950-020-219;;102-036-669-955-443;;040-651-091-410-435;;025-832-912-174-847;;066-129-492-627-899;;015-540-247-449-427;;002-266-416-749-463;;003-370-630-789-585;;056-400-940-126-055;;042-757-454-082-310;;012-431-558-746-697;;078-268-154-838-349;;113-447-444-230-922;;100-692-997-533-285;;050-870-469-074-043;;033-710-967-568-610,10.1201/9781420049510.sec20;;17218431;;10.1152/japplphysiol.00105.2006;;10.1021/ja0163164;;11525685;;11544053;;10.1016/s0956-5663(01)00173-7;;10.1016/j.aca.2008.05.022;;18558119;;pmc10069299;;10.1038/35104535;;11713525;;20225392;;10.1007/s00125-009-1649-4;;pmc2830625;;10.1089/dia.2008.0005;;10.1063/1.1763252;;10.1177/193229680800200615;;pmc2769820;;19885295;;10.3390/s8117050;;27873915;;pmc3787431;;10.1177/193229680900300121;;20046663;;pmc2769845;;20046654;;pmc2769858;;10.1177/193229680900300111;;10.1021/nl903377u;;20102189;;10.1016/0956-5663(96)82336-0;;8828165;;15790850;;10.1126/science.1109128;;10.1063/1.3160542;;12071849;;pmc1222666;;10.1042/bj20011727;;10.1109/icsens.2007.355726;;19203203;;10.1021/nl803904b;;19119280;;10.1038/nnano.2008.314;;10.1038/nature03456;;15846341,"International Search Report for corresponding PCT Application No. PCT/US2015/029042 dated Sep. 10, 2015.;;2015 National Drug Threat Assessment Summary, U.S. Department of Justice Drug Enforcement Administration, Oct. 2015.;;Bernstein, et al. “How Drugs Intended for Patients Ended Up in the Hands of Illegal Users: ‘No One Was Doing Their Job.’” The Washington Post, Oct. 22, 2016.;;Bronzino, Joseph D. “The Biomedical Engineering Handbook.” Preface. Second Edition, 2000.;;Bugdett, et al. “Novel Technology for the Provision of Power to Implantable Physiological Devices.” J Appl Physiol 102:1658-1663, 2007.;;Chen, et al., “A Miniature Biofuel Cell.” J. Am. Chem. Soc., 2001, 123, 8630-8631.;;Durick, et al., “Cellular Biosensors for Drug Discovery.” Biosens Bioelectron., Sep. 2001;16(7-8):587-92. Abstract.;;Fan, et al., “Sensitive Optical Bionsensors for Unlabeled Targets: A Review.” Anal Chim Acta., Jul. 14, 2008;620(1-2):8-26. Abstract.;;Hagleitner, et al. “Smart Single-Chip Gas Sensor Microsystem.” Nature 414, 293-296 (Nov. 15, 2001). Abstract.;;Hermanides, et al., “Sense and Nonsense in Sensors.” Diabetologia (2010) 53:593-596.;;Hones et al., “The Technology Behind Glucose Meters: Test Strips.” Diabetes Technology & Therapeutics. May 2008, 10(s1): S-10-S-26. Abstract.;;Lavrik et al., “Cantilever Transducers as a Platform for Chemical and Biological Sensors”, Review of Scientific Instruments, vol. 75, No. 7, pp. 2229-2253, Jul. 2004.;;Li, et al., “Development of Novel Glucose Sensing Fluids with Potential Application to Microelectromechanical Systems-Based Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, vol. 2, Issue 6, pp. 1066-1074, Nov. 2008.;;Martindale W., “Martindale the Extra Pharmacopoeia”, 31st Edition, Aug. 1996. Abstract.;;Mattley et al., “Blood Characterization Using UV/vis Spectroscopy”, Proc. SPIE 2388, Advances in Fluorescence Sensing Technology II, 462 (May 8, 1995). Abstract.;;Mok, et al., “Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays”, Sensors 2008, 8, 7050-7084.;;Moore, B., “The Potential Use of Radio Frequency Identification Devices for Active Monitoring of Blood Glucose Levels”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 180-183, Jan. 2009.;;Morrison et al., “Clinical Applications of Micro- and Nanoscale Biosensors”, Biomedical Nanostructures, pp. 433-454, 2008.;;Nielsen et al., “Clinical Evaluation of a Transcutaneous Interrogated Fluorescence Lifetime-Based Microsensor for Continuous Glucose Reading”, Journal of Diabetes Science and Technology, vol. 3, Issue 1, pp. 98-109, Jan. 2009.;;Physicians' Desk Reference, 2006 (60th Library/Hospital Edition), Overview.;;Qi et al., “Piezoelectric Ribbons Printed onto Rubber for Flexible Energy Conversion”, Nano Lett. Feb. 10, 2010;10(2):524-8. Abstract.;;Remington et al., “Remington's Pharmaceutical Sciences”, 1990, Publication Summary.;;Schmidt, et al., “Microbial Biosensor for Free Fatty Acids Using an Oxygen Electrode Based on Thick Film Technology”, Abstract, Biosens Bioelectron. 1996; 11(11):1139-45.;;Snow et al., “Chemical Detection With a Single-Walled Carbon Nanotube Capacitor”, Science, vol. 307, pp. 1942-1945, Mar. 25, 2005.;;Title II of the Drug Quality and Security Act, Drug Supply Chain Security, Food and Drug Administration, Jan. 1, 2015, http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm.;;Pharmacist Kian Gohari in Manhattan Federal Court for Conspiring to Distribute Oxycodone and Conspiring to Commit Healthcare Fraud, The United States Attorneys Office South District of New York, Nov. 16, 2016, https://www.justice.gov/usao-sdny/pr/pharmacist-kian-gohari-convicted-manhattan-federal-court-conspiring-distribute.;;Vahist, S. Kumar, “A Review of Microcantilevers for Sensing Applications”, AZojomo Journal of Materials Online, Jun. 18, 2007.;;Wacharasindu, et al. “Radioisotope Microbattery Based on Liquid Semiconductor”, Appl. Phys. Lett 95, 014103 (2009).;;Wadum et al., “Fluorsecently Labelled Bovine acyl-CoA-binding Protein Acting as an acyl-CoA Sensor: Interaction with CoA and acyl-CoA Esters and its Use in Measuring Free acyl-CoA Esters and Non-esterified Fatty Acids”, Biochem. J. (2002) 365, 165-172.;;Yang et al., “On-Chip Electrochemical Impedance Spectroscopy for Biosensor Arrays”, IEEE Sensors 2006, EXCO, Daegu, Korea, Oct. 22-25, 2006.;;Yang et al., “Converting Biomechanical Energy into Electricity by a Muscle-Movement-Driven Nanogenerator”, Nano Lett., 2009, 9 (3)m pp. 1201-1205.;;Yang et al., “Power Generation with Laterally Packed Piezoelectric Fine Wires”, Nature Nanotechnology 4, 34-39 (2009).;;Yusa et al., “Controlled Multiple Quantum Coherences of Nuclear Spin in a Nonometre-Scale Device”, Nature 434, 1001-1005 (Apr. 21, 2005).;;Declaration of Randice Lisa Altschul Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Declaration of Michael Mazzilli Under 37 C.F.R. 1.132 filed in U.S. Appl. No. 14/703,163, now U.S. Pat. No. 9,662,392.;;Supplementary European Search Report for related European Patent Application No. EP15803922 dated Dec. 22, 2017.;;Supplementary European Search Report dated Dec. 22, 2017.",ACTIVE
122,KR,A,KR 20200092243 A,152-944-001-246-062,2020-08-03,2020,KR 20190099781 A,2019-08-14,US 201916255923 A,2019-01-24,SYSTEM AND METHOD FOR DRYING AND ANALYTICAL TESTING OF CONTAINERS,"Embodiments of the present invention provide a system to perform drying and testing of organometallic and organosilane precursor source ampoules which are cleaned for re-use. A drying and quality control test is performed in a single location with a single device requiring only one manual connection/disconnection step of an ampoule to the device. The test includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.",VERSUM MAT US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,,https://lens.org/152-944-001-246-062,Patent Application,no,4,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,H01L21/02;;H01L21/324;;H01L21/66;;H01L21/67,,0,0,,,,ACTIVE
123,US,B2,US 10914521 B2,082-859-603-652-013,2021-02-09,2021,US 201916255923 A,2019-01-24,US 201916255923 A,2019-01-24,System and method for drying and analytical testing of containers,"Embodiments of the present invention provide a system and method to perform drying and testing of organometallic and organosilane precursor source ampoules that have been cleaned for re-use. The drying and quality control testing is performed in a single location with a single apparatus requiring only one manual connection/disconnection step of the ampoule to the apparatus. The testing includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.",VERSUM MAT US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,VERSUM MATERIALS US LLC (2019-03-07),https://lens.org/082-859-603-652-013,Granted Patent,yes,13,2,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,F26B25/22;;F26B3/00;;G01N15/06;;G01N33/00,,0,0,,,,ACTIVE
124,CN,A,CN 111473610 A,184-012-894-440-751,2020-07-31,2020,CN 201910690171 A,2019-07-29,US 201916255923 A,2019-01-24,System and method for drying and analytical testing of containers,"Embodiments of the present invention provide a system and method to perform drying and testing of organometallic and organosilane precursor source ampoules that have been cleaned for re-use. The drying and quality control testing is performed in a single location with a single apparatus requiring only one manual connection/disconnection step of the ampoule to the apparatus. The testing includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.",VERSUM MAT US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,,https://lens.org/184-012-894-440-751,Patent Application,no,6,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,F26B9/06;;F26B21/00;;F26B23/00;;G01D21/02,,0,0,,,,ACTIVE
125,JP,A,JP 2020118662 A,096-972-024-011-185,2020-08-06,2020,JP 2019085542 A,2019-04-26,US 201916255923 A,2019-01-24,SYSTEM AND METHOD FOR DRYING AND ANALYTICAL TESTING OF CONTAINERS,"To provide a system and method for drying and testing organometallic and organosilane precursor source ampoules that have been cleaned for re-use.SOLUTION: An ampoule automated drying analytical container system comprises controllable in-line heaters 310 integrated with a purified inert gas supply system 302. The inert gas supply system introduces heated high-purity inert gas via an inlet manifold 312 and valves 318 into ampoules 320 during a drying process, and directs the moisture-containing influent inert gas, produced during the drying process, out of an outlet manifold 324, leading from each ampoule bank 314, to an influent line 324 and valves 322, 358, 364. A system of sample lines 342, 348, 354, 360 leads from the outlet gas manifold 324 to one or more of a moisture analyzer 344, a particle counter 350 and a differential pressure cell 356.SELECTED DRAWING: Figure 3",VERSUM MAT US LLC,MATTHEW DAVID BERNARD;;MCDERMOTT WAYNE THOMAS;;ALLISON BARBEAU HOPKINS;;JOSEPH H SIEMER;;MICHAEL ALTSCHUL PINGITORE,,https://lens.org/096-972-024-011-185,Patent Application,no,0,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,G01M99/00;;G01M3/20,,0,0,,,,ACTIVE
126,US,A1,US 2020/0101087 A1,104-945-857-077-837,2020-04-02,2020,US 201916690282 A,2019-11-21,US 201916690282 A;;US 201916242273 A;;US 201715825982 A;;US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,PHARMACEUTICAL COMPOSITIONS AND METHODS,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/104-945-857-077-837,Patent Application,yes,4,5,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,A61K31/58;;A61K31/485;;A61K31/513;;A61K31/57;;A61K31/7068;;A61K45/06;;C07H19/06;;C07H19/067;;C07J17/00;;C07J41/00,,0,0,,,,ACTIVE
127,US,B2,US 11576921 B2,117-538-402-051-167,2023-02-14,2023,US 201916690282 A,2019-11-21,US 201916690282 A;;US 201916242273 A;;US 201715825982 A;;US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical compositions and methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/117-538-402-051-167,Granted Patent,yes,7,0,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,C07J9/00;;A61K31/485;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07D407/14;;C07H19/06;;C07H19/067;;C07J17/00;;C07J41/00,,3,2,049-795-553-719-753;;076-471-334-441-69X,23636868;;10.3851/imp2568;;pmc7714485;;24227863;;pmc3911624;;10.1128/jvi.02972-13,"Tustin, CX et al., Peregrine's Bavituximab Demonstrates Potential in Viral hemorrhagic Fever Infection Models/Synergistic Therapeutic Effects Observed When Combined Bavituximab with Ribavirin, Data Presented at the 2010 Chemical and Biological Defense Science, http://www.finanznachrichten de, from Marketwired, Nov. 17, 2010.;;Kesel, AJ, et al., Retinazone inhibits Certain Blood-Borne Human Viruses including Ebola Virus Including Ebola Virus Zaire, Antivir. Chem. Chemothera, Apr. 11, 2014:23(5): 197-15, indexed for Medline.;;Brison, E. et al., Novel Treatment with Neuroprotective and Antiviral Properties Against a Neuroinvasive Human respiratory Virus, J. Virol. Feb. 2014; 88(3); 1548-63, indexed for Medline.",ACTIVE
128,TW,A,TW 202028714 A,184-156-636-930-144,2020-08-01,2020,TW 108112616 A,2019-04-11,US 201916255923 A,2019-01-24,System and method for drying and analytical testing of containers,"Embodiments of the present invention provide a system and method to perform drying and testing of organometallic and organosilane precursor source ampoules that have been cleaned for re-use. The drying and quality control testing is performed in a single location with a single apparatus requiring only one manual connection/disconnection step of the ampoule to the apparatus. The testing includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.",VERSUM MATERIALS US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,,https://lens.org/184-156-636-930-144,Patent of Addition,no,0,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,G01M3/02;;F26B3/02,,0,0,,,,ACTIVE
129,TW,B,TW I683095 B,082-200-974-269-106,2020-01-21,2020,TW 108112616 A,2019-04-11,US 201916255923 A,2019-01-24,System and method for drying and analytical testing of containers,,VERSUM MATERIALS US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,,https://lens.org/082-200-974-269-106,Granted Patent,no,4,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,,,0,0,,,,ACTIVE
130,EP,A1,EP 3686533 A1,048-819-590-066-023,2020-07-29,2020,EP 20153742 A,2020-01-24,US 201916255923 A,2019-01-24,SYSTEM AND METHOD FOR DRYING AND ANALYTICAL TESTING OF CONTAINERS,"Embodiments of the present invention provide a system and method to perform drying and testing of organometallic and organosilane precursor source ampoules that have been cleaned for re-use. The drying and quality control testing is performed in a single location with a single apparatus requiring only one manual connection/disconnection step of the ampoule to the apparatus. The testing includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.
",VERSUM MAT US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,,https://lens.org/048-819-590-066-023,Patent Application,yes,6,1,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,F26B21/00;;B08B9/00;;B65D1/09;;F17C13/00;;F26B21/14;;F26B25/22;;G01M3/32,,0,0,,,,ACTIVE
131,US,B2,US 10517881 B2,102-482-819-798-608,2019-12-31,2019,US 201916242273 A,2019-01-08,US 201916242273 A;;US 201715825982 A;;US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical compositions and methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/102-482-819-798-608,Granted Patent,yes,3,4,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,A61K31/58;;A61K31/485;;A61K31/513;;A61K31/57;;A61K31/7068;;A61K45/06;;C07D407/14;;C07H19/06;;C07H19/067;;C07J9/00;;C07J17/00;;C07J41/00,,3,2,049-795-553-719-753;;076-471-334-441-69X,23636868;;10.3851/imp2568;;pmc7714485;;24227863;;pmc3911624;;10.1128/jvi.02972-13,"Tustin, CA et al, Peregrine's Bavituximab Demonstrates Potential inViral Hemorrhagic Fever Infection Models/Synergistic Therapeutic Effects Observed When Combining Bavituximab with Ribavirin, Data Presented at the 2010 Chemical and Biological Defense Science, http://www.fmanznachrichten de, from Marketwired, Nov. 11, 2010.;;Kesel, AJ et al, Retinazone inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire, Antivir. Chem. Chemothera., Apr. 11, 2014:23(5): 197-215, indexed for Medline.;;BRISON, E. et al, Novel Treatment with Neuroprotective and Antiviral Properties Against a Neuroinvasive Human Respiratory Virus, J. Virol, Feb. 2014; 88(3); 1548-63, indexed for Medline.",ACTIVE
132,SG,A,SG 10201903504R A,128-192-230-938-995,2020-08-28,2020,SG 10201903504R A,2019-04-18,US 201916255923 A,2019-01-24,SYSTEM AND METHOD FOR DRYING AND ANALYTICAL TESTING OF CONTAINERS,,VERSUM MATERIALS US LLC,MATTHEW DAVID BERNARD;;WAYNE THOMAS MCDERMOTT;;ALLISON BARBEAU HOPKINS;;JOSEPH J SIEMER;;MICHAEL ALTSCHUL PINGITORE,,https://lens.org/128-192-230-938-995,Unknown,no,0,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,B65D1/09;;F26B3/04;;F26B3/06;;F26B19/00;;G01M3/32,,0,0,,,,PENDING
133,US,A1,US 2019/0134062 A1,151-717-962-485-103,2019-05-09,2019,US 201916242273 A,2019-01-08,US 201916242273 A;;US 201715825982 A;;US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,PHARMACEUTICAL COMPOSITIONS AND METHODS,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/151-717-962-485-103,Patent Application,yes,1,0,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,A61K31/58;;A61K31/485;;A61K31/513;;A61K31/57;;A61K31/7068;;A61K45/06;;C07H19/06;;C07H19/067;;C07J17/00;;C07J41/00,,0,0,,,,ACTIVE
134,EP,B1,EP 3686533 B1,157-348-919-919-217,2023-04-19,2023,EP 20153742 A,2020-01-24,US 201916255923 A,2019-01-24,SYSTEM AND METHOD FOR DRYING AND ANALYTICAL TESTING OF CONTAINERS,,VERSUM MAT US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,,https://lens.org/157-348-919-919-217,Granted Patent,yes,1,0,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,F26B21/00;;B08B9/00;;B65D1/09;;F17C13/00;;F26B21/14;;F26B25/22;;G01M3/32,,0,0,,,,ACTIVE
135,US,A1,US 2020/0240709 A1,192-321-066-812-993,2020-07-30,2020,US 201916255923 A,2019-01-24,US 201916255923 A,2019-01-24,System and Method for Drying and Analytical Testing of Containers,"Embodiments of the present invention provide a system and method to perform drying and testing of organometallic and organosilane precursor source ampoules that have been cleaned for re-use. The drying and quality control testing is performed in a single location with a single apparatus requiring only one manual connection/disconnection step of the ampoule to the apparatus. The testing includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.",VERSUM MAT US LLC,BERNARD MATTHEW DAVID;;MCDERMOTT WAYNE THOMAS;;HOPKINS ALLISON BARBEAU;;SIEMER JOSEPH J;;PINGITORE MICHAEL ALTSCHUL,VERSUM MATERIALS US LLC (2019-03-07),https://lens.org/192-321-066-812-993,Patent Application,yes,10,1,13,13,0,F26B9/06;;F26B21/004;;F26B23/00;;G01D21/02;;F26B21/006;;F26B25/22;;G01M3/3281;;F26B21/14;;F17C13/00;;B08B9/46;;H01L21/02046;;H01L21/0228;;H01L21/02205;;H01L21/324;;H01L22/20;;H01L22/10;;H01L21/67034;;H01L21/67242;;H01L21/67098;;H01L21/67248;;F26B3/00;;F26B25/22;;G01N15/06;;G01N33/0036,F26B25/22;;F26B3/00;;G01N15/06;;G01N33/00,,0,0,,,,ACTIVE
136,US,B2,US 10238666 B2,018-297-158-257-222,2019-03-26,2019,US 201715825982 A,2017-11-29,US 201715825982 A;;US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical compositions and methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/018-297-158-257-222,Granted Patent,yes,3,6,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,A61K31/58;;A61K31/485;;A61K31/513;;A61K31/57;;A61K31/7068;;A61K45/06;;C07D407/14;;C07H19/06;;C07H19/067;;C07J9/00;;C07J17/00;;C07J41/00,,3,2,049-795-553-719-753;;076-471-334-441-69X,23636868;;10.3851/imp2568;;pmc7714485;;24227863;;pmc3911624;;10.1128/jvi.02972-13,"Tustin, CA et al, Peregrine's Bavituximab Demonstrates Potential in Viral Hemorrhagic Fever Infection Models/Synergistic Therapeutic Effects Observed When Combining Bavituximab with Ribavirin; Data Presented at the 2010 Chemical and Biological Defense Science, http://www.finanznachrichten.de, from Marketwired, Nov. 17, 2010.;;Kesel, AJ et al, Retinazone Inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire, Antivir. Chem. Chemothera., Apr. 11, 2014; 23(5):197-215, indexed for Medline.;;Brison, E. et al, Novel Treatment with Neuroprotective and Antiviral Properties Against a Neuroinvasive Human Respiratory Virus, J. Virol., Feb. 2014; 88(3); 1548-63, indexed for Medline.",ACTIVE
137,EP,A1,EP 3400233 A1,054-824-723-813-71X,2018-11-14,2018,EP 16833572 A,2016-07-28,US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339906 P;;US 201662339909 P;;US 201662342103 P;;US 201662342965 P;;US 201662342967 P;;US 201662345095 P;;US 201662345319 P;;US 201662349235 P;;US 201662352576 P;;US 201662352572 P;;US 201662352624 P;;US 201662358211 P;;US 201662361125 P;;US 2016/0044478 W,2015-08-03,PHARMACEUTICAL COMPOSITIONS AND METHODS,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/054-824-723-813-71X,Patent Application,yes,0,0,2,14,0,A61K31/58;;A61K31/58;;A61K31/513;;A61K31/7068;;A61K31/7068;;A61K45/06;;A61K45/06;;C07H19/067;;C07J17/00;;C07J17/00;;C07J41/0005;;C07J41/0005,C07J17/00;;A61K31/58;;A61K31/7084;;A61P31/12;;C07H19/067;;C07J41/00,,0,0,,,,PENDING
138,US,A1,US 2019/0381038 A1,173-400-549-858-503,2019-12-19,2019,US 201716338547 A,2017-10-03,US 201716338547 A;;US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P;;US 2017/0054874 W,2016-10-04,THERAPEUTIC AGENTS AND METHODS:,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2015-09-17),https://lens.org/173-400-549-858-503,Patent Application,yes,0,3,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/506;;A61K9/00;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/58,,0,0,,,,ACTIVE
139,US,A1,US 2017/0128465 A1,174-073-418-439-983,2017-05-11,2017,US 201615370680 A,2016-12-06,US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical Compositions and Methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/174-073-418-439-983,Patent Application,yes,0,2,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,A61K31/58;;A61K31/485;;A61K45/06,,0,0,,,,ACTIVE
140,EP,A4,EP 3400233 A4,126-477-086-578-02X,2020-02-26,2020,EP 16833572 A,2016-07-28,US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339906 P;;US 201662339909 P;;US 201662342103 P;;US 201662342965 P;;US 201662342967 P;;US 201662345095 P;;US 201662345319 P;;US 201662349235 P;;US 201662352576 P;;US 201662352572 P;;US 201662352624 P;;US 201662358211 P;;US 201662361125 P;;US 2016/0044478 W,2015-08-03,PHARMACEUTICAL COMPOSITIONS AND METHODS,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/126-477-086-578-02X,Search Report,no,5,0,2,14,0,A61K31/513;;A61K31/58;;C07H19/067;;C07J17/00;;A61K45/06;;A61K31/7068;;C07J41/0005;;A61K31/58;;C07J17/00;;A61K45/06;;A61K31/7068;;C07J41/0005,C07J17/00;;A61K31/58;;A61K31/7068;;A61P31/12;;C07H19/067;;C07J41/00,,4,3,104-201-598-152-49X;;051-142-415-953-916;;144-621-553-490-18X,20446002;;10.1007/s00705-010-0678-0;;3009988;;10.1016/0022-4731(86)90093-2;;20801539;;10.1016/j.jhep.2010.07.007,"JANET PATRICIA HAPGOOD ET AL: ""Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis"", ARCHIVES OF VIROLOGY ; OFFICIAL JOURNAL OF THE VIROLOGY DIVISIONOF THE INTERNATIONAL UNION OF MICROBIOLOGICAL SOCIETIES, SPRINGER-VERLAG, VI, vol. 155, no. 7, 6 May 2010 (2010-05-06), pages 1009 - 1019, XP019853346, ISSN: 1432-8798;;DIETRICH J B ET AL: ""Antagonism of glucocorticoid induction of Epstein-Barr virus early antigens by different steroids in Daudi lymphoma cells"", JOURNAL OF STEROID BIOCHEMISTRY, PERGAMON PRESS PLC, GB, vol. 24, no. 1, 1 January 1986 (1986-01-01), pages 417 - 421, XP025197388, ISSN: 0022-4731, [retrieved on 19860101], DOI: 10.1016/0022-4731(86)90093-2;;FAFI-KREMER S ET AL: ""Hepatitis C virus entry and glucocorticosteroids"", INTERNATIONAL HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 53, no. 6, 1 December 2010 (2010-12-01), pages 1148 - 1150, XP027475678, ISSN: 0168-8278, [retrieved on 20100811], DOI: 10.1016/J.JHEP.2010.07.007;;See also references of WO 2017023694A1",PENDING
141,US,B2,US 11224599 B2,009-498-972-023-767,2022-01-18,2022,US 202117242495 A,2021-04-28,US 202117242495 A;;US 2017/0054874 W;;US 201762517289 P;;US 201762501811 P;;US 201762474738 P;;US 201762449195 P;;US 201762442478 P;;US 201662440636 P;;US 201662441076 P;;US 201662433988 P;;US 201662420578 P;;US 201662412414 P;;US 201662404036 P,2016-10-04,Therapeutic agents and methods,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2011-02-15),https://lens.org/009-498-972-023-767,Granted Patent,yes,11,4,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/506;;A61K9/00;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/58;;A61K45/06,,1,1,070-658-632-342-034,32284615;;pmc7095063;;10.1038/s41591-020-0820-9,"Andersen et al., “The proximal origin of SARS-CoV-2”, 2020, Nat. Med., vol. 26, pp. 450-452. https://doi.org/10.1038/s41591-020-0820-9 (Year: 2020).",ACTIVE
142,WO,A1,WO 2017/023694 A1,168-886-680-407-97X,2017-02-09,2017,US 2016/0044478 W,2016-07-28,US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201662352576 P;;US 201662314046 P;;US 201662342103 P;;US 201562241875 P;;US 201662352572 P;;US 201662339906 P;;US 201662352624 P;;US 201662299120 P;;US 201662296673 P;;US 201562271038 P;;US 201662361125 P;;US 201662358211 P;;US 201662345095 P;;US 201662345319 P;;US 201662342965 P;;US 201662280073 P;;US 201662339909 P;;US 201662349235 P;;US 201662342967 P,2015-08-03,PHARMACEUTICAL COMPOSITIONS AND METHODS,"This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/168-886-680-407-97X,Patent Application,yes,2,15,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,C07J17/00;;A61K31/58;;A61K31/7084;;A61P31/12;;C07H19/067;;C07J41/00,,3,2,049-795-553-719-753;;076-471-334-441-69X,23636868;;10.3851/imp2568;;pmc7714485;;24227863;;pmc3911624;;10.1128/jvi.02972-13,"""Peregrine's bavituximab demonstrates broad potential in viral hemorrhagic fever infection models/synergistic therapeutic effects observed when combining bavituximab with ribavirin"", 2010, pages 1 - 2, XP009508724, Retrieved from the Internet <URL:FinanzNachrichtwe.de>;;KESEL AJ . ET AL.: ""Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire."", ANTIVIR CHEM CHEMOTHER., vol. 23, no. 5, 2014, pages 197 - 215, XP055362771;;BRISON E. ET AL.: ""Novel treatment with heuroprotective and antiviral properties against a neuroinvasive human respiratory virus."", J VIRO ., vol. 88, no. 3, 2014, pages 1548 - 1563, XP055362773",PENDING
143,WO,A2,WO 2018/067520 A2,199-054-009-658-433,2018-04-12,2018,US 2017/0054874 W,2017-10-03,US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P,2016-10-04,THERAPEUTIC AGENTS AND METHODS:,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/199-054-009-658-433,Patent Application,yes,12,1,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/7052;;A61K9/48,,15,9,022-190-260-808-662;;049-795-553-719-753;;010-445-422-382-569;;012-677-392-640-402;;028-199-159-393-131;;145-061-977-166-520;;076-573-427-681-534;;028-428-571-584-841;;054-980-079-955-454,26143299;;pmc4536150;;10.1016/j.drugalcdep.2015.06.018;;23636868;;10.3851/imp2568;;pmc7714485;;10.1016/j.cmet.2008.08.001;;18762022;;10.1021/cr030112j;;15700959;;5958716;;10.1159/000220462;;24347399;;10.1002/mrc.4028;;10.1073/pnas.45.12.1801;;16590578;;pmc222804;;10764142;;10.1038/sj.leu.2401743;;14680969;;10.1016/j.pep.2003.09.003,"REYNOLDS AR: ""Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation"", DRUG ALCOHOL DEPEND, vol. 154, 1 September 2015 (2015-09-01), pages 100 - 4, XP029256113, DOI: 10.1016/j.drugalcdep.2015.06.018;;S. RIVAL. G. SILVESTRI, ANNU. REV. MICROBIOL., vol. 16, 1972, pages 199 - 244;;LANCET, vol. 1, no. 7643, 1970, pages 1970;;E. A. SCHAFERN. J. VENKATACHARIV. AYYAVOO, ANTIVIR. RES.,, vol. 72, 2006, pages 224 - 232;;KESEL AJ.: ""Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire"", ANTIVIR CHEM CHEMOTHER, vol. 23, no. 5, 11 April 2014 (2014-04-11), pages 197 - 215;;ULRIKE LEMKE ET AL.: ""The glucocorticoid receptor controls hepatic dyslipidemia through Hesl"", CELL METAB, vol. 8, 2008, pages 212 - 223, XP029860470, DOI: 10.1016/j.cmet.2008.08.001;;FLOSS HGYU TW: ""Rifamycin-mode of action, resistance, and biosynthesis"", CHEM REV., vol. 105, no. 2, February 2005 (2005-02-01), pages 621 - 32;;MAGGI MPASQUALUCCI CRBALLOTTA RSENSI P: ""Rifampicin: a new orally active rifamycin"", CHEMOTHERAPIA, vol. 11, 1966, pages 285 - 292;;PRZYBYLSKI P ET AL.: ""13C and 15N CP/MAS, 1H-15N SCT CP/MAS and FTIR spectroscopy as tools for qualitative detection of the presence of zwitterionic and nonionic forms of ansa-macrolide 3-formylrifamycin SV and its derivatives in solid state"", MAGN. RES. CHEM., vol. 52, 2014, pages 10 - 21;;MIDDLEBROOK GCOLEMAN CMSCHAEFER WB.: ""Sulfolipid from virulent tubercle bacilli"", PROC. NATL. ACAD. SCI. U.S.A., vol. 45, 1959, pages 1801 - 1804;;GENNARO ET AL.: ""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY;;FRANKEL ET AL.: ""Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias"", LEUKEMIA, vol. 14, 2000, pages 576, XP037782451, DOI: 10.1038/sj.leu.2401743;;URIETO ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 33, 2004, pages 123 - 133;;""Physician's Desk Reference"", 2006;;See also references of EP 3534910A4",PENDING
144,US,A1,US 2017/0051007 A1,024-779-517-017-773,2017-02-23,2017,US 201615222062 A,2016-07-28,US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,PHARMACEUTICAL COMPOSITIONS AND METHODS,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/024-779-517-017-773,Patent Application,yes,0,6,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,C07J41/00;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J17/00,,0,0,,,,ACTIVE
145,US,A1,US 2021/0353623 A1,095-431-016-376-207,2021-11-18,2021,US 202117242495 A,2021-04-28,US 202117242495 A;;US 2017/0054874 W;;US 201762517289 P;;US 201762501811 P;;US 201762474738 P;;US 201762449195 P;;US 201762442478 P;;US 201662440636 P;;US 201662441076 P;;US 201662433988 P;;US 201662420578 P;;US 201662412414 P;;US 201662404036 P,2016-10-04,THERAPEUTIC AGENTS AND METHODS,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIAN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2011-02-15),https://lens.org/095-431-016-376-207,Patent Application,yes,0,0,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/506;;A61K9/00;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/58,,0,0,,,,ACTIVE
146,US,A1,US 2018/0185392 A1,139-558-457-131-929,2018-07-05,2018,US 201715825982 A,2017-11-29,US 201715825982 A;;US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical Compositions and Methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/139-558-457-131-929,Patent Application,yes,0,2,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,A61K31/58;;A61K31/485;;A61K45/06,,1,0,,,"Belanoff US Patent no 8,476,254",ACTIVE
147,US,B2,US 9598459 B2,197-496-036-764-739,2017-03-21,2017,US 201615222062 A,2016-07-28,US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical compositions and methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LTD LIABILITY COMPANY;;POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2016-07-20),https://lens.org/197-496-036-764-739,Granted Patent,yes,1,5,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,C07J9/00;;A61K31/58;;A61K31/7068;;A61K45/06;;C07D407/14;;C07H19/06;;C07J17/00;;C07J41/00,,0,0,,,,ACTIVE
148,EP,A2,EP 3534910 A2,075-664-520-001-57X,2019-09-11,2019,EP 17858992 A,2017-10-03,US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P;;US 2017/0054874 W,2016-10-04,THERAPEUTIC AGENTS AND METHODS,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/075-664-520-001-57X,Patent Application,yes,0,0,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/7052;;A61K9/48,,0,0,,,,PENDING
149,EP,A4,EP 3534910 A4,166-667-555-339-91X,2020-11-25,2020,EP 17858992 A,2017-10-03,US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P;;US 2017/0054874 W,2016-10-04,THERAPEUTIC AGENTS AND METHODS,,POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/166-667-555-339-91X,Search Report,no,0,0,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/7052;;A61K9/48;;A61P31/12,,4,3,088-350-529-582-569;;013-157-938-388-841;;120-024-788-799-652,10.1016/j.antiviral.2006.06.008;;16889838;;4562808;;10.1146/annurev.mi.26.100172.001215;;10.1016/s0140-6736(70)91526-6,"SCHAFER E A ET AL: ""Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): Targeting Vpr and its cellular partner, the glucocorticoid receptor (GR)"", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 72, no. 3, 1 December 2006 (2006-12-01), pages 224 - 232, XP027893454, ISSN: 0166-3542, [retrieved on 20061201];;SILVANO RIVA ET AL: ""RIFAMYCINS: A GENERAL VIEW INTRODUCTION"", ANNUAL REVIEW OF MICROBIOLOGY, vol. 26, 1 January 1972 (1972-01-01), pages 199 - 224, XP055715836;;ANONYMOUS: ""ANTIVIRAL ACTION OF RIFAMPICIN"", LANCET, vol. 1, no. 7643, 21 February 1970 (1970-02-21), pages 399 - 399, XP055715814;;See also references of WO 2018067520A2",PENDING
150,US,B2,US 11702443 B2,087-266-087-781-609,2023-07-18,2023,US 202117533069 A,2021-11-22,US 202117533069 A;;US 202117242495 A;;US 201916338547 A;;US 2017/0054874 W;;US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P,2016-10-04,Therapeutic agents and methods,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2011-02-15),https://lens.org/087-266-087-781-609,Granted Patent,yes,12,1,3,11,8,A61K31/137;;A61K31/7068;;A61K31/695;;A61K31/14;;A61K31/343;;A61K31/567;;A61K31/175;;A61K31/655;;C07D307/83;;C07H19/06;;A61K31/58;;C07F7/0812;;C07J17/00;;C07J41/0005;;C07J41/0083;;C07J17/00;;A61K31/175;;C07D307/83;;C07H19/06;;C07C309/50;;C07C211/63;;C07C335/40;;A61K31/58;;A61K31/695;;A61K31/343;;A61K31/7068;;A61K31/655;;A61K31/567;;A61K31/137;;A61K31/14;;C07F7/0812,C07J17/00;;A61K31/137;;A61K31/14;;A61K31/175;;A61K31/343;;A61K31/567;;A61K31/58;;A61K31/655;;A61K31/695;;A61K31/7068;;C07C211/63;;C07C309/50;;C07C335/40;;C07D307/83;;C07F7/08;;C07H19/06,,0,0,,,,ACTIVE
151,US,B2,US 11040037 B2,078-713-835-104-431,2021-06-22,2021,US 201716338547 A,2017-10-03,US 201716338547 A;;US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P;;US 2017/0054874 W,2016-10-04,Therapeutic agents and methods,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2015-09-17),https://lens.org/078-713-835-104-431,Granted Patent,yes,15,4,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/506;;A61K9/00;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/58;;A61K45/06,,1,0,,,"International Search Report for PCT/US17/54874 dated Nov. 27, 2017.",ACTIVE
152,US,A1,US 2023/0382945 A1,108-000-814-241-724,2023-11-30,2023,US 202318143457 A,2023-05-04,US 202318143457 A;;US 202117533069 A;;US 202117242495 A;;US 201916338547 A;;US 2017/0054874 W;;US 201662404036 P;;US 201662412414 P;;US 201662433988 P;;US 201662440636 P;;US 201662441076 P;;US 201662420578 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P,2016-10-04,THERAPEUTIC AGENTS AND METHODS,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/108-000-814-241-724,Patent Application,yes,0,0,3,11,0,A61K31/137;;A61K31/7068;;A61K31/695;;A61K31/14;;A61K31/343;;A61K31/567;;A61K31/175;;A61K31/655;;C07D307/83;;C07H19/06;;A61K31/58;;C07F7/0812;;C07J17/00;;C07J41/0005;;C07J41/0083;;C07J17/00;;A61K31/175;;C07D307/83;;C07H19/06;;C07C309/50;;C07C211/63;;C07C335/40;;A61K31/58;;A61K31/695;;A61K31/343;;A61K31/7068;;A61K31/655;;A61K31/567;;A61K31/137;;A61K31/14;;C07F7/0812,C07J17/00;;A61K31/137;;A61K31/14;;A61K31/175;;A61K31/343;;A61K31/567;;A61K31/58;;A61K31/655;;A61K31/695;;A61K31/7068;;C07C211/63;;C07C309/50;;C07C335/40;;C07D307/83;;C07F7/08;;C07H19/06,,0,0,,,,PENDING
153,WO,A3,WO 2018/067520 A3,145-539-874-164-557,2019-05-31,2019,US 2017/0054874 W,2017-10-03,US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P,2016-10-04,THERAPEUTIC AGENTS AND METHODS:,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/145-539-874-164-557,Search Report,yes,7,0,8,11,0,A61K9/00;;A61K45/06;;A61K31/395;;A61K31/695;;C07D498/08;;C07D317/54;;C07H19/067;;C07H99/00;;C07C309/51;;C07C211/41;;C07C335/40;;C07C2603/74;;C07J17/00;;C07J41/005;;C07J41/0083;;A61P31/12;;A61K9/0014;;A61K31/14;;A61K31/175;;A61K31/195;;A61K31/506;;A61K31/58;;A61K45/06,A61K31/58;;A61P31/12,,0,0,,,,PENDING
154,US,B2,US 9855284 B2,067-199-470-034-507,2018-01-02,2018,US 201615370680 A,2016-12-06,US 201615370680 A;;US 201615222062 A;;US 201562282525 P;;US 201562220583 P;;US 201562241875 P;;US 201562271038 P;;US 201662280073 P;;US 201662296673 P;;US 201662299120 P;;US 201662314046 P;;US 201662339909 P;;US 201662339906 P;;US 201662342103 P;;US 201662342965 P;;US 201662342966 P;;US 201662342967 P;;US 201662345319 P;;US 201662345095 P;;US 201662349235 P;;US 201662352624 P;;US 201662352611 P;;US 201662352572 P;;US 201662352576 P;;US 201662358211 P;;US 201662361125 P,2015-08-03,Pharmaceutical compositions and methods,"This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,,https://lens.org/067-199-470-034-507,Granted Patent,yes,2,5,12,14,0,C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07J41/0005;;A61P31/12;;A61P25/22;;A61P25/28;;C07H19/067;;C07J17/00;;A61K31/513;;A61K31/57;;A61K31/58;;A61K31/7068;;A61K45/06;;C07H19/06;;C07J41/0005;;A61K31/485,C07J9/00;;A61K31/485;;A61K31/58;;A61K45/06;;C07D407/14,,3,2,049-795-553-719-753;;076-471-334-441-69X,23636868;;10.3851/imp2568;;pmc7714485;;24227863;;pmc3911624;;10.1128/jvi.02972-13,"Tustin, CA et al, Peregrine's Bavituximab Demonstrates Potential in Viral Hemorrhagic Fever Infection Models/Synergistic Therapeutic Effects Observed When Combining Bavituximab with Ribavirin; Data Presented at the 2010 Chemical and Biological Defense Science, http://www.finanznachrichten.de, from Marketwired, Nov. 17, 2010.;;Kesel, AJ et al, Retinazone Inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire, Antivir. Chem. Chemothera., Apr. 11, 2014; 23(5):197-215, indexed for MEDLINE.;;Brison, E. et al, Novel Treatment with Neuroprotective and Antiviral Properties Against a Neuroinvasive Human Respiratory Virus, J. Virol., Feb. 2014; 88(3); 1548-63, indexed for MEDLINE.",ACTIVE
155,US,A1,US 2022/0298203 A1,096-956-900-842-385,2022-09-22,2022,US 202117533069 A,2021-11-22,US 202117533069 A;;US 202117242495 A;;US 201916338547 A;;US 2017/0054874 W;;US 201662404036 P;;US 201662412414 P;;US 201662420578 P;;US 201662433988 P;;US 201662441076 P;;US 201662440636 P;;US 201762442478 P;;US 201762449195 P;;US 201762474738 P;;US 201762501811 P;;US 201762517289 P,2016-10-04,THERAPEUTIC AGENTS AND METHODS,"The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.",POP TEST ONCOLOGY LLC,ALTSCHUL RANDICE LISA;;THEISE NEIL DAVID;;KESEL ANDREAS J;;RAPKIN MYRON;;O'BRIEN REBECCA;;ARMENT ANTHONY R,POP TEST ONCOLOGY LLC (2011-02-15),https://lens.org/096-956-900-842-385,Patent Application,yes,12,0,3,11,8,A61K31/137;;A61K31/7068;;A61K31/695;;A61K31/14;;A61K31/343;;A61K31/567;;A61K31/175;;A61K31/655;;C07D307/83;;C07H19/06;;A61K31/58;;C07F7/0812;;C07J17/00;;C07J41/0005;;C07J41/0083;;C07J17/00;;A61K31/175;;C07D307/83;;C07H19/06;;C07C309/50;;C07C211/63;;C07C335/40;;A61K31/58;;A61K31/695;;A61K31/343;;A61K31/7068;;A61K31/655;;A61K31/567;;A61K31/137;;A61K31/14;;C07F7/0812,C07J17/00;;A61K31/137;;A61K31/14;;A61K31/175;;A61K31/343;;A61K31/567;;A61K31/58;;A61K31/655;;A61K31/695;;A61K31/7068;;C07C211/63;;C07C309/50;;C07C335/40;;C07D307/83;;C07F7/08;;C07H19/06,,0,0,,,,ACTIVE
